

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

16 December 2021 (16.12.2021)



(10) International Publication Number

WO 2021/249529 A1

(51) International Patent Classification:

C07C 13/465 (2006.01) A61P 1/16 (2006.01)

A61K 31/015 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2021/099626

(22) International Filing Date:

11 June 2021 (11.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/038,737 12 June 2020 (12.06.2020) US

(71) Applicant: NUCMITO PHARMACEUTICALS CO., LTD. [CN/CN]; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN).

(72) Inventors: SU, Ying; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). ZHANG, Xiaokun; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). CHEN, Ziwen; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). CHEN, Qiangzhen; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). WANG, Hais-han; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). ZHANG, Xindao; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). ZENG, Zhiping; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). CAI, Li-jun; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN). ZHOU, Yuqi; 822 Liangting Road, Xiangnan, Xiamen, Fujian 361101 (CN).

(74) Agent: J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE; YU, Mingwei, Room 5022, No. 335, Guo Ding Road, YANG Pu District, Shanghai 200433 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,


UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS



INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of the priority of U.S. Provisional Application No. 63/038,737, filed June 12, 2020; the disclosure of which is incorporated herein by reference in its entirety.

REFERENCE TO A SEQUENCE LISTING

[0002] The present specification is being filed with a Sequence Listing in Computer Readable Form (CRF), which is entitled 294A002WO01_SEQ_LIST_ST25.txt of 1,427 bytes in size and created May 23, 2021; the content of which is incorporated herein by reference in its entirety.

FIELD

[0003] Provided herein are an indene compound and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

BACKGROUND


[0004] Fibrosis is the accumulation of extracellular matrix components in organs or tissues, changing their structures and leading to a disruption of normal functions, and, in many cases, ultimately leading to organ failure and death. Hernandez-Gea *et al.*, *Annu. Rev. Pathol.* **2011**, *6*, 425-56; Makarev *et al.*, *Cell Cycle* **2016**, *15*, 1667-73. Fibrosis can occur in almost any organ or tissue and is associated with a wide variety of diseases, contributing to up to 45% of deaths in the developed world. Mehal *et al.*, *Nat. Med.* **2011**, *17*, 552-3; Makarev *et al.*, *Cell Cycle* **2016**, *15*, 1667-73.

[0005] NASH (non-alcoholic steatohepatitis) is a progressive disease caused by excessive fat accumulation in the liver, unrelated to alcohol use, that induces chronic

inflammation and damage (ballooning) of hepatocytes, resulting in fibrosis that can lead to cirrhosis, liver failure, and death. Roenn, *Clin. Liver Dis. (Hoboken)* **2018**, 12, 35-6; Sheka *et al.*, *JAMA* **2020**, 323, 1175-83. The stage of liver fibrosis is a strong predictor of clinical outcomes in patients with NASH. Angulo *et al.*, *Hepatology* **1999**, 30, 1356-62; Dulai *et al.*, *Hepatology* **2017**, 65, 1557-65. Ongoing persistence of obesity with increasing rates of diabetes is expected to increase the prevalence of NASH dramatically in coming years, and the disease is projected to become the leading cause of liver transplants in the US. Roenn, *Clin. Liver Dis. (Hoboken)* **2018**, 12, 35-6; Sheka *et al.*, *JAMA* **2020**, 323, 1175-83. There are currently no FDA-approved therapies for NASH. *Id.* Therefore, there is a need for an effective therapy for treating a fibrotic disease, in particular, NASH.

SUMMARY OF THE DISCLOSURE

[0006] Provided herein is a compound of Formula (I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or heteroaryl; wherein R^{2a} , R^{2b} , and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3 , R^4 , R^5 , and R^6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$,

$-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$;

R^A is C_{6-14} arylene or heteroarylene;

R^B and X are (i), (ii), or (iii):

(i) X is $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$; and

R^B is C_{6-14} aryl or heteroaryl;

(ii) X is $-\text{N}(\text{R}^X)-$;

R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or

(iii) X is $-\text{N}(\text{R}^X)-$; and

R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl;

L is C_{1-6} alkylene, C_{2-6} alkenylene, C_{3-10} cycloalkylene, or heterocyclylene; and

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{C}(\text{O})\text{SR}^a$, $-\text{C}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{C}(\text{S})\text{R}^a$, $-\text{C}(\text{S})\text{OR}^a$, $-\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{OR}^a$, $-\text{OC}(\text{O})\text{R}^a$, $-\text{OC}(\text{O})\text{OR}^a$, $-\text{OC}(\text{O})\text{NR}^b\text{R}^c$, $-\text{OC}(\text{O})\text{SR}^a$, $-\text{OC}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{OC}(\text{S})\text{R}^a$, $-\text{OC}(\text{S})\text{OR}^a$, $-\text{OC}(\text{S})\text{NR}^b\text{R}^c$, $-\text{OS}(\text{O})\text{R}^a$, $-\text{OS}(\text{O})_2\text{R}^a$, $-\text{OS}(\text{O})\text{NR}^b\text{R}^c$, $-\text{OS}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{O})\text{R}^d$, $-\text{NR}^a\text{C}(\text{O})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{O})\text{SR}^d$, $-\text{NR}^a\text{C}(\text{NR}^d)\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{S})\text{R}^d$, $-\text{NR}^a\text{C}(\text{S})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})_2\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{SR}^a$, $-\text{S}(\text{O})\text{R}^a$, $-\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})\text{NR}^b\text{R}^c$, and $-\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, wherein each R^a ,

R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$, $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.


[0007] Also provided herein is a pharmaceutical composition comprising a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.

[0008] Additionally provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0009] Furthermore, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a proliferative disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0010] Provided herein is a method of inhibiting the growth of a cell, comprising contacting the cell with an effective amount of a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0011] Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I-A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $-\text{CN}$, $-\text{C}(\text{O})\text{OR}^{2a}$, $-\text{C}(\text{O})\text{NR}^{2b}\text{R}^{2c}$, $-\text{C}(\text{O})\text{N}(\text{R}^{2b})\text{OR}^{2c}$, $-\text{OR}^{2a}$, $-\text{NR}^{2b}\text{R}^{2c}$, or heteroaryl; wherein R^{2a} , R^{2b} , and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3 , R^4 , R^5 , and R^6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl,

heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

each R^7 is independently (a) deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; or two adjacent R^7 together with the phenyl group to which they are attached form naphthyl or bicyclic heteroaryl;

R^C is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-OR^{1a}$, $-NR^{1b}R^{1c}$, or $-NR^{1a}C(O)R^{1d}$;

L is C_{1-6} alkylene or C_{2-6} alkenylene;

n is an integer of 0, 1, 2, 3, or 4; and

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$,

$-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$,
 $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$,
 $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$,
 $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$,
 $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a ,
 R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6}
 alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is
 optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents
 Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl
 optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents
 Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro,
 and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl,
 heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$,
 $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$,
 $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$,
 $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$,
 $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$,
 $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$,
 $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is
 independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10}
 cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with
 the N atom to which they are attached form heterocyclyl.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1 shows the effect of malotilate (Mal), and compounds **A11** and **B9** on body weight in C57/BL6 mice.

[0013] FIG. 2 shows the effect of Mal, and compounds **A11** and **B9** on the mRNA level of α -SMA in C57/BL6 mice.

[0014] FIG. 3 shows the effect of Mal, and compounds **A11** and **B9** on the mRNA level

of *Colla1* in C57/BL6 mice.

[0015] FIG. 4 shows Sirius red pathological staining images of the liver samples of C57/BL6 mice treated with Mal, or compound **A11** or **B9**, indicating that each compound reversed the fibrosis induced by CCl₄.

[0016] FIG. 5 shows the effect of Mal and compound **A23** on the mRNA level of α -SMA in C57/BL6 mice.

[0017] FIG. 6 shows the effect of Mal and compound **A23** on the mRNA level of *Colla1* in C57/BL6 mice.

DETAILED DESCRIPTION

[0018] To facilitate understanding of the disclosure set forth herein, a number of terms are defined below.

[0019] Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, biochemistry, biology, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0020] The term “subject” refers to an animal, including, but not limited to, a primate (*e.g.*, human), cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms “subject” and “patient” are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. In one embodiment, the subject is a human.

[0021] The terms “treat,” “treating,” and “treatment” are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself.

[0022] The terms “prevent,” “preventing,” and “prevention” are meant to include a method of delaying and/or precluding the onset of a disorder, disease, or condition, and/or its

attendant symptoms; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject's risk of acquiring a disorder, disease, or condition.

[0023] The terms “alleviate” and “alleviating” refer to easing or reducing one or more symptoms (*e.g.*, pain) of a disorder, disease, or condition. The terms can also refer to reducing adverse effects associated with an active ingredient. Sometimes, the beneficial effects that a subject derives from a prophylactic or therapeutic agent do not result in a cure of the disorder, disease, or condition.

[0024] The term “contacting” or “contact” is meant to refer to bringing together of a therapeutic agent and a biological molecule (*e.g.*, a protein, enzyme, RNA, or DNA), cell, or tissue such that a physiological and/or chemical effect takes place as a result of such contact. Contacting can take place *in vitro*, *ex vivo*, or *in vivo*. In one embodiment, a therapeutic agent is contacted with a biological molecule *in vitro* to determine the effect of the therapeutic agent on the biological molecule. In another embodiment, a therapeutic agent is contacted with a cell in cell culture (*in vitro*) to determine the effect of the therapeutic agent on the cell. In yet another embodiment, the contacting of a therapeutic agent with a biological molecule, cell, or tissue includes the administration of a therapeutic agent to a subject having the biological molecule, cell, or tissue to be contacted.

[0025] The term “therapeutically effective amount” or “effective amount” is meant to include the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated. The term “therapeutically effective amount” or “effective amount” also refers to the amount of a compound that is sufficient to elicit a biological or medical response of a biological molecule (*e.g.*, a protein, enzyme, RNA, or DNA), cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.

[0026] The term “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” “physiologically acceptable carrier,” or “physiologically acceptable excipient” refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. In one embodiment, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a

pharmaceutical formulation, and suitable for use in contact with the tissue or organ of a subject (*e.g.*, a human) without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, and commensurate with a reasonable benefit/risk ratio. *See, e.g.*, *Remington: The Science and Practice of Pharmacy*, 23rd ed.; Adejare Ed.; Academic Press, 2020; *Handbook of Pharmaceutical Excipients*, 9th ed.; Sheskey *et al.*, Eds.; Pharmaceutical Press, 2020; *Handbook of Pharmaceutical Additives*, 3rd ed.; Ash and Ash Eds.; Synapse Information Resources, 2007; *Pharmaceutical Preformulation and Formulation*, 1st ed.; Gibson Ed.; CRC Press, 2015.

[0027] The term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, or 3 standard deviations. In certain embodiments, the term “about” or “approximately” means within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.

[0028] The term “alkyl” refers to a linear or branched saturated monovalent hydrocarbon radical, wherein the alkyl is optionally substituted with one or more substituents Q as described herein. For example, C₁₋₆ alkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 20 (C₁₋₂₀), 1 to 15 (C₁₋₁₅), 1 to 10 (C₁₋₁₀), or 1 to 6 (C₁₋₆) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. As used herein, linear C₁₋₆ and branched C₃₋₆ alkyl groups are also referred to as “lower alkyl.” Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (including all isomeric forms, *e.g.*, *n*-propyl and isopropyl), butyl (including all isomeric forms, *e.g.*, *n*-butyl, isobutyl, *sec*-butyl, and *t*-butyl), pentyl (including all isomeric forms, *e.g.*, *n*-pentyl, isopentyl, *sec*-pentyl, neopentyl, and *tert*-pentyl), and hexyl (including all isomeric forms, *e.g.*, *n*-hexyl, isohexyl, and *sec*-hexyl).

[0029] The terms “alkylene” and “alkanediyl” are used interchangeably herein in reference to a linear or branched saturated divalent hydrocarbon radical, wherein the alkylene is

optionally be substituted with one or more substituents Q as described herein. For example, C₁₋₆ alkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkylene is a linear saturated divalent hydrocarbon radical that has 1 to 30 (C₁₋₃₀), 1 to 20 (C₁₋₂₀), 1 to 15 (C₁₋₁₅), 1 to 10 (C₁₋₁₀), or 1 to 6 (C₁₋₆) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 30 (C₃₋₃₀), 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. As used herein, linear C₁₋₆ and branched C₃₋₆ alkylene groups are also referred as “lower alkylene.” Examples of alkylene groups include, but are not limited to, methylene, ethylene (including all isomeric forms, *e.g.*, ethan-1,1-diyl and ethan-1,2-diyl), propylene (including all isomeric forms, *e.g.*, propan-1,1-diyl, propan-1,2-diyl, and propan-1,3-diyl), butylene (including all isomeric forms, *e.g.*, butan-1,1-diyl, butan-1,2-diyl, butan-1,3-diyl, and butan-1,4-diyl), pentylene (including all isomeric forms, *e.g.*, pentan-1,1-diyl, pentan-1,2-diyl, pentan-1,3-diyl, and pentan-1,5-diyl), and hexylene (including all isomeric forms, *e.g.*, hexan-1,1-diyl, hexan-1,2-diyl, hexan-1,3-diyl, and hexan-1,6-diyl).

[0030] The term “alkenyl” refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond(s). The alkenyl is optionally substituted with one or more substituents Q as described herein. The term “alkenyl” embraces radicals having a “*cis*” or “*trans*” configuration or a mixture thereof, or alternatively, a “*Z*” or “*E*” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art. For example, C₂₋₆ alkenyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenyl is a linear monovalent hydrocarbon radical of 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl (including all isomeric forms, *e.g.*, propen-1-yl, propen-2-yl, and allyl), and butenyl (including all isomeric forms, *e.g.*, buten-1-yl, buten-2-yl, buten-3-yl, and 2-buten-1-yl).

[0031] The terms “alkenylene” and “alkenediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in

one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond(s). The alkenylene is optionally substituted with one or more substituents Q as described herein. The term “alkenylene” embraces radicals having a “*cis*” or “*trans*” configuration or a mixture thereof, or alternatively, a “*Z*” or “*E*” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art. For example, C₂₋₆ alkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenylene is a linear divalent hydrocarbon radical of 2 to 30 (C₂₋₃₀), 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 30 (C₃₋₃₀), 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. Examples of alkenylene groups include, but are not limited to, ethenylene (including all isomeric forms, *e.g.*, ethen-1,1-diyl or ethen-1,2-diyl), propenylene (including all isomeric forms, *e.g.*, 1-propen-1,1-diyl, 1-propen-1,2-diyl, and 1-propen-1,3-diyl), butenylene (including all isomeric forms, *e.g.*, 1-buten-1,1-diyl, 1-buten-1,2-diyl, and 1-buten-1,4-diyl), pentenylene (including all isomeric forms, *e.g.*, 1-penten-1,1-diyl, 1-penten-1,2-diyl, and 1-penten-1,5-diyl), and hexenylene (including all isomeric forms, *e.g.*, 1-hexen-1,1-diyl, 1-hexen-1,2-diyl, and 1-hexen-1,6-diyl).

[0032] The term “alkynyl” refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond(s). The alkynyl is optionally substituted with one or more substituents Q as described herein. For example, C₂₋₆ alkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 4 to 6 carbon atoms. In certain embodiments, the alkynyl is a linear monovalent hydrocarbon radical of 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched monovalent hydrocarbon radical of 4 to 20 (C₄₋₂₀), 4 to 15 (C₄₋₁₅), 4 to 10 (C₄₋₁₀), or 4 to 6 (C₄₋₆) carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (—C≡CH), propynyl (including all isomeric forms, *e.g.*, 1-propynyl (—C≡CCH₃) and propargyl (—CH₂C≡CH)), butynyl (including all isomeric forms, *e.g.*, 1-butyne-1-yl and 2-butyne-1-yl), pentynyl (including all isomeric forms, *e.g.*, 1-pentyne-1-yl and 1-methyl-2-butyne-1-yl), and hexynyl (including all isomeric forms, *e.g.*, 1-hexyne-1-yl and 2-hexyne-1-yl).

[0033] The term “cycloalkyl” refers to a cyclic monovalent hydrocarbon radical, which is

optionally substituted with one or more substituents Q as described herein. In one embodiment, the cycloalkyl is a saturated or unsaturated but non-aromatic, and/or bridged or non-bridged, and/or fused bicyclic group. In certain embodiments, the cycloalkyl has from 3 to 20 (C_{3-20}), from 3 to 15 (C_{3-15}), from 3 to 10 (C_{3-10}), or from 3 to 7 (C_{3-7}) carbon atoms. In one embodiment, the cycloalkyl is monocyclic. In another embodiment, the cycloalkyl is bicyclic. In yet another embodiment, the cycloalkyl is tricyclic. In still another embodiment, the cycloalkyl is polycyclic. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptenyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, decalyl, and adamantyl.

[0034] The terms “cycloalkylene” and “cycloalkanediyl” are used interchangeably herein in reference to a cyclic divalent hydrocarbon radical, which may be optionally substituted with one or more substituents Q as described herein. In one embodiment, cycloalkyl groups may be saturated or unsaturated but non-aromatic, and/or bridged, and/or non-bridged, and/or fused bicyclic groups. In certain embodiments, the cycloalkylene has from 3 to 30 (C_{3-30}), 3 to 20 (C_{3-20}), from 3 to 15 (C_{3-15}), from 3 to 10 (C_{3-10}), or from 3 to 7 (C_{3-10}) carbon atoms. Examples of cycloalkylene groups include, but are not limited to, cyclopropylene (including all isomeric forms, *e.g.*, cycloprop-1,1-diyl and cycloprop-1,2-diyl), cyclobutylene (including all isomeric forms, *e.g.*, cyclobut-1,1-diyl, cyclobut-1,2-diyl, and cyclobut-1,3-diyl), cyclopentylene (including all isomeric forms, *e.g.*, cyclopent-1,1-diyl, cyclopent-1,2-diyl, and cyclopent-1,3-diyl), cyclohexylene (including all isomeric forms, *e.g.*, cyclohex-1,1-diyl, cyclohex-1,2-diyl, cyclohex-1,3-diyl, and cyclohex-1,4-diyl), cycloheptylene (including all isomeric forms, *e.g.*, cyclohept-1,1-diyl, cyclohept-1,2-diyl, cyclohept-1,3-diyl, and cyclohept-1,4-diyl), decalinylene (including all isomeric forms, *e.g.*, decalin-1,1-diyl, decalin-1,2-diyl, and decalin-1,8-diyl), and adamantylene (including all isomeric forms, *e.g.*, adamant-1,2-diyl, adamant-1,3-diyl, and adamant-1,8-diyl).

[0035] The term “aryl” refers to a monovalent monocyclic aromatic hydrocarbon radical and/or monovalent polycyclic aromatic hydrocarbon radical that contain at least one aromatic carbon ring. In certain embodiments, the aryl has from 6 to 20 (C_{6-20}), from 6 to 15 (C_{6-15}), or from 6 to 10 (C_{6-10}) ring carbon atoms. Examples of aryl groups include, but are not limited to,

phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl. The aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). In one embodiment, the aryl is monocyclic. In another embodiment, the aryl is bicyclic. In yet another embodiment, the aryl is tricyclic. In still another embodiment, the aryl is polycyclic. In certain embodiments, the aryl is optionally substituted with one or more substituents Q as described herein.

[0036] The terms “arylene” and “arenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic hydrocarbon radical or divalent polycyclic aromatic hydrocarbon radical that contains at least one aromatic hydrocarbon ring. In certain embodiments, the arylene has from 6 to 20 (C_{6-20}), from 6 to 15 (C_{6-15}), or from 6 to 10 (C_{6-10}) ring atoms. Examples of arylene groups include, but are not limited to, phenylene (including all isomeric forms, *e.g.*, phen-1,2-diyl, phen-1,3-diyl, and phen-1,4-diyl), naphthylene (including all isomeric forms, *e.g.*, naphth-1,2-diyl, naphth-1,3-diyl, and naphth-1,8-diyl), fluorenylene (including all isomeric forms, *e.g.*, fluoren-1,2-diyl, fluoren-1,3-diyl, and fluoren-1,8-diyl), azulenylene (including all isomeric forms, *e.g.*, azulen-1,2-diyl, azulen-1,3-diyl, and azulen-1,8-diyl), anthrylene (including all isomeric forms, *e.g.*, anthr-1,2-diyl, anthr-1,3-diyl, and anthr-1,8-diyl), phenanthrylene (including all isomeric forms, *e.g.*, phenanthr-1,2-diyl, phenanthr-1,3-diyl, and phenanthr-1,8-diyl), pyrenylene (including all isomeric forms, *e.g.*, pyren-1,2-diyl, pyren-1,3-diyl, and pyren-1,8-diyl), biphenylene (including all isomeric forms, *e.g.*, biphen-2,3-diyl, biphen-3,4'-diyl, and biphen-4,4'-diyl), and terphenylene (including all isomeric forms, *e.g.*, terphen-2,3-diyl, terphen-3,4'-diyl, and terphen-4,4'-diyl). Arylene also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthylene (including all isomeric forms, *e.g.*, dihydronaphth-1,2-diyl or dihydronaphth-1,8-diyl), indenylene (including all isomeric forms, *e.g.*, inden-1,2-diyl, inden-1,5-diyl, or inden-1,7-diyl), indanylene (including all isomeric forms, *e.g.*, indan-1,2-diyl, indan-1,5-diyl, or indan-1,7-diyl), or tetrahydronaphthylene (tetralinylene) (including all isomeric forms, *e.g.*, tetrahydronaphth-1,2-diyl, tetrahydronaphth-1,5-diyl, or tetrahydronaphth-1,8-diyl). In certain embodiments, arylene is optionally substituted with one or more substituents Q as described herein.

[0037] The term “aralkyl” or “arylalkyl” refers to a monovalent alkyl group substituted with one or more aryl groups. In certain embodiments, the aralkyl has from 7 to 30 (C₇₋₃₀), from 7 to 20 (C₇₋₂₀), or from 7 to 16 (C₇₋₁₆) carbon atoms. Examples of aralkyl groups include, but are not limited to, benzyl, phenylethyl (including all isomeric forms, *e.g.*, 1-phenylethyl and 2-phenylethyl), and phenylpropyl (including all isomeric forms, *e.g.*, 1-phenylpropyl, 2-phenylpropyl, and 3-phenylpropyl). In certain embodiments, the aralkyl is optionally substituted with one or more substituents Q as described herein.

[0038] The term “heteroaryl” refers to a monovalent monocyclic aromatic group or monovalent polycyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms, each independently selected from O, S, and N, in the ring. The heteroaryl is bonded to the rest of a molecule through the aromatic ring. Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms; provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. In one embodiment, the heteroaryl is monocyclic. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl. In another embodiment, the heteroaryl is bicyclic. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indoliziny, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinoliny, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinoliny, quinoxaliny, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. In yet another embodiment, the heteroaryl is tricyclic. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, the heteroaryl is optionally substituted with one or more substituents Q as described herein.

[0039] The terms “heteroarylene” and “heteroarenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic group or divalent polycyclic aromatic group that contains at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms in the ring, each of which is independently selected from O, S, and N. A heteroarylene group has at least one linkage to the rest of a molecule *via* its aromatic ring(s). Each ring of a heteroarylene group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroarylene has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. Examples of monocyclic heteroarylene groups include, but are not limited to, furanylene, imidazolylene, isothiazolylene, isoxazolylene, oxadiazolylene, oxadiazolylene, oxazolylene, pyrazinylene, pyrazolylene, pyridazinylene, pyridylene, pyrimidinylene, pyrrolylene, thiadiazolylene, thiazolylene, thienylene, tetrazolylene, triazinylene, and triazolylene. Examples of bicyclic heteroarylene groups include, but are not limited to, benzofuranylene, benzimidazolylene, benzoisoxazolylene, benzopyranylene, benzothiadiazolylene, benzothiazolylene, benzothienylene, benzotriazolylene, benzoxazolylene, furopyridylene, imidazopyridinylene, imidazothiazolylene, indolizinylenylene, indolylene, indazolylene, isobenzofuranylene, isobenzothienylene, isoindolylene, isoquinolinylenylene, isothiazolylene, naphthyridinylene, oxazolopyridinylene, phthalazinylene, pteridinylene, purinylene, pyridopyridylene, pyrrolopyridylene, quinolinylenylene, quinoxalinylenylene, quinazolinylenylene, thiadiazolopyrimidinylene, and thienopyridylene. Examples of tricyclic heteroarylene groups include, but are not limited to, acridinylene, benzindolylene, carbazolylene, dibenzofuranylene, perimidinylene, phenanthrolinylenylene, phenanthridinylene, phenarsazinylene, phenazinylene, phenothiazinylene, phenoxazinylene, and xanthenylene. In certain embodiments, heteroarylene is optionally substituted with one or more substituents Q as described herein.

[0040] The term “heterocyclyl” or “heterocyclic” refers to a monovalent monocyclic non-aromatic ring system or monovalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms, each independently selected from O, S, and N; and the remaining ring atoms are carbon atoms. In certain embodiments, the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. The heterocyclyl is bonded to the rest of a molecule through the non-aromatic ring. In certain embodiments, the heterocyclyl is a

monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic. The heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of heterocyclyls and heterocyclic groups include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranlyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, β -carbolinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzothiazinyl, dihydrobenzoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolyl, indolyl, isobenzotetrahydrofuranlyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, the heterocyclyl is optionally substituted with one or more substituents Q as described herein.

[0041] The term “heterocyclylene” refers to a divalent monocyclic non-aromatic ring system or divalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from O, S, and N; and the remaining ring atoms are carbon atoms. Heterocyclylene groups are bonded to the rest of a molecule through the non-aromatic ring. In certain embodiments, the heterocyclylene group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. In certain embodiments, the heterocyclylene is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic. The heterocyclylene may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of such heterocyclylene groups include, but are not limited to, azepinylene, benzodioxanylene, benzodioxolylene, benzofuranonylene, benzopyranonylene, benzopyranylene,

benzotetrahydrofuranylene, benzotetrahydrothienylene, benzothiopyranylene, benzoxazinylene, β -carbolinylene, chromanylene, chromonylene, cinnolinylene, coumarinylene, decahydroisoquinolinylene, dihydrobenzothiazinylene, dihydrobenzoxazinylene, dihydrofurylene, dihydroisoindolylene, dihydropyranylene, dihydropyrazolylene, dihydropyrazinylene, dihydropyridinylene, dihydropyrimidinylene, dihydropyrrolylene, dioxolanylene, 1,4-dithianylene, furanonylene, imidazolidinylene, imidazolinylene, indolinylene, isobenzotetrahydrofuranylene, isobenzotetrahydrothienylene, isochromanylene, isocoumarinylene, isoindolinylene, isothiazolidinylene, isoxazolidinylene, morpholinylene, octahydroindolylene, octahydroisoindolylene, oxazolidinonylene, oxazolidinylene, oxiranylene, piperazinylene, piperidinylene, 4-piperidonylene, pyrazolidinylene, pyrazolinylene, pyrrolidinylene, pyrrolinylene, quinuclidinylene, tetrahydrofurylene, tetrahydroisoquinolinylene, tetrahydropyranylene, tetrahydrothienylene, thiamorpholinylene, thiazolidinylene, tetrahydroquinolinylene, and 1,3,5-trithianylene. In certain embodiments, the heterocyclylene is optionally substituted with one or more substituents Q as described herein.

[0042] The term “halogen”, “halide,” or “halo” refers to fluoro, chloro, bromo, and/or iodo.

[0043] The term “optionally substituted” is intended to mean that a group or substituent, such as an alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene group, may be substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, each of which is independently selected from, *e.g.*, (a) deuterium ($-D$), cyano ($-CN$), halo, nitro ($-NO_2$), and oxo ($=O$); (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a ,

R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a . As used herein, all groups that can be substituted are “optionally substituted.”

[0044] In one embodiment, each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$, $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

[0045] In certain embodiments, “optically active” and “enantiomerically active” refer to a collection of molecules, which has an enantiomeric excess of no less than about 80%, no less than about 90%, no less than about 91%, no less than about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, an optically active compound comprises about 95% or more of one enantiomer and about 5% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 98% or more of one enantiomer and about 2% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 99% or more of one enantiomer and about 1% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.

[0046] In describing an optically active compound, the prefixes *R* and *S* are used to denote the absolute configuration of the compound about its chiral center(s). The (+) and (-) are used to denote the optical rotation of the compound, that is, the direction in which a plane of polarized light is rotated by the optically active compound. The (-) prefix indicates that the compound is levorotatory, that is, the compound rotates the plane of polarized light to the left or counterclockwise. The (+) prefix indicates that the compound is dextrorotatory, that is, the compound rotates the plane of polarized light to the right or clockwise. However, the sign of optical rotation, (+) and (-), is not related to the absolute configuration of the compound, *R* and *S*.

[0047] The term “isotopically enriched” refers to a compound that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a compound. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (^1H), deuterium (^2H), tritium (^3H), carbon-11 (^{11}C), carbon-12 (^{12}C), carbon-13 (^{13}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), fluorine-18 (^{18}F), phosphorus-31 (^{31}P), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-35 (^{35}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-36 (^{36}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), iodine-123 (^{123}I), iodine-125 (^{125}I), iodine-127 (^{127}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). In certain embodiments, an isotopically enriched compound is in a stable form, that is, non-radioactive. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (^1H), deuterium (^2H), carbon-12 (^{12}C), carbon-13 (^{13}C), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), phosphorus-31 (^{31}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), and iodine-127 (^{127}I). In certain embodiments, an isotopically enriched compound is in an unstable form, that is, radioactive. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, tritium (^3H), carbon-11 (^{11}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), fluorine-18 (^{18}F), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-35 (^{35}S), chlorine-36 (^{36}Cl), iodine-123 (^{123}I), iodine-125 (^{125}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). It will be understood that, in a compound as provided herein, any hydrogen can be ^2H , as example,

or any carbon can be ^{13}C , as example, or any nitrogen can be ^{15}N , as example, or any oxygen can be ^{18}O , as example, where feasible according to the judgment of one of ordinary skill in the art.

[0048] The term “isotopic enrichment” refers to the percentage of incorporation of a less prevalent isotope (*e.g.*, D for deuterium or hydrogen-2) of an element at a given position in a molecule in the place of a more prevalent isotope (*e.g.*, ^1H for protium or hydrogen-1) of the element. As used herein, when an atom at a particular position in a molecule is designated as a particular less prevalent isotope, it is understood that the abundance of that isotope at that position is substantially greater than its natural abundance.

[0049] The term “isotopic enrichment factor” refers the ratio of the isotopic abundance in an isotopically enriched compound over the natural abundance of a specific isotope.

[0050] The term “hydrogen” or the symbol “H” refers to the composition of naturally occurring hydrogen isotopes, which include protium (^1H), deuterium (^2H or D), and tritium (^3H), in their natural abundances. Protium is the most common hydrogen isotope having a natural abundance of more than 99.98%. Deuterium is a less prevalent hydrogen isotope having a natural abundance of about 0.0156%.

[0051] The term “deuterium enrichment” refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of 1% at a given position means that 1% of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156% on average, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156% on average. As used herein, when a particular position in an isotopically enriched compound is designated as having deuterium, it is understood that the abundance of deuterium at that position in the compound is substantially greater than its natural abundance (0.0156%).

[0052] The term “carbon” or the symbol “C” refers to the composition of naturally occurring carbon isotopes, which include carbon-12 (^{12}C) and carbon-13 (^{13}C) in their natural abundances. Carbon-12 is the most common carbon isotope having a natural abundance of more than 98.89%. Carbon-13 is a less prevalent carbon isotope having a natural abundance of about

1.11%.

[0053] The term “carbon-13 enrichment” or “ ^{13}C enrichment” refers to the percentage of incorporation of carbon-13 at a given position in a molecule in the place of carbon. For example, carbon-13 enrichment of 10% at a given position means that 10% of molecules in a given sample contain carbon-13 at the specified position. Because the naturally occurring distribution of carbon-13 is about 1.11% on average, carbon-13 enrichment at any position in a compound synthesized using non-enriched starting materials is about 1.11% on average. As used herein, when a particular position in an isotopically enriched compound is designated as having carbon-13, it is understood that the abundance of carbon-13 at that position in the compound is substantially greater than its natural abundance (1.11%).

[0054] The terms “substantially pure” and “substantially homogeneous” mean sufficiently homogeneous to appear free of readily detectable impurities as determined by standard analytical methods used by one of ordinary skill in the art, including, but not limited to, thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance (NMR), and mass spectrometry (MS); or sufficiently pure such that further purification would not detectably alter the physical, chemical, biological, and/or pharmacological properties, such as enzymatic and biological activities, of the substance. In certain embodiments, “substantially pure” or “substantially homogeneous” refers to a collection of molecules, wherein at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% by weight of the molecules are a single compound, including a single enantiomer, a racemic mixture, or a mixture of enantiomers, as determined by a standard analytical method. As used herein, when an atom at a particular position in an isotopically enriched molecule is designated as a particular less prevalent isotope, a molecule that contains other than the designated isotope at the specified position is an impurity with respect to the isotopically enriched compound. Thus, for a deuterated compound that has an atom at a particular position designated as deuterium, a compound that contains a protium at the same position is an impurity.

[0055] The term “solvate” refers to a complex or aggregate formed by one or more molecules of a solute, *e.g.*, a compound provided herein, and one or more molecules of a solvent,


which are present in a stoichiometric or non-stoichiometric amount. Suitable solvents include, but are not limited to, water, methanol, ethanol, *n*-propanol, isopropanol, and acetic acid. In certain embodiments, the solvent is pharmaceutically acceptable. In one embodiment, the complex or aggregate is in a crystalline form. In another embodiment, the complex or aggregate is in a noncrystalline form. Where the solvent is water, the solvate is a hydrate. Examples of hydrates include, but are not limited to, a hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and pentahydrate.

[0056] For a divalent group described herein, no orientation is implied by the direction in which the divalent group is presented. For example, unless a particular orientation is specified, the formula $-C(O)NH-$ represents both $-C(O)NH-$ and $-NHC(O)-$.

[0057] The phrase “an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof” has the same meaning as the phrase “(i) an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant of the compound referenced therein; (ii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of the compound referenced therein; or (iii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant of the compound referenced therein.”

Compounds

[0058] In one embodiment, provided herein is a compound of Formula (I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or heteroaryl; wherein R^{2a} , R^{2b} , and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3 , R^4 , R^5 , and R^6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

R^A is C_{6-14} arylene or heteroarylene;

R^B is C_{6-14} aryl or heteroaryl;

R^B and X are (i), (ii), or (iii):

(iv) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is C_{6-14} aryl or heteroaryl;

(v) X is $-N(R^X)-$;

R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or

(vi) X is $-N(R^X)-$; and

R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl;

L is C_{1-6} alkylene, C_{2-6} alkenylene, C_{3-10} cycloalkylene, or heterocyclylene; and


each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl,

cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a; and (c) -C(O)R^a, -C(O)OR^a, -C(O)NR^bR^c, -C(O)SR^a, -C(NR^a)NR^bR^c, -C(S)R^a, -C(S)OR^a, -C(S)NR^bR^c, -OR^a, -OC(O)R^a, -OC(O)OR^a, -OC(O)NR^bR^c, -OC(O)SR^a, -OC(NR^a)NR^bR^c, -OC(S)R^a, -OC(S)OR^a, -OC(S)NR^bR^c, -OS(O)R^a, -OS(O)₂R^a, -OS(O)NR^bR^c, -OS(O)₂NR^bR^c, -NR^bR^c, -NR^aC(O)R^d, -NR^aC(O)OR^d, -NR^aC(O)NR^bR^c, -NR^aC(O)SR^d, -NR^aC(NR^d)NR^bR^c, -NR^aC(S)R^d, -NR^aC(S)OR^d, -NR^aC(S)NR^bR^c, -NR^aS(O)R^d, -NR^aS(O)₂R^d, -NR^aS(O)NR^bR^c, -NR^aS(O)₂NR^bR^c, -SR^a, -S(O)R^a, -S(O)₂R^a, -S(O)NR^bR^c, and -S(O)₂NR^bR^c, wherein each R^a, R^b, R^c, and R^d is independently (i) hydrogen or deuterium; (ii) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, and heterocyclyl; and (c) -C(O)R^e, -C(O)OR^e, -C(O)NR^fR^g, -C(O)SR^e, -C(NR^e)NR^fR^g, -C(S)R^e, -C(S)OR^e, -C(S)NR^fR^g, -OR^e, -OC(O)R^e, -OC(O)OR^e, -OC(O)NR^fR^g, -OC(O)SR^e, -OC(NR^e)NR^fR^g, -OC(S)R^e, -OC(S)OR^e, -OC(S)NR^fR^g, -OS(O)R^e, -OS(O)₂R^e, -OS(O)NR^fR^g, -OS(O)₂NR^fR^g, -NR^fR^g, -NR^eC(O)R^h, -NR^eC(O)OR^f, -NR^eC(O)NR^fR^g, -NR^eC(O)SR^f, -NR^eC(NR^h)NR^fR^g, -NR^eC(S)R^h, -NR^eC(S)OR^f, -NR^eC(S)NR^fR^g, -NR^eS(O)R^h, -NR^eS(O)₂R^h, -NR^eS(O)NR^fR^g, -NR^eS(O)₂NR^fR^g, -SR^e, -S(O)R^e, -S(O)₂R^e, -S(O)NR^fR^g, and -S(O)₂NR^fR^g; wherein each R^e, R^f, R^g, and R^h is independently (i) hydrogen or deuterium; (ii) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

[0059] In another embodiment, provided herein is a compound of Formula (II):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^A , R^B , L , and X are each as defined herein.

[0060] In one embodiment, in Formula (I) or (II),

R^1 is halo or C_{1-6} alkyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or heteroaryl, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^A is C_{6-14} arylene or heteroarylene;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is C_{6-14} aryl or heteroaryl;

(ii) X is $-NR^X-$;

R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl; and

L is C_{1-6} alkylene, C_{2-6} alkenylene, or C_{3-10} cycloalkylene;

wherein each alkyl, alkylene, alkenylene, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[0061] In another embodiment, in Formula (I) or (II),

R^1 is halo or C_{1-6} alkyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or monocyclic heteroaryl, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^A is C_{6-14} arylene or monocyclic heteroarylene;
 R^B and X are (i), (ii), or (iii):
 (i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and
 R^B is C_{6-14} aryl or heteroaryl;
 (ii) X is $-NR^X-$;
 R^B is C_{6-14} aryl or heteroaryl; and
 R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
 (iii) X is $-NR^X-$; and
 R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl; and
 L is C_{1-6} alkylene or C_{2-6} alkenylene;
 wherein each alkyl, alkylene, alkenylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[0062] In yet another embodiment, in Formula (I) or (II),
 R^1 is C_{1-6} alkyl;
 R^2 is $-C(O)OH$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or 5-membered heteroaryl, wherein each R^{2b} and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;
 R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^5 and R^6 are each independently hydrogen or deuterium;
 R^A is C_{6-14} arylene or 6-membered heteroarylene;
 R^B and X are (i), (ii), or (iii):
 (i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and
 R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl;
 (ii) X is $-NR^X-$;

R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl; and

L is C_{1-6} alkylene or C_{2-6} alkenylene;

wherein each alkyl, alkylene, alkenylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[0063] In yet another embodiment, in Formula (I) or (II),

R^1 is methyl;

R^2 is $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, $-C(O)NHOH$, $-C(O)NH(tetrazolyl)$, tetrazolyl, or 1,2,4-oxadiazolyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^A is phenylene, chloro-phenylene, methoxy-phenylene, pyridylene, or methyl-pyridylene;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny;

(ii) X is $-NR^X-$;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny; and

R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl; and

L is methylene, ethylene, or ethenylene.

[0064] In still another embodiment, in Formula (I) or (II),

R^1 is methyl;

R^2 is $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, $-C(O)NHOH$, $-C(O)NH(tetrazol-5-yl)$, tetrazol-5-yl, or 1,2,4-oxadiazol-5-yl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^A is phen-1,3-diyl, phen-1,4-diyl, 2-chloro-phen-1,4-diyl, 2-methoxy-phen-1,4-diyl, pyrid-2,5-diyl, or 3-methyl-pyrid-2,5-diyl;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

(ii) X is $-NR^X-$;


R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-

fluorophenyl, 4-formylphenyl, or benzyl; or

(iii) X is $-\text{NR}^{\text{X}}-$; and

R^{B} and R^{X} together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl; and L is methylene, ethan-1,2-diyl, or ethen-1,2-diyl.

[0065] In yet another embodiment, provided herein is a compound of Formula (III):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

U^1 , V^1 , W^1 , and X^1 are each independently (i) C or N; or (ii) $-\text{CR}^{7\text{a}}=$, $-\text{N}=$, $-\text{NR}^{7\text{b}}-$, $-\text{O}-$, or $-\text{S}-$;

Y^1 is (i) C or N; or (ii) a bond, $-\text{CR}^{7\text{a}}=$, $-\text{N}=$, $-\text{NR}^{7\text{b}}-$, $-\text{O}-$, or $-\text{S}-$;

Z^1 is C or N;

each $\text{R}^{7\text{a}}$ is independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-\text{C}(\text{O})\text{R}^{1\text{a}}$, $-\text{C}(\text{O})\text{OR}^{1\text{a}}$, $-\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{R}^{1\text{a}}$, $-\text{OC}(\text{O})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})\text{R}^{1\text{a}}$, $-\text{OS}(\text{O})_2\text{R}^{1\text{a}}$, $-\text{OS}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{OR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{NR}^{1\text{d}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})_2\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{SR}^{1\text{a}}$, $-\text{S}(\text{O})\text{R}^{1\text{a}}$, $-\text{S}(\text{O})_2\text{R}^{1\text{a}}$, $-\text{S}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, or $-\text{S}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$;


each $\text{R}^{7\text{b}}$ is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^{B} , $\text{R}^{1\text{a}}$, $\text{R}^{1\text{b}}$, $\text{R}^{1\text{c}}$, $\text{R}^{1\text{d}}$, L, and X are each as defined herein;

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and


heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[0066] In yet another embodiment, provided herein is a compound of Formula (IV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^B , L , X , U^1 , V^1 , W^1 , X^1 , Y^1 , and Z^1 are each as defined herein.

[0067] In yet another embodiment, provided herein is a compound of Formula (V):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:


U^1 , V^1 , and X^1 are each independently $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$;

W^1 is C or N;

Y^1 is a bond, $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$; and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^B , R^{7a} , R^{7b} , L , X , and Z^1 are each as defined herein.

[0068] In yet another embodiment, provided herein is a compound of Formula (VI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:


U^1 , V^1 , and X^1 are each independently $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$;

W^1 is C or N;

Y^1 is a bond, $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$; and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^B , R^{7a} , R^{7b} , L , X , and Z^1 are each as defined herein.

[0069] In yet another embodiment, provided herein is a compound of Formula (VII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:


U^1 , W^1 , and X^1 are each independently $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$;

V^1 is C or N;

Y^1 is a bond, $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$; and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^B , R^{7a} , R^{7b} , L , X , and Z^1 are each as defined herein.

[0070] In yet another embodiment, provided herein is a compound of Formula (VIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:


U^1 , W^1 , and X^1 are each independently $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$;

V^1 is C or N;

Y^1 is a bond, $-CR^{7a}=$, $-N=$, $-NR^{7b}-$, $-O-$, or $-S-$; and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^B , R^{7a} , R^{7b} , L , X , and Z^1 are each as defined herein.

[0071] In yet another embodiment, provided herein is a compound of Formula (IX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:


each R^7 is independently (a) deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

1. n is an integer of 0, 1, 2, 3, or 4; and

$R^1, R^2, R^3, R^4, R^5, R^6, R^B, R^{1a}, R^{1b}, R^{1c}, R^{1d}, L$, and X are each as defined herein;


wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q .

[0072] In yet another embodiment, provided herein is a compound of Formula (X):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^B, L, X$, and n are each as defined herein.

[0073] In yet another embodiment, provided herein is a compound of Formula (XI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^B, L, X$, and n are each as defined herein.

[0074] In yet another embodiment, provided herein is a compound of Formula (XII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^{7a} , R^B , L , and X are each as defined herein.

[0075] In yet another embodiment, provided herein is a compound of Formula (XIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , L , X , and n are each as defined herein.

[0076] In one embodiment, in any one of Formulae (IX) to (XI) and (XIII),

R^1 is halo or C_{1-6} alkyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or heteroaryl, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is C_{6-14} aryl or heteroaryl;

- (ii) X is $-\text{NR}^{\text{X}}-$;
 R^{B} is C_{6-14} aryl or heteroaryl; and
 R^{X} is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
 (iii) X is $-\text{NR}^{\text{X}}-$; and
 R^{B} and R^{X} together with the N atom to which they are attached form
 heteroaryl or heterocyclyl;

L is C_{1-6} alkylene, C_{2-6} alkenylene, or C_{3-10} cycloalkylene; and

n is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, alkylene, alkenylene, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[0077] In another embodiment, in any one of Formulae (IX) to (XI) and (XIII),

R^1 is halo or C_{1-6} alkyl;

R^2 is $-\text{C}(\text{O})\text{OR}^{2\text{a}}$, $-\text{C}(\text{O})\text{NR}^{2\text{b}}\text{R}^{2\text{c}}$, $-\text{C}(\text{O})\text{N}(\text{R}^{2\text{b}})\text{OR}^{2\text{c}}$, or monocyclic heteroaryl,

wherein each $\text{R}^{2\text{a}}$, $\text{R}^{2\text{b}}$, and $\text{R}^{2\text{c}}$ is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^7 is deuterium, halo, or $-\text{O}-\text{C}_{1-6}$ alkyl;

R^{B} and X are (i), (ii), or (iii):

- (i) X is $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$; and

R^{B} is C_{6-14} aryl or heteroaryl;

- (ii) X is $-\text{NR}^{\text{X}}-$;

R^{B} is C_{6-14} aryl or heteroaryl; and

R^{X} is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

- (iii) X is $-\text{NR}^{\text{X}}-$; and

R^{B} and R^{X} together with the N atom to which they are attached form
 heteroaryl or heterocyclyl;

L is C_{1-6} alkylene or C_{2-6} alkenylene; and

n is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^{a} ; and (iii) $-\text{C}(\text{O})\text{R}^{\text{a}}$, $-\text{OR}^{\text{a}}$, and $-\text{NR}^{\text{b}}\text{R}^{\text{c}}$, where each

R^a , R^b , and R^c is as defined herein.

[0078] In yet another embodiment, in any one of Formulae (IX) to (XI) and (XIII),
 R^1 is C_{1-6} alkyl;
 R^2 is $-C(O)OH$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or 5-membered heteroaryl,
 wherein each R^{2b} and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;
 R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^5 and R^6 are each independently hydrogen or deuterium;
 R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B and X are (i), (ii), or (iii):
 (i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and
 R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl;
 (ii) X is $-NR^X-$;
 R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl; and
 R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
 (iii) X is $-NR^X-$; and
 R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
 L is C_{1-6} alkylene or C_{2-6} alkenylene; and
 n is an integer of 0, 1, or 2;
 wherein each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q , each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[0079] In yet another embodiment, in any one of Formulae (IX) to (XI) and (XIII),
 R^1 is methyl;
 R^2 is $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, $-C(O)NHOH$, $-C(O)NH$ (tetrazolyl), tetrazolyl, or 1,2,4-oxadiazolyl;
 R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolyl;

(ii) X is $-NR^X-$;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolyl; and

R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form pyrrolidiny, piperidiny, morpholiny, pyrroly, amino-imidazolyl, or indolyl;

L is methylene, ethylene, or ethenylene; and

n is an integer of 0 or 1.

[0080] In still another embodiment, in any one of Formulae (IX) to (XI) and (XIII),

R^1 is methyl;

R^2 is $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, $-C(O)NHOH$, $-C(O)NH(tetrazol-5-yl)$, tetrazol-5-yl, or 1,2,4-oxadiazol-5-yl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-

cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

(ii) X is $-\text{NR}^{\text{X}}-$;

R^{B} is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R^{X} is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or

(iii) X is $-\text{NR}^{\text{X}}-$; and

R^{B} and R^{X} together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl;

L is methylene, ethan-1,2-diyl, or ethen-1,2-diyl; and

n is an integer of 0 or 1.

[0081] In one embodiment, in Formula (XII),

R^1 is halo or C_{1-6} alkyl;

R^2 is $-\text{C}(\text{O})\text{OR}^{2\text{a}}$, $-\text{C}(\text{O})\text{NR}^{2\text{b}}\text{R}^{2\text{c}}$, $-\text{C}(\text{O})\text{N}(\text{R}^{2\text{b}})\text{OR}^{2\text{c}}$, or heteroaryl, wherein each $\text{R}^{2\text{a}}$, $\text{R}^{2\text{b}}$, and $\text{R}^{2\text{c}}$ is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

$\text{R}^{7\text{a}}$ is hydrogen, deuterium, halo, or $-\text{O}-\text{C}_{1-6}$ alkyl;

R^{B} and X are (i), (ii), or (iii):

(i) X is $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$; and

R^{B} is C_{6-14} aryl or heteroaryl;

(ii) X is $-\text{NR}^{\text{X}}-$;

R^{B} is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl; and

L is C_{1-6} alkylene, C_{2-6} alkenylene, or C_{3-10} cycloalkylene;

wherein each alkyl, alkylene, alkenylene, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[0082] In another embodiment, in Formula (XII),

R^1 is halo or C_{1-6} alkyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or monocyclic heteroaryl,

wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is C_{6-14} aryl or heteroaryl;

(ii) X is $-NR^X-$;

R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl; and

L is C_{1-6} alkylene or C_{2-6} alkenylene;

wherein each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[0083] In yet another embodiment, in Formula (XII),

R^1 is C_{1-6} alkyl;

R^2 is $-C(O)OH$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or 5-membered heteroaryl, wherein each R^{2b} and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl;

(ii) X is $-NR^X-$;

R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl; and

L is C_{1-6} alkylene or C_{2-6} alkenylene;

wherein each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[0084] In yet another embodiment, in Formula (XII),

R^1 is methyl;

R^2 is $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, $-C(O)NHOH$, $-C(O)NH$ (tetrazolyl), tetrazolyl, or 1,2,4-oxadiazolyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;

(ii) X is $-NR^X-$;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and

R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or

(iii) X is $-NR^X-$; and

R^B and R^X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl; and

L is methylene, ethylene, or ethenylene.

[0085] In still another embodiment, in Formula (XII),

R^1 is methyl;

R^2 is $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, $-C(O)NHOH$, $-C(O)NH(tetrazol-5-yl)$, tetrazol-5-yl, or 1,2,4-oxadiazol-5-yl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;


R^B and X are (i), (ii), or (iii):

(i) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

- (ii) X is $-\text{NR}^{\text{X}}-$;
 R^{B} is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and
 R^{X} is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
- (iii) X is $-\text{NR}^{\text{X}}-$; and
 R^{B} and R^{X} together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl; and
L is methylene, ethan-1,2-diyl, or ethen-1,2-diyl.

[0086] In yet another embodiment, provided herein is a compound of Formula (XIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

$\text{R}^{2\text{A}}$ is $-\text{OR}^{2\text{a}}$, $-\text{NR}^{2\text{b}}\text{R}^{2\text{c}}$, or $-\text{N}(\text{R}^{2\text{b}})\text{OR}^{2\text{c}}$;

p is an integer of 1, 2, or 3; and


R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^{B} , $\text{R}^{2\text{a}}$, $\text{R}^{2\text{b}}$, $\text{R}^{2\text{c}}$, and *n* are each as defined herein.

[0087] In yet another embodiment, provided herein is a compound of Formula (XV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^{2A} , n , and p are each as defined herein.

[0088] In yet another embodiment, provided herein is a compound of Formula (XVI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^{2A} , n , and p are each as defined herein.


[0089] In yet another embodiment, provided herein is a compound of Formula (XVII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more

diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^{7a} , R^B , R^{2A} , and p are each as defined herein.

[0090] In yet another embodiment, provided herein is a compound of Formula (XVIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^{2A} , n , and p are each as defined herein.

[0091] In one embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R^1 is halo or C_{1-6} alkyl;

R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B is C_{6-14} aryl or heteroaryl;

n is an integer of 0, 1, 2, 3, or 4; and

p is an integer of 1, 2, or 3;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q .

[0092] In another embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R^1 is halo or C_{1-6} alkyl;

R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B is C_{6-14} aryl or heteroaryl;

n is an integer of 0, 1, 2, 3, or 4; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q , each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[0093] In yet another embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R^1 is C_{1-6} alkyl;

R^{2A} is $-OH$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2b} and R^{2c} is

independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl;

n is an integer of 0, 1, or 2; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q , each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[0094] In yet another embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R^1 is methyl;

R^{2A} is $-OH$, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, $-NHOH$, or $-NH(\text{tetrazolyl})$;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-

fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[0095] In yet another embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R¹ is methyl;

R^{2A} is -OH, -NH₂, -NHCH₃, -NHCH₂CH₂OH, -NHOH, or -NH(tetrazolyl);

R³ and R⁴ are each independently hydrogen, deuterium, fluoro, or methyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R⁷ is chloro or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[0096] In yet another embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R¹ is methyl;

R^{2A} is -OH, -NH₂, -NHCH₃, -NHCH₂CH₂OH, -NHOH, or -NH(tetrazol-5-yl);

R³ and R⁴ are each independently hydrogen, deuterium, fluoro, or methyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R⁷ is chloro or methoxy;

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[0097] In still another embodiment, in any one of Formulae (XIV) to (XVI) and (XVIII),

R^1 is methyl;

R^{2A} is $-OH$, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, $-NHOH$, or $-NH(tetrazol-5-yl)$;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[0098] In one embodiment, in Formula (XVII),

R^1 is halo or C_{1-6} alkyl;

R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B is C_{6-14} aryl or heteroaryl; and

p is an integer of 1, 2, or 3;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.

[0099] In another embodiment, in Formula (XVII),

R^1 is halo or C_{1-6} alkyl;

R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B is C_{6-14} aryl or heteroaryl; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or

three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C₁₋₆ alkyl optionally substituted with one or more substituents Q^a; and (iii) -C(O)R^a, -OR^a, and -NR^bR^c, where each R^a, R^b, and R^c is as defined herein.

[00100] In yet another embodiment, in Formula (XVII),

R¹ is C₁₋₆ alkyl;

R^{2A} is -OH, -NR^{2b}R^{2c}, or -N(R^{2b})OR^{2c}, wherein each R^{2b} and R^{2c} is

independently hydrogen, C₁₋₆ alkyl, or heteroaryl;

R³ and R⁴ are each independently hydrogen, deuterium, halo, or C₁₋₆ alkyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, halo, or -O-C₁₋₆ alkyl;

R^B is monocyclic or bicyclic C₆₋₁₄ aryl, or monocyclic or bicyclic heteroaryl; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00101] In yet another embodiment, in Formula (XVII),

R¹ is methyl;

R^{2A} is -OH, -NH₂, -NHCH₃, -NHCH₂CH₂OH, -NHOH, or -NH(tetrazolyl);

R³ and R⁴ are each independently hydrogen, deuterium, fluoro, or methyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny; and

p is an integer of 1 or 2.

[00102] In yet another embodiment, in Formula (XVII),

R¹ is methyl;

R^{2A} is -OH, -NH₂, -NHCH₃, -NHCH₂CH₂OH, -NHOH, or -NH(tetrazolyl);

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and p is an integer of 1 or 2.

[00103] In yet another embodiment, in Formula (XVII),

R^1 is methyl;

R^{2A} is $-OH$, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, $-NHOH$, or $-NH(tetrazol-5-yl)$;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and

p is an integer of 1 or 2.

[00104] In still another embodiment, in Formula (XVII),

R^1 is methyl;

R^{2A} is $-OH$, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, $-NHOH$, or $-NH(tetrazol-5-yl)$;

R^3 , R^5 , and R^6 are each independently hydrogen or deuterium;


R^4 is hydrogen, deuterium, or fluoro;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and


p is an integer of 1 or 2.

[00105] In yet another embodiment, provided herein is a compound of Formula (XIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , R^{2A} , n , and p are each as defined herein.

[00106] In yet another embodiment, provided herein is a compound of Formula (XX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , R^{2A} , n , and p are each as defined herein.

[00107] In yet another embodiment, provided herein is a compound of Formula (XXI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , R^{2A} , n , and p are each as defined herein.

[00108] In yet another embodiment, provided herein is a compound of Formula (XXII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^{7a} , R^B , R^X , R^{2A} , and p are each as defined herein.

[00109] In yet another embodiment, provided herein is a compound of Formula (XXIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , R^{2A} , n , and p are each as defined herein.

[00110] In one embodiment, in any one of Formulae (XIX) to (XXI) and (XXIII),
 R^1 is halo or C_{1-6} alkyl;
 R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B and R^X are (i) or (ii):
 (i) R^B is C_{6-14} aryl or heteroaryl; and
 R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
 (ii) R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl;
 n is an integer of 0, 1, 2, 3, or 4; and
 p is an integer of 1, 2, or 3;
 wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[00111] In another embodiment, in any one of Formulae (XIX) to (XXI) and (XXIII),
 R^1 is halo or C_{1-6} alkyl;
 R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B and R^X are (i) or (ii):
 (i) R^B is C_{6-14} aryl or heteroaryl; and
 R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
 (ii) R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl;

n is an integer of 0, 1, 2, 3, or 4; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C₁₋₆ alkyl optionally substituted with one or more substituents Q^a; and (iii) -C(O)R^a, -OR^a, and -NR^bR^c, where each R^a, R^b, and R^c is as defined herein.

[00112] In yet another embodiment, in any one of Formulae (XIX) to (XXI) and (XXIII),

R¹ is C₁₋₆ alkyl;

R^{2A} is -OH, -NR^{2b}R^{2c}, or -N(R^{2b})OR^{2c}, wherein each R^{2b} and R^{2c} is independently hydrogen, C₁₋₆ alkyl, or heteroaryl;

R³ and R⁴ are each independently hydrogen, deuterium, halo, or C₁₋₆ alkyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R⁷ is deuterium, halo, or -O-C₁₋₆ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is monocyclic or bicyclic C₆₋₁₄ aryl, or monocyclic or bicyclic heteroaryl; and

R^X is hydrogen, C₁₋₆ alkyl, C₆₋₁₄ aryl, or C₇₋₁₅ aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;

n is an integer of 0, 1, or 2; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00113] In yet another embodiment, in any one of Formulae (XIX) to (XXI) and (XXIII),

R¹ is methyl;

R^{2A} is -OH, -NH₂, -NHCH₃, -NHCH₂CH₂OH, -NHOH, or -NH(tetrazolyl);

R³ and R⁴ are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny; and R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form pyrrolidiny, piperidiny, morpholiny, pyrroly, amino-imidazolyl, or indolyl;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00114] In still another embodiment, in any one of Formulae (XIX) to (XXI) and (XXIII),

R^1 is methyl;

R^{2A} is $-OH$, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, $-NHOH$, or $-NH(tetrazol-5-yl)$;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-

1-yl, or 4-morpholin-4-yl;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00115] In one embodiment, in Formula (XXII),

R^1 is halo or C_{1-6} alkyl;

R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl; and

p is an integer of 1, 2, or 3;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[00116] In another embodiment, in Formula (XXII),

R^1 is halo or C_{1-6} alkyl;

R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen, C_{1-6} alkyl, or heteroaryl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally

substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C₁₋₆ alkyl optionally substituted with one or more substituents Q^a; and (iii) -C(O)R^a, -OR^a, and -NR^bR^c, where each R^a, R^b, and R^c is as defined herein.

[00117] In yet another embodiment, in Formula (XXII),

R¹ is C₁₋₆ alkyl;

R^{2A} is -OH, -NR^{2b}R^{2c}, or -N(R^{2b})OR^{2c}, wherein each R^{2b} and R^{2c} is independently hydrogen, C₁₋₆ alkyl, or heteroaryl;

R³ and R⁴ are each independently hydrogen, deuterium, halo, or C₁₋₆ alkyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, halo or -O-C₁₋₆ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is monocyclic or bicyclic C₆₋₁₄ aryl, or monocyclic or bicyclic heteroaryl; and

R^X is hydrogen, C₁₋₆ alkyl, C₆₋₁₄ aryl, or C₇₋₁₅ aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00118] In yet another embodiment, in Formula (XXII),

R¹ is methyl;

R^{2A} is -OH, -NH₂, -NHCH₃, -NHCH₂CH₂OH, -NHOH, or -NH(tetrazolyl);

R³ and R⁴ are each independently hydrogen, deuterium, fluoro, or methyl;

R⁵ and R⁶ are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolyl; and R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl; and

p is an integer of 1 or 2.

[00119] In still another embodiment, in Formula (XXII),

R^1 is methyl;

R^{2A} is $-OH$, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, $-NHOH$, or $-NH(tetrazol-5-yl)$;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;


R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl; and

p is an integer of 1 or 2.

[00120] In yet another embodiment, provided herein is a compound of Formula (XXIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

U^2 is $-N=$ or $-O-$;

V^2 is $-N=$ or $-C(OH)=$; and


R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , n , and p are each as defined herein.

[00121] In yet another embodiment, provided herein is a compound of Formula (XXV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , U^2 , V^2 , n , and p are each as defined herein.

[00122] In yet another embodiment, provided herein is a compound of Formula (XXVI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , U^2 , V^2 , n , and p are each as defined herein.

[00123] In yet another embodiment, provided herein is a compound of Formula (XXVII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^{7a} , R^B , U^2 , V^2 , and p are each as defined herein.

[00124] In yet another embodiment, provided herein is a compound of Formula (XXVIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more

diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , U^2 , V^2 , n , and p are each as defined herein.

[00125] In one embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),
 R^1 is halo or C_{1-6} alkyl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B is C_{6-14} aryl or heteroaryl;
 U^2 is $-N=$ or $-O-$;
 V^2 is $-N=$ or $-C(OH)=$;
 n is an integer of 0, 1, 2, 3, or 4; and
 p is an integer of 1, 2, or 3;
 wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.

[00126] In another embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),
 R^1 is halo or C_{1-6} alkyl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B is C_{6-14} aryl or heteroaryl;
 U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;
 n is an integer of 0, 1, 2, 3, or 4; and
 p is an integer of 1 or 2;
 wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[00127] In yet another embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),
 R^1 is C_{1-6} alkyl;

R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0, 1, or 2; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q , each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00128] In yet another embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00129] In yet another embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl,

trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00130] In yet another embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00131] In still another embodiment, in any one of Formulae (XXIV) to (XXVI) and (XXVIII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00132] In one embodiment, in Formula (XXVII),
 R^1 is halo or C_{1-6} alkyl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B is C_{6-14} aryl or heteroaryl;
 U^2 is $-N=$ or $-O-$;
 V^2 is $-N=$ or $-C(OH)=$; and
 p is an integer of 1, 2, or 3;
 wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.

[00133] In another embodiment, in Formula (XXVII),
 R^1 is halo or C_{1-6} alkyl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B is C_{6-14} aryl or heteroaryl;
 U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and
 p is an integer of 1 or 2;
 wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[00134] In yet another embodiment, in Formula (XXVII),
 R^1 is C_{1-6} alkyl;
 R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^5 and R^6 are each independently hydrogen or deuterium;
 R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00135] In yet another embodiment, in Formula (XXVII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is chloro or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2.

[00136] In yet another embodiment, in Formula (XXVII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is chloro or methoxy;

R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2.

[00137] In yet another embodiment, in Formula (XXVII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2.

[00138] In still another embodiment, in Formula (XXVII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;


R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2.


[00139] In yet another embodiment, provided herein is a compound of Formula (XXIX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 ,


R^6 , R^7 , R^B , R^X , U^2 , V^2 , n , and p are each as defined herein.

[00140] In yet another embodiment, provided herein is a compound of Formula (XXX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , U^2 , V^2 , n , and p are each as defined herein.

[00141] In yet another embodiment, provided herein is a compound of Formula (XXXI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , U^2 , V^2 , n , and p are each as defined herein.

[00142] In yet another embodiment, provided herein is a compound of Formula (XXXII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^{7a} , R^B , R^X , U^2 , V^2 , and p are each as defined herein.

[00143] In still another embodiment, provided herein is a compound of Formula (XXXIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^B , R^X , U^2 , V^2 , n , and p are each as defined herein.

[00144] In one embodiment, in any one of Formulae (XXIX) to (XXXI) and (XXXIII), R^1 is halo or C_{1-6} alkyl;
 R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;
 R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;
 R^B and R^X are (i) or (ii):
 (i) R^B is C_{6-14} aryl or heteroaryl; and
 R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
 (ii) R^B and R^X together with the N atom to which they are attached form

heteroaryl or heterocyclyl;

U^2 is $-N=$ or $-O-$;

V^2 is $-N=$ or $-C(OH)=$;

n is an integer of 0, 1, 2, 3, or 4; and

p is an integer of 1, 2, or 3;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[00145] In another embodiment, in any one of Formulae (XXIX) to (XXXI) and (XXXIII),

R^1 is halo or C_{1-6} alkyl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0, 1, 2, 3, or 4; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[00146] In yet another embodiment, in any one of Formulae (XXIX) to (XXXI) and (XXXIII),

R^1 is C_{1-6} alkyl;

R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0, 1, or 2; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00147] In yet another embodiment, in any one of Formulae (XXIX) to (XXXI) and (XXXIII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B and R^X are (i) or (ii):

(i) R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or

(ii) R^B and R^X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00148] In still another embodiment, in any one of Formulae (XXIX) to (XXXI) and (XXXIII),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^7 is chloro or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$;

n is an integer of 0 or 1; and

p is an integer of 1 or 2.

[00149] In one embodiment, in Formula (XXX),

R^1 is halo or C_{1-6} alkyl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

- (i) R^B is C_{6-14} aryl or heteroaryl; and R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form

heteroaryl or heterocyclyl;

U^2 is $-N=$ or $-O-$;

V^2 is $-N=$ or $-C(OH)=$; and

p is an integer of 1, 2, or 3;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q .

[00150] In another embodiment, in Formula (XXX),

R^1 is halo or C_{1-6} alkyl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

(ii) R^B and R^X together with the N atom to which they are attached form

heteroaryl or heterocyclyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q , each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-C(O)R^a$, $-OR^a$, and $-NR^bR^c$, where each R^a , R^b , and R^c is as defined herein.

[00151] In yet another embodiment, in Formula (XXX),

R^1 is C_{1-6} alkyl;

R^3 and R^4 are each independently hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl;

R^B and R^X are (i) or (ii):

(i) R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl; or

- (ii) R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2;

wherein each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.

[00152] In yet another embodiment, in Formula (XXX),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny; and R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or

- (ii) R^B and R^X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2.

[00153] In still another embodiment, in Formula (XXX),

R^1 is methyl;

R^3 and R^4 are each independently hydrogen, deuterium, fluoro, or methyl;

R^5 and R^6 are each independently hydrogen or deuterium;

R^{7a} is hydrogen, deuterium, chloro, or methoxy;

R^B and R^X are (i) or (ii):

- (i) R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
- (ii) R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl;

U^2 and V^2 are each $-N=$; or U^2 is $-O-$ and V^2 is $-C(OH)=$; and

p is an integer of 1 or 2.

[00154] The groups, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^{2A} , R^{7a} , R^A , R^B , R^X , L , X , U^1 , V^1 , W^1 , X^1 , Y^1 , Z^1 , U^2 , V^2 , n , and p , in formulae described herein, including Formulae (I) to (XXXIII), are further defined in the embodiments described herein. All combinations of the embodiments provided herein for such groups are within the scope of this disclosure.

[00155] In certain embodiments, R^1 is hydrogen. In certain embodiments, R^1 is deuterium. In certain embodiments, R^1 is cyano. In certain embodiments, R^1 is halo. In certain embodiments, R^1 is fluoro or chloro. In certain embodiments, R^1 is nitro. In certain embodiments, R^1 is C_{1-6} alkyl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is methyl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is methyl. In certain embodiments, R^1 is C_{2-6} alkenyl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is C_{2-6} alkynyl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is C_{6-14} aryl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is C_{7-15} aralkyl, optionally substituted with one or more substituents Q . In certain embodiments, R^1 is

heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^1 is heterocyclyl, optionally substituted with one or more substituents Q.

[00156] In certain embodiments, R^2 is $-C(O)OR^{2a}$, wherein R^{2a} is as defined herein. In certain embodiments, R^2 is $-C(O)OH$. In certain embodiments, R^2 is $-C(O)O-C_{1-6}$ alkyl, wherein the alkyl is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NR^{2b}R^{2c}$, wherein R^{2b} and R^{2c} are each as defined herein. In certain embodiments, R^2 is $-C(O)NR^{2b}R^{2c}$, wherein R^{2b} and R^{2c} are each independently (i) hydrogen; or (ii) C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NR^{2b}R^{2c}$, wherein R^{2b} and R^{2c} are each independently (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NHR^{2c}$, wherein R^{2c} is as defined herein. In certain embodiments, R^2 is $-C(O)NHR^{2c}$, wherein R^{2c} is (i) hydrogen; or (ii) C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NHR^{2c}$, wherein R^{2c} is (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2CH_2OH$, or $-C(O)NH(tetrazolyl)$. In certain embodiments, R^2 is $-C(O)N(R^{2b})OR^{2c}$, wherein R^{2b} and R^{2c} are each as defined herein. In certain embodiments, R^2 is $-C(O)N(R^{2b})OR^{2c}$, wherein R^{2b} and R^{2c} are each independently hydrogen or C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NHOR^{2c}$, wherein R^{2c} is as defined herein. In certain embodiments, R^2 is $-C(O)NHOR^{2c}$, wherein R^{2c} is hydrogen or C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NHO-C_{1-6}$ alkyl, wherein the alkyl is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is $-C(O)NHOH$. In certain embodiments, R^2 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^2 is monocyclic heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^2 is 6-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^2 is 5-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^2 is tetrazolyl or 1,2,4-oxadiazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^2 is tetrazol-5-yl or 5-hydroxyl-1,2,4-oxadiazol-5-yl.

[00157] In certain embodiments, R^3 is hydrogen. In certain embodiments, R^3 is deuterium. In certain embodiments, R^3 is cyano. In certain embodiments, R^3 is halo. In certain embodiments, R^3 is fluoro. In certain embodiments, R^3 is chloro. In certain embodiments, R^3 is nitro. In certain embodiments, R^3 is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is methyl. In certain embodiments, R^3 is C_{2-6} alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is C_{2-6} alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^3 is heterocyclyl, optionally substituted with one or more substituents Q.

[00158] In certain embodiments, R^3 is $-C(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-C(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-C(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-C(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is methoxy. In certain embodiments, R^3 is $-OC(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-OC(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-OC(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-OC(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-OS(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-OS(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-OS(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-OS(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}C(O)OR^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}C(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}S(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined

herein. In certain embodiments, R^3 is $-NR^{1a}S(O)_2R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}S(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-SR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-S(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-S(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^3 is $-S(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^3 is $-S(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein.

[00159] In certain embodiments, R^4 is hydrogen. In certain embodiments, R^4 is deuterium. In certain embodiments, R^4 is cyano. In certain embodiments, R^4 is halo. In certain embodiments, R^4 is fluoro. In certain embodiments, R^4 is chloro. In certain embodiments, R^4 is nitro. In certain embodiments, R^4 is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is methyl. In certain embodiments, R^4 is C_{2-6} alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is C_{2-6} alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^4 is heterocyclyl, optionally substituted with one or more substituents Q.

[00160] In certain embodiments, R^4 is $-C(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-C(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-C(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-C(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is methoxy. In certain embodiments, R^4 is $-OC(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-OC(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-OC(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-OC(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-OS(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments,

R^4 is $-\text{OS}(\text{O})_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-\text{OS}(\text{O})\text{NR}^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{OS}(\text{O})_2\text{NR}^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{C}(\text{O})R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{S}(\text{O})R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{S}(\text{O})_2R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{SR}^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-\text{S}(\text{O})R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-\text{S}(\text{O})_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^4 is $-\text{S}(\text{O})\text{NR}^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^4 is $-\text{S}(\text{O})_2\text{NR}^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein.

[00161] In certain embodiments, R^5 is hydrogen. In certain embodiments, R^5 is deuterium. In certain embodiments, R^5 is cyano. In certain embodiments, R^5 is halo. In certain embodiments, R^5 is fluoro. In certain embodiments, R^5 is chloro. In certain embodiments, R^5 is nitro. In certain embodiments, R^5 is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is methyl. In certain embodiments, R^5 is C_{2-6} alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is C_{2-6} alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^5 is heterocyclyl, optionally substituted with one or more substituents Q.

[00162] In certain embodiments, R^5 is $-\text{C}(\text{O})R^{1a}$, wherein R^{1a} is as defined herein. In

certain embodiments, R^5 is $-C(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-C(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-C(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is methoxy. In certain embodiments, R^5 is $-OC(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-OC(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-OC(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-OC(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-OS(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-OS(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-OS(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-OS(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}C(O)OR^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}C(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}S(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}S(O)_2R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}S(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-SR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-S(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-S(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^5 is $-S(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^5 is $-S(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein.

[00163] In certain embodiments, R^6 is hydrogen. In certain embodiments, R^6 is deuterium. In certain embodiments, R^6 is cyano. In certain embodiments, R^6 is halo. In certain embodiments, R^6 is fluoro. In certain embodiments, R^6 is chloro. In certain embodiments, R^6 is nitro. In certain embodiments, R^6 is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^6 is methyl. In certain embodiments, R^6 is C_{2-6} alkenyl,

optionally substituted with one or more substituents Q. In certain embodiments, R^6 is C_{2-6} alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^6 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^6 is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^6 is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^6 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^6 is heterocyclyl, optionally substituted with one or more substituents Q.

[00164] In certain embodiments, R^6 is $-C(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-C(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-C(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-C(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is methoxy. In certain embodiments, R^6 is $-OC(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-OC(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-OC(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-OC(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-OS(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-OS(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-OS(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-OS(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}C(O)OR^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}C(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}S(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}S(O)_2R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}S(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-SR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-S(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments,

R^6 is $-S(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^6 is $-S(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^6 is $-S(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein.

[00165] In certain embodiments, R^7 is deuterium. In certain embodiments, R^7 is cyano. In certain embodiments, R^7 is halo. In certain embodiments, R^7 is fluoro. In certain embodiments, R^7 is chloro. In certain embodiments, R^7 is nitro. In certain embodiments, R^7 is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is methyl. In certain embodiments, R^7 is C_{2-6} alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is C_{2-6} alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^7 is heterocyclyl, optionally substituted with one or more substituents Q.

[00166] In certain embodiments, R^7 is $-C(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-C(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-C(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-C(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is methoxy. In certain embodiments, R^7 is $-OC(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-OC(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-OC(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-OC(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-OS(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-OS(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-OS(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-OS(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^7 is

$-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^7 is $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, R^7 is $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^7 is $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^7 is $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-\text{SR}^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-\text{S}(\text{O})\text{R}^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-\text{S}(\text{O})_2\text{R}^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^7 is $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^7 is $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein.

[00167] In certain embodiments, R^{2A} is $-\text{OR}^{2a}$, wherein R^{2a} is as defined herein. In certain embodiments, R^{2A} is $-\text{OH}$. In certain embodiments, R^{2A} is $-\text{O}-\text{C}_{1-6}$ alkyl, wherein the alkyl is optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NR}^{2b}\text{R}^{2c}$, wherein R^{2b} and R^{2c} are each as defined herein. In certain embodiments, R^{2A} is $-\text{NR}^{2b}\text{R}^{2c}$, wherein R^{2b} and R^{2c} are each independently (i) hydrogen; or (ii) C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NR}^{2b}\text{R}^{2c}$, wherein R^{2b} and R^{2c} are each independently (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NHR}^{2c}$, wherein R^{2c} is as defined herein. In certain embodiments, R^{2A} is $-\text{NHR}^{2c}$, wherein R^{2c} is (i) hydrogen; or (ii) C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NHR}^{2c}$, wherein R^{2c} is (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_2\text{OH}$, or $-\text{NH}(\text{tetrazolyl})$. In certain embodiments, R^{2A} is $-\text{N}(\text{R}^{2b})\text{OR}^{2c}$, wherein R^{2b} and R^{2c} are each as defined herein. In certain embodiments, R^{2A} is $-\text{N}(\text{R}^{2b})\text{OR}^{2c}$, wherein R^{2b} and R^{2c} are each independently hydrogen or C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NHOR}^{2c}$, wherein R^{2c} is as defined herein. In certain embodiments, R^{2A} is $-\text{NHO}-\text{C}_{1-6}$ alkyl, wherein the alkyl is optionally substituted with one or more substituents Q. In certain embodiments, R^{2A} is $-\text{NHOH}$.

[00168] In certain embodiments, R^{7a} is hydrogen. In certain embodiments, R^{7a} is deuterium. In certain embodiments, R^{7a} is cyano. In certain embodiments, R^{7a} is halo. In certain embodiments, R^{7a} is fluoro. In certain embodiments, R^{7a} is chloro. In certain embodiments, R^{7a} is nitro. In certain embodiments, R^{7a} is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is methyl. In certain embodiments, R^{7a} is C_{2-6} alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is C_{2-6} alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^{7a} is heterocyclyl, optionally substituted with one or more substituents Q.

[00169] In certain embodiments, R^{7a} is $-C(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-C(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-C(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-C(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is methoxy. In certain embodiments, R^{7a} is $-OC(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-OC(O)OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-OC(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-OC(NR^{1a})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-OS(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-OS(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-OS(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-OS(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}C(O)OR^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}C(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined

herein. In certain embodiments, R^{7a} is $-NR^{1a}S(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}S(O)_2R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}S(O)NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-SR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-S(O)R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-S(O)_2R^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, R^{7a} is $-S(O)NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, R^{7a} is $-S(O)_2NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein.

[00170] In certain embodiments, R^A is C_{6-14} arylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is phenylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is phen-1,2-diyl, optionally substituted with one or more substituents Q. In certain embodiments, R^A is phen-1,3-diyl, optionally substituted with one or more substituents Q. In certain embodiments, R^A is phen-1,4-diyl, optionally substituted with one or more substituents Q. In certain embodiments, R^A is phen-1,3-diyl or phen-1,4-diyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R^A is phen-1,3-diyl or phen-1,4-diyl, each of which is optionally substituted with halo or $-O-C_{1-6}$ alkyl. In certain embodiments, R^A is phen-1,3-diyl or phen-1,4-diyl, each of which is optionally substituted with fluoro, chloro, or methoxy. In certain embodiments, R^A is phen-1,3-diyl, phen-1,4-diyl, 2-chloro-phen-1,4-diyl, 2-methoxy-phen-1,4-diyl. In certain embodiments, R^A is naphthylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is heteroarylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is monocyclic heteroarylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is 5-membered heteroarylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is 6-membered heteroarylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is pyridylene, optionally substituted with one or more substituents Q. In certain embodiments, R^A is pyrid-2,5-diyl, optionally substituted with one or more substituents Q. In certain embodiments, R^A is pyridylene or methyl-pyridylene. In certain embodiments, R^A is pyrid-2,5-diyl or 3-methyl-pyrid-2,5-diyl. In certain embodiments, R^A is bicyclic heteroarylene, optionally substituted with one or more substituents Q.

[00171] In certain embodiments, R^B is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is monocyclic C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is phenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is phenyl, optionally substituted with one, two, or three substituents Q, each of which is independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C_{1-6} alkyl optionally substituted with one or more substituents Q^a ; and (iii) $-OR^a$ and $-C(O)R^a$, where each R^a is as defined herein. In certain embodiments, R^B is phenyl, optionally substituted with one, two, or three substituents Q, each of which is independently selected from bromo, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, methoxy, and formyl. In certain embodiments, R^B is phenyl, optionally substituted with one, two, or three substituents Q, each of which is independently selected from bromo, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, and methoxy. In certain embodiments, R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, or trifluorophenyl. In certain embodiments, R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, or trifluorophenyl. In certain embodiments, R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, or 2,4,5-trifluorophenyl. In certain embodiments, R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, or 2,4,5-trifluorophenyl.

[00172] In certain embodiments, R^B is bicyclic C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is naphthyl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is naphth-1-yl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is naphth-2-yl, optionally substituted with one or more substituents Q.

[00173] In certain embodiments, R^B is heteroaryl, optionally substituted with one or more

substituents Q. In certain embodiments, R^B is monocyclic heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is 5-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is 6-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is pyridyl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is fluoropyridyl or fluoro-methylpyridyl. In certain embodiments, R^B is 2-fluoropyrid-5-yl or 2-fluoro-3-methyl-pyrid-5-yl.

[00174] In certain embodiments, R^B is bicyclic heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is 5,6-fused heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is 6,6-fused heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is quinolinyl, optionally substituted with one or more substituents Q. In certain embodiments, R^B is quinolin-5-yl, optionally substituted with one or more substituents Q.

[00175] In certain embodiments, R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl. In certain embodiments, R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.

[00176] In certain embodiments, R^X is hydrogen. In certain embodiments, R^X is C₁₋₆ alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is methyl, ethyl, or propyl, each optionally substituted with one or more substituents Q. In certain embodiments, R^X is methyl, ethyl, 2-hydroxyethyl, or *n*-propyl. In certain embodiments, R^X is C₂₋₆ alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is C₂₋₆ alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is C₃₋₁₀ cycloalkyl, optionally substituted with one or more substituents Q. In certain

embodiments, R^X is C_{6-14} aryl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is phenyl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is phenyl, fluorophenyl, or formylphenyl. In certain embodiments, R^X is phenyl, 4-fluorophenyl, or 4-formylphenyl. In certain embodiments, R^X is C_{7-15} aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is benzyl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R^X is heterocyclyl, optionally substituted with one or more substituents Q.

[00177] In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form monocyclic heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form 5-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form pyrrolyl or imidazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl or 2-amino-imidazol-1-yl. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form 6-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form bicyclic heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form indolyl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form monocyclic heterocyclyl, optionally substituted with one or more substituents Q.

In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form 5- or 6-membered heterocyclyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, or morpholinyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl. In certain embodiments, when X is $-N(R^X)-$, R^B and R^X together with the N atom to which they are attached form bicyclic heterocyclyl, optionally substituted with one or more substituents Q.

[00178] In certain embodiments, L is C_{1-6} alkylene, optionally substituted with one or more substituents Q. In certain embodiments, L is methylene, ethylene, or propylene, each of which is optionally substituted with one or more substituents Q. In certain embodiments, L is $-(CH_2)_p-$, wherein p is an integer of 1, 2, 3, or 4. In certain embodiments, L is $-(CH_2)_p-$, wherein p is an integer of 1, 2, or 3. In certain embodiments, L is $-(CH_2)_p-$, wherein p is an integer of 1 or 2. In certain embodiments, L is $-CH_2CH_2-$. In certain embodiments, L is $-CH_2-$. In certain embodiments, L is C_{2-6} alkenylene, optionally substituted with one or more substituents Q. In certain embodiments, L is ethenylene, optionally substituted with one or more substituents Q. In certain embodiments, L is ethen-1,2-diyl, optionally substituted with one or more substituents Q. In certain embodiments, L is (E)-ethen-1,2-diyl. In certain embodiments, L is (Z)-ethen-1,2-diyl. In certain embodiments, L is C_{3-10} cycloalkylene, optionally substituted with one or more substituents Q. In certain embodiments, L is heterocyclylene, optionally substituted with one or more substituents Q.

[00179] In certain embodiments, X is $-O-$. In certain embodiments, X is $-NR^X-$, wherein R^X is as defined herein. In certain embodiments, X is $-NH-$. In certain embodiments, X is $-S-$. In certain embodiments, X is $-S(O)-$. In certain embodiments, X is $-S(O)_2-$.

[00180] In certain embodiments, U^1 is C. In certain embodiments, U^1 is N. In certain embodiments, U^1 is $-CR^{7a}=$, wherein R^{7a} is as defined herein. In certain embodiments, U^1 is $-N=$. In certain embodiments, U^1 is $-NR^{7b}-$, wherein R^{7b} is as defined herein. In certain embodiments, U^1 is $-O-$. In certain embodiments, U^1 is $-S-$.

[00181] In certain embodiments, V^1 is C. In certain embodiments, V^1 is N. In certain embodiments, V^1 is $-CR^{7a}=$, wherein R^{7a} is as defined herein. In certain embodiments, V^1 is $-N=$. In certain embodiments, V^1 is $-NR^{7b}-$, wherein R^{7b} is as defined herein. In certain embodiments, V^1 is $-O-$. In certain embodiments, V^1 is $-S-$.

[00182] In certain embodiments, W^1 is C. In certain embodiments, W^1 is N. In certain embodiments, W^1 is $-CR^{7a}=$, wherein R^{7a} is as defined herein. In certain embodiments, W^1 is $-N=$. In certain embodiments, W^1 is $-NR^{7b}-$, wherein R^{7b} is as defined herein. In certain embodiments, W^1 is $-O-$. In certain embodiments, W^1 is $-S-$.

[00183] In certain embodiments, X^1 is C. In certain embodiments, X^1 is N. In certain embodiments, X^1 is $-CR^{7a}=$, wherein R^{7a} is as defined herein. In certain embodiments, X^1 is $-N=$. In certain embodiments, X^1 is $-NR^{7b}-$, wherein R^{7b} is as defined herein. In certain embodiments, X^1 is $-O-$. In certain embodiments, X^1 is $-S-$.

[00184] In certain embodiments, Y^1 is C. In certain embodiments, Y^1 is N. In certain embodiments, Y^1 is a bond. In certain embodiments, Y^1 is $-CR^{7a}=$, wherein R^{7a} is as defined herein. In certain embodiments, Y^1 is $-N=$. In certain embodiments, Y^1 is $-NR^{7b}-$, wherein R^{7b} is as defined herein. In certain embodiments, Y^1 is $-O-$. In certain embodiments, Y^1 is $-S-$.

[00185] In certain embodiments, Z^1 is C. In certain embodiments, Z^1 is N.

[00186] In certain embodiments, U^2 is $-N=$. In certain embodiments, U^2 is $-O-$.

[00187] In certain embodiments, V^2 is $-N=$. In certain embodiments, V^2 is $-O-$. In certain embodiments, V^2 is $-C(OH)=$.

[00188] In certain embodiments, U^2 and V^2 are each $-N=$. In certain embodiments, U^2 is $-O-$ and V^2 is $-C(OH)=$.

[00189] In certain embodiments, n is an integer of 0. In certain embodiments, n is an integer of 1. In certain embodiments, n is an integer of 2. In certain embodiments, n is an integer of 3. In certain embodiments, n is an integer of 4.

[00190] In certain embodiments, p is an integer of 1. In certain embodiments, p is an

integer of 2. In certain embodiments, p is an integer of 3. In certain embodiments, p is an integer of 4.

[00191] In one embodiment, provided herein is a compound of:

2-[(1Z)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **A1**;

2-[(1Z)-5-fluoro-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A2**;

2-[(1Z)-1-({2-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A3**;

2-[(1Z)-5-fluoro-2-methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A4**;

2-[(1Z)-5-fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A5**;

2-[(1Z)-1-{[4-(4-bromophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A6**;

2-[(1Z)-5-fluoro-2-methyl-1-{[4-(3-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A7**;

2-[(1Z)-1-{[4-(3-cyanophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A8**;

(Z)-2-(5-fluoro-2-methyl-1-(4-(3-(trifluoromethyl)phenoxy)benzylidene)-1*H*-inden-3-yl)acetic acid **A9**;

2-[(1Z)-1-{[4-(4-ethylphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A10**;

2-[(1Z)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A11**;

2-[(1Z)-1-{[2-chloro-4-(4-methoxyphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A12**;

2-[(1Z)-5-fluoro-1-({2-methoxy-4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A13**;

2-[(1Z)-5-fluoro-2-methyl-1-{[4-(naphthalen-2-yloxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A14**;

2-[(1*Z*)-1-({2-chloro-4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A15**;

2-[(1*Z*)-1-{[4-(2,4-difluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A16**;

2-[(1*Z*)-1-{[4-(2-bromo-4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A17**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(2,4,5-trifluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A18**;

3-[(1*Z*)-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]propanoic acid **A19**;

2-[(1*Z*)-5-fluoro-1-({4-[(6-fluoropyridin-3-yl)oxy]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A20**;

2-[(1*Z*)-5-fluoro-1-({4-[(6-fluoro-5-methylpyridin-3-yl)oxy]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A21**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(quinolin-5-yloxy)benzylidene)-1*H*-inden-3-yl)acetic acid **A22**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A23**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A24**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetamide **A25**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-methylacetamide **A26**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-(2-hydroxyethyl)acetamide **A27**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)-*N*-(1*H*-tetrazol-5-yl)acetamide **A28**;

(2*E*)-3-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]prop-2-enoic acid **A61**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-

1*H*-inden-3-yl]acetic acid **A62**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfinyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A63**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A64**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A65**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A66**;

(2*E*)-4-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]but-2-enoic acid **A67**;

2-[(1*Z*)-4,5-difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A68**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]acetic acid **A69**;

(2*E*)-3-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyprop-2-enamide **A76**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A77**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfinyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A78**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A79**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A80**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A81**;

(2*E*)-4-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxybut-2-enamide **A82**;

2-[(1*Z*)-4,5-difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A83**; or

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A84**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00192] In another embodiment, provided herein is a compound of:

2-[(1*Z*)-5-fluoro-2-methyl-1-(4-[methyl(phenyl)amino]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **A29**;

2-[(1*Z*)-1-(4-[benzyl(4-fluorophenyl)amino]phenyl)methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A30**;

2-[(1*Z*)-5-fluoro-1-(4-[(4-fluorophenyl)(methyl)amino]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A31**;

2-[(1*Z*)-1-(4-[ethyl(4-fluorophenyl)amino]phenyl)methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A32**;

2-[(1*Z*)-5-fluoro-1-(4-[(4-fluorophenyl)(propyl)amino]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A33**;

2-[(1*Z*)-5-fluoro-1-(4-[(4-fluorophenyl)(2-hydroxyethyl)amino]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A34**;

2-[(1*Z*)-5-fluoro-1-(4-[(4-fluorophenyl)(4-formylphenyl)amino]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A35**;

2-[(1*Z*)-5-fluoro-1-(4-[(4-formylphenyl)(phenyl)amino]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A36**;

2-[(1*Z*)-5-fluoro-2-methyl-1-(4-[methyl(phenyl)amino]phenyl)methylidene)-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A37**;

2-[(1*Z*)-1-(4-[benzyl(4-fluorophenyl)amino]phenyl)methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A38**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[4-(morpholin-4-yl)phenyl]methylidene)-1*H*-inden-3-yl]acetic acid **A55**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[4-(piperidin-1-yl)phenyl]methylidene)-1*H*-inden-3-yl]acetic acid **A56**;

2-[(1*Z*)-5-fluoro-1-[4-(1*H*-indol-1-yl)phenyl]methylidene)-2-methyl-1*H*-inden-3-

-yl]acetic acid **A57**;

2-[(1*Z*)-1-{[4-(2-amino-1*H*-imidazol-1-yl)phenyl]methylidene}-5-fluoro-2-methyl-1-1*H*-inden-3-yl]acetic acid **A58**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(pyrrolidin-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A59**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(1*H*-pyrrol-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid

A60; 2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(morpholin-4-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A70**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(piperidin-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A71**;

2-[(1*Z*)-5-fluoro-1-{[4-(1*H*-indol-1-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A72**;

2-[(1*Z*)-1-{[4-(2-amino-1*H*-imidazol-1-yl)phenyl]methylidene}-5-fluoro-2-methyl-1-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A73**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(pyrrolidin-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A74**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(1*H*-pyrrol-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A75**; or

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(2-hydroxyethyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A85**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00193] In yet another embodiment, provided herein is a compound of:

5-{[(1*Z*)-2-methyl-1-[(3-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A39**;

5-{[(1*Z*)-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A40**;

5-{2-[(1*Z*)-2-methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A41**;

5-{2-[(1Z)-1-{[4-(4-bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A42**;

5-{2-[(1Z)-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A43**;

5-{2-[(1Z)-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A44**;

5-{2-[(1Z)-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A45**;

5-{2-[(1Z)-2-methyl-1-({4-(3-methylphenoxy)phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A46**;

3-(4-{[(1Z)-2-methyl-3-[2-(1*H*-1,2,3,4-tetrazol-5-yl)ethyl]-1*H*-inden-1-ylidene]methyl}phenoxy)benzonitrile **A47**;

5-{2-[(1Z)-1-{[4-(3-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A48**;

5-{2-[(1Z)-1-{[4-(3-bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A49**;

5-{2-[(1Z)-2-methyl-1-({4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A50**;

5-{2-[(1Z)-2-methyl-1-({4-(naphthalen-2-yloxy)phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A51**; or

(*Z*)-3-((2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)methyl)-1,2,4-oxadiazol-5(4*H*)-one **A52**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00194] In yet another embodiment, provided herein is a compound of 5-([(1*E*)-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl)-1*H*-1,2,3,4-tetrazole **A53**; or 5-([(1*E*)-1-[(3-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl)-1*H*-1,2,3,4-tetrazole **A54**; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00195] In yet another embodiment, provided herein is a compound of:

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]-*N*-hydroxy-*N*-methylacetamide **C1**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxy-*N*-methylacetamide **C2**; or

(*Z*)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)-*N*-hydroxy-*N*-methylacetamide **C3**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00196] In yet another embodiment, provided herein is a compound of:

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]-*N*-hydroxyacetamide **D1**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(*tert*-butyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D2**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-(*tert*-butyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-fluoro-4-methylphenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D4**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3,4-difluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D5**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-nitrophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D6**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D7**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-(2-methylpropyl)-1*H*-inden-3-yl]acetic acid **D8**;

2-[(1*Z*)-5-fluoro-2-benzyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D9**;

2-[(1*Z*)-5-methoxy-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D10**;

2-[(1*Z*)-5-methoxy-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-

yl]acetic acid **D11**;

2-[(1Z)-1-{[2-trifluoromethyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D12**;

2-[(1Z)-1-{[3-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D13**;

2-[(1Z)-1-{[2-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D14**;

2-[(1Z)-5,7-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D15**;

2-[(1Z)-4,6-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D16**;

2-[(1Z)-5-*tert*-butyl-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D17**;

(Z)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)acetic acid **D18**;

2-[(1Z)-5-fluoro-1-(2-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D19**;

2-[(1Z)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D20**;

2-[(1Z)-4,6-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D21**;

2-[(1Z)-5-fluoro-2-methyl-1-({3-[4-methoxyphenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D22**;

2-[(1Z)-5-fluoro-1-(4-fluoro-3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D23**;

2-[(1Z)-5-fluoro-2-methyl-1-({3-[4-cyanophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D24**;

2-[(1Z)-5-fluoro-2-methyl-1-({3-[4-chlorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D25**;

2-[(1Z)-5-fluoro-2-methyl-1-({3-[4-trifluoromethylphenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D26**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[3-trifluoromethylphenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D27**;

2-[(1Z)-4-methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D28**;

2-[(1Z)-6-methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D29**;

2-[(1Z)-6-trifluoromethyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D30**;

2-[(1Z)-5-trifluoromethyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D31**;

2-[(1Z)-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **D32**;

2-[(1Z)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **D33**;

2-[(1Z)-5-trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D34**;

2-[(1Z)-6-methoxy-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D35**;

2-[(1Z)-6-trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D36**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[methyl(phenyl)amino]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D37**; or

2-[(1Z)-5-fluoro-1-[(3-methoxy-5-phenoxyphenyl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **D38**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00197] In still another embodiment, provided herein is a compound of:

2-[(1*E*)-5-fluoro-2-methyl-1-(4-[3,4-difluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **E1**;

2-[(1*E*)-5-fluoro-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **E2**;

2-[(1*E*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **E3**;

2-[(1*E*)-5,7-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E4**;

5-{2-[(1*E*)-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **E5**; and

2-[(1*E*)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **E6**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00198] In certain embodiments, a compound provided herein is deuterium-enriched. In certain embodiments, a compound provided herein is carbon-13 enriched. In certain embodiments, a compound provided herein is carbon-14 enriched. In certain embodiments, a compound provided herein contains one or more less prevalent isotopes for other elements, including, but not limited to, ¹⁵N for nitrogen; ¹⁷O or ¹⁸O for oxygen, and ³⁴S, ³⁵S, or ³⁶S for sulfur.

[00199] In certain embodiments, a compound provided herein has an isotopic enrichment factor of no less than about 5, no less than about 10, no less than about 20, no less than about 50, no less than about 100, no less than about 200, no less than about 500, no less than about 1,000, no less than about 2,000, no less than about 5,000, or no less than about 10,000. In any events, however, an isotopic enrichment factor for a specified isotope is no greater than the maximum isotopic enrichment factor for the specified isotope, which is the isotopic enrichment factor when a compound at a given position is 100% enriched with the specified isotope. Thus, the maximum isotopic enrichment factor is different for different isotopes. The maximum isotopic enrichment factor is 6,410 for deuterium and 90 for carbon-13.

[00200] In certain embodiments, a compound provided herein has a deuterium enrichment factor of no less than about 64 (about 1% deuterium enrichment), no less than about 130 (about 2% deuterium enrichment), no less than about 320 (about 5% deuterium enrichment), no less than about 640 (about 10% deuterium enrichment), no less than about 1,300 (about 20% deuterium

enrichment), no less than about 3,200 (about 50% deuterium enrichment), no less than about 4,800 (about 75% deuterium enrichment), no less than about 5,130 (about 80% deuterium enrichment), no less than about 5,450 (about 85% deuterium enrichment), no less than about 5,770 (about 90% deuterium enrichment), no less than about 6,090 (about 95% deuterium enrichment), no less than about 6,220 (about 97% deuterium enrichment), no less than about 6,280 (about 98% deuterium enrichment), no less than about 6,350 (about 99% deuterium enrichment), or no less than about 6,380 (about 99.5% deuterium enrichment). The deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy. In certain embodiments, at least one of the atoms of a compound provided herein, as specified as deuterium-enriched, has deuterium enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.

[00201] In certain embodiments, a compound provided herein is isolated or purified. In certain embodiments, a compound provided herein has a purity of at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% by weight.

[00202] The compounds provided herein are intended to encompass all possible stereoisomers, unless a particular stereochemistry is specified. Where a compound provided herein contains an alkenyl group, the compound may exist as one or mixture of geometric *cis/trans* (or *Z/E*) isomers. Where structural isomers are interconvertible, the compound may exist as a single tautomer or a mixture of tautomers. This can take the form of proton tautomerism in the compound that contains, for example, an imino, keto, or oxime group; or so-called valence tautomerism in the compound that contains an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.

[00203] The compound provided herein can be enantiomerically pure, such as a single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture of enantiomers, *e.g.*, a racemic mixture of two enantiomers; or a mixture of two or more diastereomers. As such, one of ordinary skill in the art will recognize that administration of a

compound in its (*R*) form is equivalent, for the compound that undergoes epimerization *in vivo*, to administration of the compound in its (*S*) form. Conventional techniques for the preparation/isolation of individual enantiomers include synthesis from a suitable optically pure precursor, asymmetric synthesis from achiral starting materials, or resolution of an enantiomeric mixture, for example, chiral chromatography, recrystallization, resolution, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.

[00204] When a compound provided herein contains an acidic or basic moiety, it can also be provided as a pharmaceutically acceptable salt. See, Berge *et al.*, *J. Pharm. Sci.* **1977**, *66*, 1-19; *Handbook of Pharmaceutical Salts: Properties, Selection, and Use*, 2nd ed.; Stahl and Wermuth Eds.; John Wiley & Sons, 2011. In certain embodiments, a pharmaceutically acceptable salt of a compound provided herein is a solvate. In certain embodiments, a pharmaceutically acceptable salt of a compound provided herein is a hydrate.

[00205] Suitable acids for use in the preparation of pharmaceutically acceptable salts of a compound provided herein include, but are not limited to, acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1*S*)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, α -oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, (+)-L-lactic acid, ($\pm$)-DL-lactic acid, lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid, malonic acid, ($\pm$)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, *p*-toluenesulfonic acid, undecylenic acid, and valeric acid.

[00206] Suitable bases for use in the preparation of pharmaceutically acceptable salts of a

compound provided herein include, but are not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, or sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including, but not limited to, L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, *N*-methylglucamine, hydrabamine, 1*H*-imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, quinoline, isoquinoline, triethanolamine, trimethylamine, triethylamine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, and tromethamine.

[00207] A compound provided herein may also be provided as a prodrug, which is a functional derivative of the compound and is readily convertible into the parent compound *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not. The prodrug may also have enhanced solubility in pharmaceutical compositions over the parent compound. A prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.

Pharmaceutical Compositions

[00208] In one embodiment, provided herein is a pharmaceutical composition, comprising a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.

[00209] The pharmaceutical composition provided herein can be formulated in various dosage forms, including, but not limited to, dosage forms for oral, parenteral, and topical administration. The pharmaceutical composition can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those

skilled in the art. *See, e.g., Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Delivery Technology*, 2nd ed.; Rathbone *et al.*, Eds.; Drugs and the Pharmaceutical Sciences 184; CRC Press: Boca Raton, FL, 2008.

[00210] In one embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for oral administration. In another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for parenteral administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for intravenous administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for intramuscular administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for subcutaneous administration. In still another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for topical administration.

[00211] The pharmaceutical composition provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) (*e.g.*, a compound provided herein) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical excipient(s). Examples of a unit-dosage form include, but are not limited to, an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in a segregated unit-dosage form. Examples of a multiple-dosage form include, are not limited to, a vial, bottle of tablets or capsules, or bottle of pints or gallons.

[00212] The pharmaceutical composition provided herein can be administered at once or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the subject being treated, and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the subject's need and the professional

judgment of the person administering or supervising the administration of the pharmaceutical composition.

A. Oral Administration

[00213] The pharmaceutical composition provided herein for oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical composition can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.

[00214] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (*e.g.*, STARCH 1500®); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), VEEGUM®, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); and microcrystalline celluloses, such as AVICEL® PH-101, AVICEL® PH-103, AVICEL® PH-105, and AVICEL® RC-581. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, and pre-gelatinized starch. The amount of a binder or filler in the pharmaceutical composition provided herein varies upon

the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical composition provided herein.

[00215] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.

[00216] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and VEEGUM® HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrillin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; and algin. The amount of a disintegrant in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical composition provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.

[00217] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; and silica or silica gels, such as AEROSIL® 200 and CAB-O-SIL®. The amount of a lubricant in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.

[00218] Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL[®], and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes. A color lake is a combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN[®] 20), polyoxyethylene sorbitan monooleate 80 (TWEEN[®] 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, VEEGUM[®], acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic acid, and sodium benzoate and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.

[00219] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.

[00220] The pharmaceutical composition provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredient(s) from the acidic environment of the stomach. Enteric-coatings include, but are not limited to,

fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.

[00221] The tablet dosage forms can be prepared from an active ingredient(s) in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[00222] The pharmaceutical composition provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient(s). The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient(s).

[00223] The pharmaceutical composition provided herein for oral administration can be

provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups. An emulsion is a two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil. Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative. Suspensions may include a pharmaceutically acceptable suspending agent and preservative. Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, *e.g.*, acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, and hydroalcoholic solutions. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative. For a liquid dosage form, for example, a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, *e.g.*, water, to be measured conveniently for administration.

[00224] Other useful liquid and semisolid dosage forms include, but are not limited to, those containing an active ingredient(s), and a dialkylated mono- or poly-alkylene glycol, including, 1,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol. These dosage forms can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.

[00225] The pharmaceutical composition provided herein for oral administration can be also provided in the forms of liposomes, micelles, microspheres, or nanosystems. Micellar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458.

[00226] The pharmaceutical composition provided herein for oral administration can be provided as non-effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form. Pharmaceutically acceptable carriers and excipients used in the non-

effervescent granules or powders may include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.

[00227] Coloring and flavoring agents can be used in all of the dosage forms described herein.

[00228] The pharmaceutical composition provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

B. Parenteral Administration

[00229] The pharmaceutical composition provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.

[00230] The pharmaceutical composition provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including, but not limited to, solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science. *See, e.g., Remington: The Science and Practice of Pharmacy, supra.*

[00231] The pharmaceutical composition provided herein for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.

[00232] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringer's injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (*e.g.*, polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, *N*-methyl-2-pyrrolidone, *N,N*-dimethylacetamide, and dimethyl sulfoxide.

[00233] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl *p*-hydroxybenzoates, thimerosal, benzalkonium chloride (*e.g.*, benzethonium chloride), methyl- and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants include those described herein, such as bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents include those described herein, such as sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents include those described herein, such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to, EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α -cyclodextrin, β -cyclodextrin, hydroxypropyl- β -cyclodextrin, sulfobutylether- β -cyclodextrin, and sulfobutylether 7- β -cyclodextrin (CAPTISOL[®]).

[00234] When the pharmaceutical composition provided herein is formulated for multiple dosage administration, multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.

[00235] In one embodiment, the pharmaceutical composition for parenteral administration is provided as a ready-to-use sterile solution. In another embodiment, the pharmaceutical composition is provided as a sterile dry soluble product, including a lyophilized powder and hypodermic tablet, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical composition is provided as a ready-to-use sterile suspension. In yet another embodiment, the pharmaceutical composition is provided as a sterile dry insoluble product to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical composition is provided as a ready-to-use sterile emulsion.

[00236] The pharmaceutical composition provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

[00237] The pharmaceutical composition provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical composition provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient(s) in the pharmaceutical composition to diffuse through.

[00238] Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers (such as hydrogels of esters of acrylic and methacrylic acid), collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.

[00239] Suitable outer polymeric membranes include, but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber

epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.

C. Topical Administration

[00240] The pharmaceutical composition provided herein can be administered topically to the skin, orifices, or mucosa. The topical administration, as used herein, includes (intra)dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration.

[00241] The pharmaceutical composition provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including, but not limited to, emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, and dermal patches. The topical formulations of the pharmaceutical composition provided herein can also comprise liposomes, micelles, microspheres, and nanosystems.

[00242] Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.

[00243] The pharmaceutical composition can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as POWDERJECT™ and BIOJECT™.

[00244] The pharmaceutical composition provided herein can be provided in the forms of ointments, creams, and gels. Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin

sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid. *See, e.g., Remington: The Science and Practice of Pharmacy, supra.* These vehicles are emollient but generally require addition of antioxidants and preservatives.

[00245] Suitable cream base can be oil-in-water or water-in-oil. Suitable cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase is also called the “internal” phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.

[00246] Gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier. Suitable gelling agents include, but are not limited to, crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, and CARBOPOL®; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.

[00247] The pharmaceutical composition provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas. These dosage forms can be manufactured using conventional processes as described in *Remington: The Science and Practice of Pharmacy, supra.*

[00248] Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body

orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient(s) inside the orifices. Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening agents, which produce a melting point in the proximity of body temperature, when formulated with an active ingredient(s); and antioxidants as described herein, including bisulfite and sodium metabisulfite. Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di- and triglycerides of fatty acids, and hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, and polyacrylic acid. Combinations of the various vehicles can also be used. Rectal and vaginal suppositories may be prepared by compressing or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g.

[00249] The pharmaceutical composition provided herein can be administered ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.

[00250] The pharmaceutical composition provided herein can be administered intranasally or by inhalation to the respiratory tract. The pharmaceutical composition can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. The pharmaceutical composition can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops. For intranasal use, the powder can comprise a bioadhesive agent, including chitosan or cyclodextrin.

[00251] Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of an active ingredient(s); a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

[00252] The pharmaceutical composition provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10

micrometers or less. Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.

[00253] Capsules, blisters, and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical composition provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as *L*-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate. Other suitable excipients or carriers include, but are not limited to, dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose. The pharmaceutical composition provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol; and/or sweeteners, such as saccharin and saccharin sodium.

[00254] The pharmaceutical composition provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.

D. Modified Release

[00255] The pharmaceutical composition provided herein can be formulated as a modified release dosage form. As used herein, the term “modified release” refers to a dosage form in which the rate or place of release of an active ingredient(s) is different from that of an immediate dosage form when administered by the same route. Modified release dosage forms include, but are not limited to, delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. The pharmaceutical composition in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix-controlled release devices, osmotic controlled release devices, multiparticulate controlled release devices, ion-exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof. The release rate of the active ingredient(s) can also be modified by varying the particle sizes and polymorphism of the active ingredient(s).

1. Matrix Controlled Release Devices

[00256] The pharmaceutical composition provided herein in a modified release dosage form can be fabricated using a matrix-controlled release device known to those skilled in the art. See, e.g., Takada *et al.* in *Encyclopedia of Controlled Drug Delivery*, Mathiowitz Ed.; Wiley, 1999; Vol. 2.

[00257] In certain embodiments, the pharmaceutical composition provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water-swallowable, erodible, or soluble polymers, including, but not limited to, synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.

[00258] Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; cellulose, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethyl hydroxyethyl cellulose (EHEC); polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT®); poly(2-hydroxyethyl-methacrylate); polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid; and other acrylic acid derivatives, such as homopolymers and copolymers of butylmethacrylate, methyl methacrylate, ethyl methacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and (trimethylaminoethyl)methacrylate chloride.

[00259] In certain embodiments, the pharmaceutical composition provided herein is formulated with a non-erodible matrix device. The active ingredient(s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once

administered. Materials suitable for use as a non-erodible matrix device include, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl methacrylate copolymers, ethylene-vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubbers, epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, ethylene/vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubbers, polydimethylsiloxanes, and silicone carbonate copolymers; hydrophilic polymers, such as ethyl cellulose, cellulose acetate, crospovidone, and cross-linked partially hydrolyzed polyvinyl acetate; and fatty compounds, such as carnauba wax, microcrystalline wax, and triglycerides.

[00260] In a matrix-controlled release system, the desired release kinetics can be controlled, for example, *via* the polymer type employed, the polymer viscosity, the particle sizes of the polymer and/or the active ingredient(s), the ratio of the active ingredient(s) versus the polymer, and other excipients or carriers in the compositions.

[00261] The pharmaceutical composition provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, and melt-granulation followed by compression.

2. Osmotic Controlled Release Devices

[00262] The pharmaceutical composition provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including, but not limited to, one-chamber system, two-chamber system, asymmetric membrane technology (AMT), and extruding core system (ECS). In general, such devices have at least two components: (a) a core which contains an active ingredient; and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core. The semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port(s).

[00263] In addition to the active ingredient(s), the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device. One class of osmotic agents is water-swellaable hydrophilic polymers, which are also referred to as “osmopolymers” and “hydrogels.” Suitable water-swellaable hydrophilic polymers as osmotic agents include, but are not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly(2-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC) and carboxyethyl cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.

[00264] The other class of osmotic agents is osmogens, which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol; organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and mixtures thereof.

[00265] Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient(s) is initially delivered from the dosage form. For example, amorphous sugars, such as MANNOGEM[™] EZ can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an extended period of time. In this case, the active ingredient(s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.

[00266] The core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.

[00267] Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water-insoluble at physiologically relevant pHs or are susceptible to being rendered water-insoluble by chemical alteration, such as crosslinking. Examples of suitable polymers useful in forming the coating, include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly-(methacrylic) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan, collagen, gelatin, polyalkenes, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl esters and ethers, natural waxes, and synthetic waxes.

[00268] Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798,119. Such hydrophobic but water-vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.

[00269] The delivery port(s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation

in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220.

[00270] The total amount of the active ingredient(s) released and the release rate can substantially be modulated *via* the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports.

[00271] The pharmaceutical composition in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.

[00272] The osmotic controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. *See, e.g., Remington: The Science and Practice of Pharmacy, supra; Santus and Baker, J. Controlled Release, 1995, 35, 1-21; Verma et al., Drug Dev. Ind. Pharm., 2000, 26, 695-708; Verma et al., J. Controlled Release, 2002, 79, 7-27.*

[00273] In certain embodiments, the pharmaceutical composition provided herein is formulated as an AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient(s) and other pharmaceutically acceptable excipients or carriers. *See, e.g., U.S. Pat. No. 5,612,059 and WO 2002/17918.* The AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.

[00274] In certain embodiments, the pharmaceutical composition provided herein is formulated as an ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient(s), a hydroxyethyl cellulose, and other pharmaceutically acceptable excipients or carriers.

3. Multiparticulate Controlled Release Devices

[00275] The pharmaceutical composition provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a

multiplicity of particles, granules, or pellets, ranging from about 10 μm to about 3 mm, about 50 μm to about 2.5 mm, or from about 100 μm to about 1 mm in diameter. Such multiparticulates can be made by the processes known to those skilled in the art, including wet-and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores. *See, e.g., Multiparticulate Oral Drug Delivery*; Ghebre-Sellassie Eds.; Drugs and the Pharmaceutical Sciences 65; CRC Press: 1994; and *Pharmaceutical Pelletization Technology*; Ghebre-Sellassie Eds.; Drugs and the Pharmaceutical Sciences 37; CRC Press: 1989.

[00276] Other excipients or carriers as described herein can be blended with the pharmaceutical composition to aid in processing and forming the multiparticulates. The resulting particles can themselves constitute the multiparticulate device or can be coated by various film-forming materials, such as enteric polymers, water-swellaable, and water-soluble polymers. The multiparticulates can be further processed as a capsule or a tablet.

4. Targeted Delivery


[00277] The pharmaceutical composition provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated, including liposome-, resealed erythrocyte-, and antibody-based delivery systems. Examples include, but are not limited to, those disclosed in U.S. Pat. Nos. 6,316,652; 6,274,552; 6,271,359; 6,253,872; 6,139,865; 6,131,570; 6,120,751; 6,071,495; 6,060,082; 6,048,736; 6,039,975; 6,004,534; 5,985,307; 5,972,366; 5,900,252; 5,840,674; 5,759,542; and 5,709,874.

Methods of Use

[00278] In one embodiment, provided herein is a method of treating, ameliorating, or preventing one or more symptoms of a fibrotic disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00279] In another embodiment, provided herein is a method of treating, ameliorating, or preventing one or more symptoms of a fibrotic disease in a subject, comprising administering to

the subject in need thereof a therapeutically effective amount of a compound of Formula (I-A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $-CN$, $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, $-OR^{2a}$, $-NR^{2b}R^{2c}$, or heteroaryl; wherein R^{2a} , R^{2b} , and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3 , R^4 , R^5 , and R^6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

each R^7 is independently (a) deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; or two adjacent R^7 together with the phenyl group to which they are attached form naphthyl or bicyclic

heteroaryl;

R^C is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-OR^{1a}$, $-NR^{1b}R^{1c}$, or $-NR^{1a}C(O)R^{1d}$;

L is C_{1-6} alkylene or C_{2-6} alkenylene;

n is an integer of 0, 1, 2, 3, or 4; and


each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$,


$-\text{C}(\text{NR}^{\text{e}})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{C}(\text{S})\text{R}^{\text{e}}$, $-\text{C}(\text{S})\text{OR}^{\text{e}}$, $-\text{C}(\text{S})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OR}^{\text{e}}$, $-\text{OC}(\text{O})\text{R}^{\text{e}}$, $-\text{OC}(\text{O})\text{OR}^{\text{e}}$,
 $-\text{OC}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OC}(\text{O})\text{SR}^{\text{e}}$, $-\text{OC}(\text{NR}^{\text{e}})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OC}(\text{S})\text{R}^{\text{e}}$, $-\text{OC}(\text{S})\text{OR}^{\text{e}}$, $-\text{OC}(\text{S})\text{NR}^{\text{f}}\text{R}^{\text{g}}$,
 $-\text{OS}(\text{O})\text{R}^{\text{e}}$, $-\text{OS}(\text{O})_2\text{R}^{\text{e}}$, $-\text{OS}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OS}(\text{O})_2\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{OR}^{\text{f}}$,
 $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{SR}^{\text{f}}$, $-\text{NR}^{\text{e}}\text{C}(\text{NR}^{\text{h}})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{C}(\text{S})\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{C}(\text{S})\text{OR}^{\text{f}}$,
 $-\text{NR}^{\text{e}}\text{C}(\text{S})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})_2\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})_2\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{SR}^{\text{e}}$,
 $-\text{S}(\text{O})\text{R}^{\text{e}}$, $-\text{S}(\text{O})_2\text{R}^{\text{e}}$, $-\text{S}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, and $-\text{S}(\text{O})_2\text{NR}^{\text{f}}\text{R}^{\text{g}}$; wherein each R^{e} , R^{f} , R^{g} , and R^{h} is
independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10}
cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^{f} and R^{g} together with
the N atom to which they are attached form heterocyclyl.

[00280] In one embodiment, the compound of Formula (I-A) has the structure of Formula (II-A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , L , and n are each as defined herein.


[00281] In another embodiment, the compound of Formula (I-A) has the structure of Formula (III-A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more

diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^C , L , and n are each as defined herein.

[00282] In yet another embodiment, the compound of Formula (I-A) has the structure of Formula (VI-A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^C , L , and n are each as defined herein.

[00283] In one embodiment, in any one of Formulae (I-A) to (IV-A),

R^1 is hydrogen or C_{1-6} alkyl;

R^2 is $-CN$, $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-OR^{2a}$, $-NR^{2b}R^{2c}$, or heteroaryl, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen or C_{1-6} alkyl;

R^3 , R^4 , R^5 , and R^6 are each independently hydrogen, deuterium, halo, C_{1-6} alkyl, or $-O-C_{1-6}$ alkyl;

R^7 and n are (i) or (ii):

(i) n is an integer of 0, 1, 2, 3, or 4; and

each R^7 is independently deuterium, halo, C_{1-6} alkyl, or $-O-C_{1-6}$ alkyl; or

(ii) n is an integer of 2, 3, or 4; and

two adjacent R^7 together with the phenyl group to which they are attached form naphthyl;

R^C is hydrogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, heteroaryl, heterocyclyl, $-O-C_{1-6}$ alkyl, $-NHC(O)-C_{1-6}$ alkyl, or $-N(C_{1-6} \text{ alkyl})_2$; and

L is C_{1-6} alkylene or C_{2-6} alkenylene;

wherein each alkyl, alkylene, alkenyl, alkenylene, cycloalkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[00284] In another embodiment, in any one of Formulae (I-A) to (IV-A),

R^1 is hydrogen or C_{1-6} alkyl;

R^2 is $-CN$, $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-OR^{2a}$, $-NR^{2b}R^{2c}$, or 5-membered heteroaryl, wherein each R^{2a} , R^{2b} , and R^{2c} is independently hydrogen or C_{1-6} alkyl;

R^3 and R^5 are each independently hydrogen or deuterium;

R^4 and R^6 are each independently hydrogen, deuterium, halo, C_{1-6} alkyl, or $-O-C_{1-6}$ alkyl;

R^7 and n are (i) or (ii):

(iii) n is an integer of 0, 1, or 2; and

each R^7 is independently deuterium, halo, C_{1-6} alkyl, or $-O-C_{1-6}$ alkyl; or

(iv) n is an integer of 2; and

two adjacent R^7 together with the phenyl group to which they are attached form naphth-1-yl or naphth-2-yl;

R^C is hydrogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, heteroaryl, heterocyclyl, $-O-C_{1-6}$ alkyl, $-NHC(O)-C_{1-6}$ alkyl, or $-N(C_{1-6} \text{ alkyl})_2$; and

L is C_{1-6} alkylene or C_{2-6} alkenylene;

wherein each alkyl, alkylene, alkenyl, alkenylene, cycloalkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.

[00285] In yet another embodiment, in any one of Formulae (I-A) to (IV-A),

R^1 is hydrogen, methyl, ethyl, or butyl;

R^2 is $-CN$, $-C(O)OH$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-OH$, $-NH_2$, or tetrazolyl;

R^3 and R^5 are each independently hydrogen or deuterium;

R^4 is hydrogen, fluoro, chloro, methyl, ethyl, isopropyl, methoxy, or ethoxy;

R^6 is hydrogen, deuterium, or fluoro;

R^7 and n are (i) or (ii):

(i) n is an integer of 0, 1, or 2; and

each R^7 is independently fluoro, chloro, or methoxy; or

(ii) n is an integer of 2; and

two adjacent R⁷ together with the phenyl group to which they are attached form naphth-1-yl or naphth-2-yl;

R^C is hydrogen, cyano, methyl, trifluoromethyl, ethyl, propyl, fluoropropyl, difluoropropyl, hexafluoropropyl, butyl, propenyl, cyclopropyl, cyclopentyl, pyridyl, pyrrolidinyl, hydroxyl, methoxy, ethoxy, acetamido, or dimethylamino; and

L is methylene, ethylene, or ethenylene.

[00286] In still another embodiment, in any one of Formulae (I-A) to (IV-A),

R¹ is hydrogen, methyl, ethyl, or (2-methyl)propyl;

R² is -CN, -C(O)OH, -C(O)NH₂, -C(O)NHCH₃, -OH, -NH₂, or tetrazol-5-yl;

R³ and R⁵ are each independently hydrogen or deuterium;

R⁴ is hydrogen, fluoro, chloro, methyl, ethyl, isopropyl, methoxy, or ethoxy;

R⁶ is hydrogen, deuterium, or fluoro;

R⁷ and n are (i) or (ii):

(i) n is an integer of 0, 1, or 2; and

each R⁷ is fluoro; or

(ii) n is an integer of 2; and

two adjacent R⁷ together with the phenyl group to which they are attached form naphth-1-yl or naphth-2-yl;

R^C is hydrogen, cyano, methyl, trifluoromethyl, ethyl, 2-fluoropropan-2-yl, 1,3-difluoropropane-2-yl, di(trifluoromethyl)methyl, isopropyl, *t*-butyl, prop-1-en-2-yl, cyclopropyl, cyclopentyl, pyrid-2-yl, pyrrolidin-1-yl, hydroxyl, methoxy, ethoxy, acetamido, or dimethylamino; and

L is methylene, ethan-1,2-diyl, or ethen-1,2-diyl.

[00287] In one embodiment, the compound of Formula (I-A) is:

(*Z*)-2-(2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B1**;

(*Z*)-2-(5-fluoro-2-methyl-1-(benzylidene)-1*H*-inden-3-yl)acetic acid **B2**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-cyanobenzylidene)-1*H*-inden-3-yl)acetic acid **B3**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-cyanobenzylidene)-1*H*-inden-3-yl)acetic acid **B4**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-methylbenzylidene)-1*H*-inden-3-yl)acetic acid **B5**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-trifluoromethylbenzylidene)-1*H*-inden-3-yl)acetic

acid **B6**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-trifluoromethylbenzylidene)-1*H*-inden-3-yl)acetic

acid **B7**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-ethylbenzylidene)-1*H*-inden-3-yl)acetic acid **B8**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid

B9;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-*t*-butylbenzylidene)-1*H*-inden-3-yl)acetic acid **B10**;

(*Z*)-2-(5-fluoro-2-ethyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B11**;

(*Z*)-2-(5-fluoro-2-(2-methylpropyl)-1-(4-isopropylbenzylidene)-1*H*-inden-3-

yl)acetic acid **B12**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-methoxybenzylidene)-1*H*-inden-3-yl)acetic acid

B13;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-methoxybenzylidene)-1*H*-inden-3-yl)acetic acid

B14;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-ethoxybenzylidene)-1*H*-inden-3-yl)acetic acid **B15**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(pyrrolidin-1-yl)benzylidene)-1*H*-inden-3-yl)acetic

acid **B16**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(pyrid-2-yl) benzylidene)-1*H*-inden-3-yl)acetic

acid **B17**;

(*Z*)-2-(5-chloro-2-methyl-1-(4-*t*-butylbenzylidene)-1*H*-inden-3-yl)acetic acid **B18**;

(*Z*)-2-(5-methyl-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid

B19;

(*Z*)-2-(5-ethyl-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid

B20;

(*Z*)-2-(5-isopropyl-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic

acid **B21**;

(*Z*)-2-(5-methoxy-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid

B22;

(*Z*)-2-(5-ethoxy-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid

B23;

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)acetamide

B24;

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)-*N*-methylacetamide **B25;**

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)-*N,N*-dimethylacetamide **B26;**

(*Z*)-2-(1-(4-acetamidobenzylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl)acetic acid

B27;

(*Z*)-3-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)propanoic acid **B28;**

(*Z*)-5-(2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethyl)-1*H*-tetrazole **B29;**

(*Z*)-5-(2-(1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethyl)-1*H*-tetrazole

B30;

(*Z*)-2-(4-fluoro-2-methyl-1-(benzylidene)-1*H*-inden-3-yl)acetic acid **B31;**

(*Z*)-2-(5-fluoro-1-(4-dimethylaminobenzylidene)-2-methyl-1*H*-inden-3-yl)propanoic acid **B32;**

2-[(1*Z*)-5-fluoro-1-[(2-hydroxynaphthalen-1-yl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **B33;**

2-[(1*Z*)-5-fluoro-2-methyl-1-[(naphthalen-2-yl)methylidene]-1*H*-inden-3-yl]acetic acid **B34;**

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-methylnaphthalen-1-yl)methylidene]-1*H*-inden-3-yl]acetic acid **B35;**

2-[(1*Z*)-5-fluoro-1-[(2-methoxynaphthalen-1-yl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **B36;**

2-[(1*Z*)-1-[(4-cyclopropylphenyl)methylidene]-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B37;**

2-[(1*Z*)-1-[(4-cyclopentylphenyl)methylidene]-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B38;**

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(prop-1-en-2-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **B39;**

2-[(1*Z*)-5-fluoro-1-{[4-(2-fluoropropan-2-yl)phenyl]methylidene}-2-methyl-1*H*-

inden-3-yl]acetic acid **B40**;

2-[(1*Z*)-1-{[4-(dimethylamino)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B41**;

2-[(1*Z*)-5-fluoro-1-{[4-(1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **B42**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1*H*-inden-3-yl]propanoic acid **B43**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(trifluoromethyl)phenyl]methylidene}-1*H*-inden-3-yl]propanoic acid **B44**;

2-[(1*Z*)-7-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **B45**;

2-[(1*Z*)-7-fluoro-2-methyl-1-{[4-(trifluoromethyl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **B46**;

2-[(1*Z*)-1-{[4-(1,3-difluoropropan-2-yl)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B47**; or

2-[(1*Z*)-5-fluoro-1-{[3-fluoro-4-(propan-2-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **B48**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00288] In another embodiment, the compound of Formula (I-A) is:

(*E*)-2-(5-fluoro-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B49**;

(*E*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)acetamide **B50**; or

(*E*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)-*N*-methylacetamide **B51**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00289] In yet another embodiment, the compound of Formula (I-A) is:

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethan-1-ol

B52;

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethan-1-amino **B53**; or

(*Z*)-3-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)propanenitrile **B54**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00290] In certain embodiments, the compound of Formula (I-A) is one of those described in U.S. Pat. No. 9,611,235, the disclosure of which is incorporated herein by reference in its entirety.

[00291] In certain embodiment, the fibrotic disease is a liver fibrotic disease. In certain embodiment, the fibrotic disease is a metabolic disease. In certain embodiment, the fibrotic disease is a liver fibrosis. In certain embodiment, the fibrotic disease is nonalcoholic fatty liver disease (NAFLD). In certain embodiment, the fibrotic disease is nonalcoholic steatohepatitis (NASH). In certain embodiment, the fibrotic disease is a pulmonary fibrotic disease. In certain embodiment, the fibrotic disease is idiopathic pulmonary fibrosis. In certain embodiment, the fibrotic disease is primary biliary cholangitis (PBC). In certain embodiment, the fibrotic disease is scleroderma.

[00292] In yet another embodiment, provided herein is a method of treating, ameliorating, or preventing one or more symptoms of a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or (I-A), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00293] In certain embodiments, the proliferative disease is cancer. In certain embodiments, the cancer is liver cancer. In certain embodiments, the cancer is metastatic. In certain embodiments, the cancer is refractory. In certain embodiments, the cancer is relapsed. In certain embodiments, the cancer is drug-resistant. In certain embodiments, the cancer is multidrug-resistant.

[00294] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human.

[00295] In certain embodiments, the therapeutically effective amount of a compound described herein is ranging from about 0.1 to about 100 mg/kg/day, from about 0.2 to about 50 mg/kg/day, from about 0.5 to about 25 mg/kg/day, or from about 1 to about 10 mg/kg/day. In one embodiment, the therapeutically effective amount is ranging from about 0.1 to about 100 mg/kg/day. In another embodiment, the therapeutically effective amount is ranging from about 0.2 to about 50 mg/kg/day. In yet another embodiment, the therapeutically effective amount is ranging from about 0.5 to about 25 mg/kg/day. In still another embodiment, the therapeutically effective amount is ranging from about 1 to about 10 mg/kg/day.

[00296] It is understood that the administered dose can also be expressed in units other than mg/kg/day. For example, doses for parenteral administration can be expressed as mg/m²/day. One of ordinary skill in the art would readily know how to convert doses from mg/kg/day to mg/m²/day to given either the height or weight of a subject or both. For example, a dose of 1 mg/m²/day for a 65 kg human is approximately equal to 58 mg/kg/day.

[00297] Depending on the disease to be treated and the subject's condition, a compound provided herein may be administered by oral, parenteral (*e.g.*, intramuscular, intraperitoneal, intravenous, CIV, intracisternal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (*e.g.*, transdermal or local) routes of administration. A compound provided herein may be formulated in suitable dosage unit with a pharmaceutically acceptable excipient, carrier, adjuvant, or vehicle, appropriate for each route of administration.

[00298] In one embodiment, a compound provided herein is administered orally. In another embodiment, a compound provided herein is administered parenterally. In yet another embodiment, a compound provided herein is administered intravenously. In yet another embodiment, a compound provided herein is administered intramuscularly. In yet another embodiment, a compound provided herein is administered subcutaneously. In still another embodiment, a compound provided herein is administered topically.

[00299] A compound provided herein can be delivered as a single dose such as, *e.g.*, a single bolus injection, or oral tablets or pills; or over time such as, *e.g.*, continuous infusion over time or divided bolus doses over time. A compound provided herein can be administered repetitively if necessary, for example, until the subject experiences stable disease or regression, or until the subject experiences disease progression or unacceptable toxicity. Stable disease or lack thereof is determined by methods known in the art such as evaluation of subject's symptoms, physical examination, visualization of the cancer that has been imaged using X-ray, CAT, PET, or MRI scan and other commonly accepted evaluation modalities.

[00300] A compound provided herein can be administered once daily (QD) or divided into multiple daily doses such as twice daily (BID), and three times daily (TID). In addition, the administration can be continuous, *i.e.*, every day, or intermittently. The term "intermittent" or "intermittently" as used herein is intended to mean stopping and starting at either regular or irregular intervals. For example, intermittent administration of a compound provided herein is administration for one to six days per week, administration in cycles (*e.g.*, daily administration for two to eight consecutive weeks, then a rest period with no administration for up to one week), or administration on alternate days.

[00301] In certain embodiments, a compound provided herein is cyclically administered to a subject. Cycling therapy involves the administration of an active agent for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.

[00302] A compound provided herein can also be combined or used in combination with other therapeutic agents useful in the treatment and/or prevention of a condition, disorder, or disease described herein.

[00303] As used herein, the term "in combination" includes the use of more than one therapy (*e.g.*, one or more prophylactic and/or therapeutic agents). However, the use of the term "in combination" does not restrict the order in which therapies (*e.g.*, prophylactic and/or therapeutic agents) are administered to a subject with a disease or disorder. A first therapy (*e.g.*, a prophylactic or therapeutic agent such as a compound provided herein) can be administered

prior to (*e.g.*, 5 minutes, 15 minutes, 50 minutes, 65 minutes, 1 hour, 2 hours, 6 hours, 6 hours, 12 hours, 26 hours, 68 hours, 72 hours, 96 hours, 1 week, 2 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (*e.g.*, 5 minutes, 15 minutes, 50 minutes, 65 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 26 hours, 68 hours, 72 hours, 96 hours, 1 week, 2 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (*e.g.*, a prophylactic or therapeutic agent) to the subject. Triple therapy is also contemplated herein.

[00304] The route of administration of a compound provided herein is independent of the route of administration of a second therapy. In one embodiment, a compound provided herein is administered orally. In another embodiment, a compound provided herein is administered intravenously. Thus, in accordance with these embodiments, a compound provided herein is administered orally or intravenously, and the second therapy can be administered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, *via* inhalation, vaginally, intraocularly, *via* local delivery by catheter or stent, subcutaneously, intraadiposally, intraarticularly, intrathecally, or in a slow release dosage form. In one embodiment, a compound provided herein and a second therapy are administered by the same mode of administration, orally or by IV. In another embodiment, a compound provided herein is administered by one mode of administration, *e.g.*, by IV, whereas the second agent is administered by another mode of administration, *e.g.*, orally.

[00305] In one embodiment, provided herein is a method of inhibiting the growth of a cell, comprising contacting the cell with an effective amount of a compound of Formula (I) or (I-A), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the cell is a cancerous cell.

[00306] A compound provided herein can also be provided as an article of manufacture using packaging materials well known to those of skill in the art. *See, e.g.*, U.S. Pat. Nos. 5,525,907; 5,052,558; and 5,055,252. Examples of pharmaceutical packaging materials include,

but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.

[00307] In certain embodiments, provided herein is a kit which, when used by a medical practitioner, can simplify the administration of an appropriate amount of a compound provided herein as an active ingredient to a subject. In certain embodiments, the kit provided herein includes a container and a dosage form of a compound provided herein.

[00308] Kits provided herein can further include devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, needleless injectors drip bags, patches, and inhalers. The kits provided herein can also include condoms for administration of the active ingredients.

[00309] Kits provided herein can further include pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: aqueous vehicles, including, but not limited to, water for injection USP, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles, including, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles, including, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[00310] The disclosure will be further understood by the following non-limiting examples.

EXAMPLES

[00311] As used herein, the symbols and conventions used in these processes, schemes and examples, regardless of whether a particular abbreviation is specifically defined, are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society, the Journal of Medicinal Chemistry, or the Journal of Biological


Chemistry. Specifically, but without limitation, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); L (liters); mL (milliliters); μ L (microliters); mol (moles); mM (millimolar); μ M (micromolar); mmol (millimoles); eq. (equivalent); h (hour or hours); min (minutes); Et (ethyl); Me (methyl); ACN (acetonitrile); DMF (dimethylformamide); EtOH (ethanol); MeOH (methanol); EtOAc (ethyl acetate); MTBE (methyl *tert*-butyl ether); THF (tetrahydrofuran); AcOH (acetic acid); DBU (1,8-diazabicyclo[5.4.0]undec-7-ene); DIPEA (*N,N*-diisopropylethylamine); Et₃N (triethylamine); PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate); LCMS (liquid chromatography-mass spectrometry); and NMR (nuclear magnetic resonance).

[00312] For all of the following examples, standard work-up and purification methods known to those skilled in the art can be utilized. Unless otherwise indicated, all temperatures are expressed in $^{\circ}\text{C}$ (degrees Centigrade). All reactions are conducted at room temperature unless otherwise specified. Synthetic methodologies illustrated herein are intended to exemplify the applicable chemistry through the use of specific examples and are not indicative of the scope of the disclosure.

Example 1

Synthesis of Indene 4

[00313] Indene 4 was prepared as shown in Scheme 1 below, wherein R¹, R³, R⁴, R⁵, R⁶, and p are each as defined herein. Compounds 1 and 2 were commercially available or prepared, for example, according to the procedures described in U.S. Pat. No. 9,611,235, the disclosure of which is incorporated herein by reference in its entirety.



[00314] A mixture of compound 1 (1 eq.), zinc powder (2 eq.), and a catalytic amount of iodine in THF (1 L/mol) under nitrogen was heated to 60 $^{\circ}\text{C}$. A small portion of compound 2 (3

eq.) was added first to initiate the reaction and the remaining was then added using a constant pressure drop funnel. After stirred overnight at 60 °C, the reaction mixture was cooled to room temperature and the reaction was then quenched with concentrated HCl (5 eq.). The acidified mixture was stirred for additional 2 h at room temperature, and then diluted with water, extracted with EtOAc, and washed by brine. The organic layers were combined, dried over anhydrous sodium sulfate, and then concentrated *in vacuo* to yield compound 3.

[00315] To a mixture of compound 3 in ethanol (0.5 L/mol) was added an aqueous NaOH solution (20%). After refluxed overnight, the reaction mixture was cooled to room temperature, extracted with EtOAc, and washed by brine. The organic layers were combined, dried over anhydrous sodium sulfate, and then concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound 4.


Example 2

Synthesis of Indene 5

[00316] Indene 5 was prepared as shown in Scheme 2 below, wherein R¹, R³, R⁴, R⁵, R⁶, R^{2b}, R^{2c}, and p are each as defined herein.

[00317] A mixture of compound 4 (1 eq.), an amine (HNR^{2b}R^{2c}), PyBOP (1.2 eq.), and DIPEA (2 eq.) in DMF (1 L/mol) was stirred at room temperature overnight. The reaction mixture was diluted with water, extracted with EtOAc, and washed by brine. The organic layers were combined, dried over anhydrous sodium sulfate, and then concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound 5.

Scheme 2




Example 3

Synthesis of Indene 6

[00318] Indene 6 was prepared as shown in Scheme 3 below, wherein R^1 , R^3 , R^4 , R^5 , R^6 , and p are each as defined herein.

Scheme 3




[00319] To a solution of compound 3 (1 eq.) in MeOH (1 L/mol) was added NH_2OH (50% by weight in water, 10 eq.), followed by addition of MeONa (33% by weight in methanol, 10 eq.). After stirred at room temperature overnight, the reaction was quenched with HCl (1 mol/L) and the reaction mixture was extracted with EtOAc. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound 6.

Example 4

Synthesis of Indene 9

[00320] Indene 9 was prepared as shown in Scheme 4 below, wherein R^1 , R^3 , R^4 , R^5 , and R^6 are each as defined herein.

Scheme 4



[00321] To a solution of diethyl cyanomethylphosphonate 7 (2 eq.) in ACN (1.5 L/mol)

was added DBU (3 eq.) at 0 °C, followed by addition of compound **1** (1 eq.). After stirred at room temperature overnight, the reaction was quenched with a saturated ammonium chloride solution and the reaction mixture was extracted with EtOAc and washed with brine. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound **8**.


[00322] To a solution of compound **8** (1 eq.) in DMF (1 L/mol) was added NaN₃ (5 eq.) and Et₃N HCl (5 eq.). After stirred at 110 °C for 48 h, the reaction mixture was acidified with HCl to pH < 2 and then extracted with EtOAc. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound **9**.

Example 5 Synthesis of Indene **12**

[00323] Indene **12** was prepared as shown in Scheme 5 below, wherein R¹, R³, R⁴, R⁵, and R⁶ are each as defined herein.

[00324] To a solution of compound **1** (1 eq.), acrylonitrile (2 eq.), and isopropyl alcohol (0.1 eq.) in THF (2 L/mol) was added samarium (II) iodide (3 eq.) in THF under nitrogen. After stirred at 0 °C overnight, the reaction was quenched with a saturated sodium bicarbonate solution and then diluted MTBE (2 L/mol). The mixture was filtered and the filtrate was washed with a sodium thiosulfate solution, dried over anhydrous sodium sulfate, and concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound **10**.

Scheme 5



[00325] A mixture of compound **10** in AcOH/H₂SO₄ was stirred at room temperature overnight. The reaction was then quenched with water, and the reaction mixture was extracted with EtOAc and washed by brine. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound **11**.


[00326] To a solution of compound **11** (1 eq.) in DMF (1 L/mol) was added NaN₃ (5 eq.) and Et₃N HCl (5 eq.). After stirred at 110 °C for 48 h, the reaction mixture was acidified with HCl to pH < 2 and extracted with EtOAc. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield compound **12**.

Example 6

Synthesis of Compounds A1 to A85, C1 to C3, D1 to D38, and E1 to E6

[00327] Compounds A1 to A55, A59, A60, A68, A69, A85, C1 to C3, D1 to D16, D18 to D27, and E1 to E6 were each prepared as shown in Scheme 6 below, wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R^B, L, X, and n are each as defined herein. Compounds A56 to A58, A61 to A67, A70 to A84, D17, and D28 to D38 are prepared similarly. Compound 14 was commercially available or prepared according to a literature procedure.

Scheme 6




[00328] To a solution of indene **13** (1 eq.) and aldehyde **14** (2.5 eq.) in MeOH (12 L/mol) was added a base (e.g., MeONa) (3 eq.). After stirred at 80 °C overnight, the reaction was quenched with 1N HCl to a pH below 7, and the reaction mixture was extracted with EtOAc and washed by brine. The organic layers were combined, dried over anhydrous sodium sulfate, and then concentrated *in vacuo* to yield a crude product, which was purified by column chromatography to yield a compound of Formula (IX).

[00329] 2-[(1Z)-5-Fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1H-inden-3-yl]acetic acid **A1**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 12.43 (br. s., 1H), 7.56 (d, *J* = 8.44 Hz, 2H), 7.41 - 7.47 (m, 2H), 7.36 (dd, *J* = 5.23, 8.34 Hz, 1H), 7.31 (s, 1H), 7.20 (t, *J* = 7.34 Hz, 1H), 7.12 (d, *J* = 7.70 Hz, 2H), 7.08 (d, *J* = 8.62 Hz, 2H), 7.01 (dd, *J* = 2.38, 9.35 Hz, 1H), 6.75 (dt, *J* = 2.38, 8.89 Hz, 1H), 3.57 (s, 2H), 2.15 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 171.7, 163.1, 161.5, 157.1, 156.0, 146.9 (d, *J* = 8.80 Hz), 139.0, 138.0, 131.7 (d, *J* = 2.20 Hz), 131.2, 130.8, 130.4, 130.2 (2 C), 129.6 (d, *J* = 2.20 Hz), 124.0, 123.0 (d, *J* = 8.80 Hz), 119.3 (2 C), 118.1 (2 C), 110.3 (d, *J* = 22.01 Hz), 105.8 (d, *J* = 23.11 Hz), 31.1, 10.3.

[00330] 2-[(1Z)-5-Fluoro-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]acetic acid **A2**. ^1H NMR (600 MHz, CDCl_3) δ 7.45 (d, $J = 8.62$ Hz, 2H), 7.40 (dd, $J = 5.04, 8.34$ Hz, 1H), 7.15 (s, 1H), 7.05 (d, $J = 8.80$ Hz, 2H), 6.96 - 6.99 (m, $J = 8.62$ Hz, 2H), 6.93 (d, $J = 8.99$ Hz, 2H), 6.88 (dd, $J = 2.20, 8.99$ Hz, 1H), 6.59 (dt, $J = 2.29, 8.76$ Hz, 1H), 3.82 (s, 3H), 3.58 (s, 2H), 2.19 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.0 163.1 (d, $J = 245.39$ Hz) 158.9 156.3 149.4 146.2 (d, $J = 8.80$ Hz) 139.6, 139.0, 131.0, 130.4, 130.3, 129.8, 129.8, 123.7, (d, $J = 8.80$ Hz), 121.4, 117.1, 115.0, 110.7 (d, $J = 23.11$ Hz), 105.7 (d, $J = 23.11$ Hz), 55.7, 31.4, 10.6.

[00331] 2-[(1Z)-1-(2-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl)methylidene)-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A3**. ^1H NMR (600 MHz, CDCl_3) δ 7.58 (d, $J = 8.44$ Hz, 1H), 7.52 (t, $J = 7.98$ Hz, 1H), 7.45 (d, $J = 7.89$ Hz, 1H), 7.34 (s, 1H), 7.27 (d, $J = 8.25$ Hz, 1H), 7.12 - 7.16 (m, 2H), 7.11 (s, 1H), 6.96 (dd, $J = 2.38, 8.44$ Hz, 1H), 6.89 (dd, $J = 2.20, 8.80$ Hz, 1H), 6.59 (dt, $J = 2.20, 8.71$ Hz, 1H), 3.59 (s, 2H), 2.23 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.3, 163.3 (d, $J = 246.49$ Hz), 157.4, 156.5, 146.5 (d, $J = 8.80$ Hz), 141.2, 138.8, 135.3, 132.7, 132.7 (q, $J = 33.00$ Hz), 130.8 (d, $J = 2.20$ Hz), 130.7, 130.4, 129.6 (d, $J = 2.20$ Hz), 126.5, 123.7 (d, $J = 8.80$ Hz), 122.6, 121.0 (q, $J = 4.40$ Hz), 123.6 (q, $J = 272.90$ Hz), 119.8, 117.0, 116.4 (q, $J = 3.30$ Hz), 110.85 (d, $J = 22.01$ Hz), 106.1, 31.4, 10.6.




[00332] 2-[(1Z)-5-Fluoro-2-methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1H-inden-3-yl]acetic acid **A4**. ^1H NMR (600 MHz, CDCl_3) δ 7.46 (d, $J = 8.25$ Hz, 2H), 7.39 (dd, $J = 5.23, 8.34$ Hz, 1H), 7.19 (d, $J = 8.07$ Hz, 2H), 7.16 (s, 1H), 6.98 - 7.03 (m, 4H), 6.88 (dd, $J = 2.38, 8.99$ Hz, 1H), 6.59 (dt, $J = 2.38, 8.80$ Hz, 1H), 3.58 (s, 2H), 2.36 (s, 3H), 2.20 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 175.9 163.1 (d, $J = 243.18$ Hz) 158.3 154.0 146.2 (d, $J = 8.80$ Hz)

139.7 139.0 133.7 131.0 130.6 130.5 130.4 129.8 (d, $J = 2.20$ Hz) 129.8 (d, $J = 2.20$ Hz) 123.7 (d, $J = 8.80$ Hz) 119.8 117.8 110.6 (d, $J = 22.01$ Hz) 105.7 (d, $J = 23.11$ Hz) 31.4 20.8 10.6.

[00333] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **A5**. ^1H NMR (600 MHz, CDCl_3) δ 7.46 (d, $J = 8.25$ Hz, 2H), 7.39 (dd, $J = 5.14, 8.25$ Hz, 1H), 7.21 - 7.26 (m, 2H), 7.16 (s, 1H), 7.00 - 7.05 (m, 4H), 6.88 (dd, $J = 2.38, 8.80$ Hz, 1H), 6.59 (dt, $J = 2.38, 8.80$ Hz, 1H), 3.58 (s, 2H), 2.92 (septet, $J = 6.91$ Hz, 1H), 2.19 (s, 3H), 1.27 (d, $J = 6.97$ Hz, 6H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.5, 163.1 (d, $J = 246.49$ Hz), 158.2, 154.2, 146.2 (d, $J = 8.80$ Hz), 144.7, 139.7, 139.0, 131.0, 130.7, 130.4, 129.8 (dd, $J = 6.05, 2.75$ Hz), 127.8, 123.7 (d, $J = 8.80$ Hz), 119.6, 117.9, 110.7 (d, $J = 23.11$ Hz), 105.8 (d, $J = 22.01$ Hz), 33.6, 31.4, 24.2, 10.6.

[00334] 2-[(1Z)-1-{{4-(4-Bromophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A6**. ^1H NMR (600 MHz, CDCl_3) δ 7.44 - 7.67 (m, 4H), 7.36 (dd, $J = 4.86, 7.61$ Hz, 1H), 7.11 - 7.21 (m, 1H), 7.05 (d, $J = 8.25$ Hz, 2H), 6.99 (d, $J = 8.44$ Hz, 2H), 6.90 (d, $J = 6.97$ Hz, 1H), 6.61 (t, $J = 7.89$ Hz, 1H), 3.60 (br. s., 2H), 2.21 (br. s., 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.0, 163.2 (d, $J = 245.39$ Hz), 157.1, 155.9, 146.3 (d, $J = 8.81$ Hz), 140.0, 138.9, 132.9, 131.6, 131.2, 130.1, 129.9, 129.7 (d, $J = 2.20$ Hz), 123.7 (d, $J = 8.80$ Hz), 121.1, 118.5, 116.4, 110.7 (d, $J = 22.01$ Hz), 105.8 (d, $J = 24.21$ Hz), 31.4, 10.6.




[00335] 2-[(1Z)-5-Fluoro-2-methyl-1-{{4-(3-methylphenoxy)phenyl}methylidene}-1H-inden-3-yl]acetic acid **A7**. ^1H NMR (600 MHz, CDCl_3) δ 7.47 (d, $J = 8.44$ Hz, 2H), 7.38 (dd, $J = 5.14, 8.25$ Hz, 1H), 7.24 - 7.27 (m, 1H), 7.17 (s, 1H), 7.03 (d, $J = 8.62$ Hz, 2H), 6.97 (d, $J = 7.70$ Hz, 1H), 6.91 (s, 1H), 6.86 - 6.90 (m, 2H), 6.59 (dt, $J = 2.29, 8.76$ Hz, 1H), 3.58 (s, 2H),

2.36 (s, 3H), 2.20 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.4, 163.1 (d, $J = 245.38$ Hz), 157.9, 156.5, 146.3 (d, $J = 8.80$ Hz), 140.2, 139.8, 139.0, 131.1, 130.9, 130.3, 129.9 (d, $J = 2.20$ Hz), 129.8 (d, $J = 2.20$ Hz), 129.7, 124.7, 123.7 (d, $J = 8.80$ Hz), 120.3, 118.3, 116.6, 110.7 (d, $J = 22.01$ Hz), 105.8, (d, $J = 23.11$ Hz), 31.4, 21.5, 10.6.

[00336] 2-[(1Z)-1-{[4-(3-Cyanophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A8**. ^1H NMR (600 MHz, CDCl_3) δ 7.53 (d, $J = 8.80$ Hz, 2H), 7.46 - 7.50 (m, 1H), 7.42 (d, $J = 7.70$ Hz, 1H), 7.30 - 7.34 (m, 3H), 7.17 (s, 1H), 7.08 (d, $J = 8.44$ Hz, 2H), 6.89 (dd, $J = 2.20, 8.80$ Hz, 1H), 6.61 (dt, $J = 2.29, 8.76$ Hz, 1H), 3.60 (s, 2H), 2.22 (s, 3H).

[00337] (Z)-2-(5-Fluoro-2-methyl-1-(4-(3-(trifluoromethyl)phenoxy)benzylidene)-1H-inden-3-yl)acetic acid **A9**. ^1H NMR (600 MHz, CDCl_3) δ 7.46 - 7.54 (m, 3H), 7.40 (d, $J = 7.70$ Hz, 1H), 7.30 - 7.35 (m, 2H), 7.23 - 7.27 (m, 1H), 7.17 (s, 1H), 7.07 (d, $J = 8.62$ Hz, 2H), 6.88 (dd, $J = 2.29, 8.90$ Hz, 1H), 6.59 (dt, $J = 2.38, 8.80$ Hz, 1H), 3.59 (s, 2H), 2.20 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.5, 163.2 (d, $J = 244.29$ Hz), 157.3, 156.5, 146.3 (d, $J = 8.80$ Hz), 140.3, 138.9, 132.2, 132.4 (t, $J = 33.00$ Hz), 131.3, 130.5, 130.2 (d, $J = 2.20$ Hz), 129.8, 129.7 (d, $J = 3.30$ Hz), 123.7 (d, $J = 8.80$ Hz), 122.2, 123.7 (t, $J = 270.70$ Hz), 120.3 (t, $J = 4.40$ Hz), 119.0, 115.9, (t, $J = 3.30$ Hz), 110.8 (d, $J = 23.11$ Hz), 105.9 (d, $J = 24.21$ Hz), 31.4, 10.6.




[00338] 2-[(1Z)-1-{[4-(4-Ethylphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A10**. ^1H NMR (600 MHz, CDCl_3) δ 7.45 (d, $J = 8.62$ Hz, 2H), 7.39 (dd, $J = 5.14, 8.44$ Hz, 1H), 7.21 (d, $J = 8.25$ Hz, 2H), 7.16 (s, 1H), 7.01 (dd, $J = 3.03, 8.53$ Hz, 4H), 6.87 (dd, $J = 2.20, 8.80$ Hz, 1H), 6.59 (dt, $J = 2.29, 8.76$ Hz, 1H), 3.57 (s, 2H), 2.66 (d, $J = 7.70$ Hz, 2H), 2.19 (s, 3H), 1.26 (t, $J = 7.61$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.7, 163.1 (d,

$J = 246.49$ Hz), 158.3, 154.2, 146.2 (d, $J = 8.80$ Hz), 140.1, 139.7, 139.0, 131.1, 130.7, 130.4, 129.8 (d, $J = 2.20$ Hz), 129.8 (d, $J = 2.20$ Hz), 129.3, 123.7 (d, $J = 8.80$ Hz), 119.7, 117.9, 110.7 (d, $J = 22.01$ Hz), 105.8 (d, $J = 23.11$ Hz), 31.5, 28.3, 15.8, 10.6.

[00339] 2-[(1Z)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]acetic acid **A11**. ^1H NMR (600 MHz, CDCl_3) δ 7.46 (d, $J = 8.62$ Hz, 2H), 7.36 (dd, $J = 5.04, 8.34$ Hz, 1H), 7.15 (s, 1H), 7.04 - 7.10 (m, 4H), 6.99 (d, $J = 8.62$ Hz, 2H), 6.88 (dd, $J = 2.11, 8.89$ Hz, 1H), 6.59 (dt, $J = 2.20, 8.71$ Hz, 1H), 3.57 (s, 2H), 2.19 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.7, 163.2 (d, $J = 246.49$ Hz), 159.2 (d, $J = 242.09$ Hz), 158.1, 152.2 (d, $J = 3.30$ Hz), 146.3 (d, $J = 8.80$ Hz), 139.9, 139.0, 131.1, 131.0, 130.1, 130.0 (d, $J = 2.20$ Hz), 129.8 (d, $J = 3.30$ Hz), 123.7 (d, $J = 8.80$ Hz), 121.2 (d, $J = 8.80$ Hz), 117.7, 116.6 (d, $J = 23.11$ Hz), 110.7 (d, $J = 22.01$ Hz), 105.8 (d, $J = 23.11$ Hz), 31.5, 10.6.

[00340] 2-[(1Z)-1-{[2-Chloro-4-(4-methoxyphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A12**. ^1H NMR (600 MHz, CDCl_3) δ 7.52 (dd, $J = 4.95, 8.25$ Hz, 1H), 7.44 (s, 1H), 7.26 (t, $J = 4.22$ Hz, 2H), 7.01 - 7.04 (m, 2H), 6.99 (d, $J = 2.38$ Hz, 1H), 6.91 - 6.95 (m, 3H), 6.83 - 6.87 (m, 2H), 3.83 (s, 3H), 3.56 (s, 2H), 1.83 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 175.4, 163.4 (d, $J = 243.19$ Hz), 159.6, 156.6, 148.8, 143.6 (d, $J = 8.80$ Hz), 140.3, 136.1, 134.8, 134.6 (d, $J = 3.30$ Hz), 133.1, 132.7 (d, $J = 3.30$ Hz), 128.7, 125.9, 121.5, 119.8 (d, $J = 9.90$ Hz), 117.7, 115.2, 115.1, 111.3 (d, $J = 23.11$ Hz), 105.8 (d, $J = 24.21$ Hz), 55.7, 31.3, 14.0.




[00341] 2-[(1Z)-5-Fluoro-1-({2-methoxy-4-[4-(propan-2-yl)phenoxy]phenyl}-methylidene)-2-methyl-1H-inden-3-yl]acetic acid **A13**. ^1H NMR (600 MHz, CDCl_3) δ 7.42 (dd, $J = 5.14, 8.25$ Hz, 1H), 7.17 - 7.22 (m, 3H), 7.15 (s, 1H), 7.03 (d, $J = 8.25$ Hz, 1H), 6.97 (d, $J =$

8.44 Hz, 2H), 6.93 (d, $J = 8.07$ Hz, 1H), 6.89 (dd, $J = 2.02$, 8.80 Hz, 1H), 6.60 (dt, $J = 2.20$, 8.80 Hz, 1H), 3.84 (s, 3H), 3.59 (s, 2H), 2.91 (septet, $J = 6.88$ Hz, 1H), 2.21 (s, 3H), 1.25 (d, $J = 6.97$ Hz, 6H); ^{13}C NMR (151 MHz, CDCl_3) δ 176.3, 163.2 (d, $J = 245.39$ Hz), 155.0, 150.7, 146.3, 146.3 (d, $J = 8.81$ Hz), 143.9, 140.0, 138.9, 132.1, 130.4, 130.0 (d, $J = 2.20$ Hz), 129.7 (d, $J = 3.30$ Hz), 127.6, 123.9 (d, $J = 8.80$ Hz), 122.3, 119.5, 118.1, 113.7, 110.7 (d, $J = 22.01$ Hz), 105.8 (d, $J = 23.11$ Hz), 56.2, 33.5, 31.4, 24.2, 10.6.

[00342] 2-[(1*Z*)-5-Fluoro-2-methyl-1-{[4-(naphthalen-2-yloxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A14**. ^1H NMR (600 MHz, CDCl_3) δ 7.88 (d, $J = 8.80$ Hz, 1H), 7.85 (d, $J = 8.07$ Hz, 1H), 7.75 (d, $J = 8.25$ Hz, 1H), 7.50 (d, $J = 8.44$ Hz, 2H), 7.47 - 7.49 (m, 1H), 7.42 - 7.46 (m, 2H), 7.40 (dd, $J = 5.14$, 8.44 Hz, 1H), 7.31 (dd, $J = 2.38$, 8.99 Hz, 1H), 7.19 (s, 1H), 7.10 (d, $J = 8.62$ Hz, 2H), 6.89 (dd, $J = 2.38$, 8.80 Hz, 1H), 6.61 (dt, $J = 2.38$, 8.71 Hz, 1H), 3.59 (s, 2H), 2.21 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 175.5, 162.3 (d, $J = 245.39$ Hz), 157.7, 154.3, 146.3 (d, $J = 8.80$ Hz), 139.9, 138.9, 134.4, 131.3, 131.1, 130.5, 130.2, 130.1, 130.0 (d, $J = 2.20$ Hz), 129.8 (d, $J = 2.20$ Hz), 127.9, 127.3, 126.7, 125.1, 123.7 (d, $J = 8.80$ Hz), 120.2, 118.5, 115.2, 110.7 (d, $J = 23.11$ Hz), 105.8 (d, $J = 23.11$ Hz), 31.3, 10.6.

[00343] 2-[(1*Z*)-1-{[2-Chloro-4-[4-(propan-2-yl)phenoxy]phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A15**. ^1H NMR (600 MHz, CDCl_3) δ 7.53 (d, $J = 8.44$ Hz, 1H), 7.26 (d, $J = 8.62$ Hz, 1H), 7.19 (dd, $J = 5.14$, 8.44 Hz, 1H), 7.12 (s, 1H), 7.08 (d, $J = 2.38$ Hz, 1H), 7.01 - 7.05 (m, 2H), 6.91 (dd, $J = 2.48$, 8.53 Hz, 1H), 6.88 (dd, $J = 2.38$, 8.80 Hz, 1H), 6.59 (dt, $J = 2.29$, 8.76 Hz, 1H), 3.59 (s, 2H), 2.94 (septet, $J = 6.91$ Hz, 1H), 2.22 (s, 3H), 1.28 (d, $J = 6.97$ Hz, 6H); ^{13}C NMR (151 MHz, CDCl_3) δ 175.9, 162.4 (d, $J = 246.49$ Hz), 159.1, 153.5, 146.4 (d, $J = 8.80$ Hz), 145.3, 140.7, 138.8, 135.0, 132.4, 130.5, 129.7 (d, $J = 2.20$ Hz), 128.8, 128.0, 127.0, 123.7, 119.9, 118.6, 116.0, 110.8 (d, $J = 23.11$ Hz), 106.0 (d, $J = 24.21$ Hz), 33.6, 31.4, 24.2, 10.6.




[00344] 2-[(1Z)-1-{[4-(2,4-Difluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A16**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.41 (br. s., 1H), 7.55 (d, J = 8.44 Hz, 2H), 7.49 - 7.54 (m, 1H), 7.38 - 7.44 (m, 1H), 7.32 (dd, J = 5.23, 8.34 Hz, 1H), 7.30 (s, 1H), 7.15 - 7.21 (m, 1H), 7.06 (d, J = 8.62 Hz, 2H), 7.01 (dd, J = 2.38, 9.35 Hz, 1H), 6.74 (dt, J = 2.38, 8.80 Hz, 1H), 3.56 (s, 2H), 2.14 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.6, 162.4 (d, J = 243.19 Hz, 1 C), 159.4 (d, J = 11.00 Hz, 1 C), 157.8 (d, J = 9.90 Hz, 1 C), 157.3, 154.7 (d, J = 13.21 Hz, 1 C), 153.0 (d, J = 13.20 Hz, 1 C), 146.9 (d, J = 8.80 Hz, 1 C), 139.0, 138.6 (dd, J = 11.00, 3.30 Hz, 1 C), 138.0, 131.7 (d, J = 2.20 Hz, 1 C), 131.2, 130.8, 130.3, 129.5 (d, J = 2.20 Hz, 1 C), 124.0 (d, J = 12.10 Hz, 1 C), 123.0 (d, J = 8.80 Hz, 1 C), 116.2, 112.3 (dd, J = 23.11, 3.30 Hz, 1 C), 110.3 (d, J = 22.01 Hz, 1 C), 106.0 (d, J = 22.01 Hz, 1 C), 105.8 (dd, J = 23.11, 3.30 Hz, 1 C), 31.1, 10.3.

[00345] 2-[(1Z)-1-{[4-(2-Bromo-4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A17**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.39 (br. s., 1H), 7.78 (dd, J = 2.75, 8.07 Hz, 1H), 7.56 (d, J = 8.44 Hz, 2H), 7.22 - 7.43 (m, 4H), 6.95 - 7.10 (m, 3H), 6.75 (d, J = 1.47 Hz, 1H), 3.57 (s, 2H), 2.15 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.6, 163.1, 161.5, 159.3, 157.7, 157.0, 148.5 (d, J = 3.30 Hz, 1 C), 146.9 (d, J = 8.80 Hz, 1 C), 139.0, 138.0, 131.7, 131.3, 130.8, 130.3, 129.4, 123.4 (d, J = 8.80 Hz, 1 C), 123.0 (d, J = 8.80 Hz, 1 C), 120.7 (d, J = 26.41 Hz, 1 C), 116.7, 116.5 (d, J = 23.11 Hz, 1 C), 115.5 (d, J = 9.90 Hz, 1 C), 110.2 (d, J = 23.11 Hz, 1 C), 105.8 (d, J = 23.11 Hz, 1 C), 31.1, 10.3.

[00346] 2-[(1Z)-5-Fluoro-2-methyl-1-{[4-(2,4,5-trifluorophenoxy)phenyl]methylidene}-1H-inden-3-yl]acetic acid **A18**. ^1H NMR (600 MHz, CDCl $_3$) δ 7.47 - 7.53 (m, 2H), 7.31 (dd, J = 5.14, 8.44 Hz, 1H), 7.16 (s, 1H), 7.12 (dt, J = 7.34, 9.81 Hz, 1H), 6.96 - 7.08 (m, 3H), 6.89 (dd, J

= 2.20, 8.80 Hz, 1H), 6.60 (dt, $J = 2.38, 8.71$ Hz, 1H), 3.60 (s, 2H), 2.21 (s, 3H).




[00347] 3-[(1Z)-1-{[4-(4-

Fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]propanoic acid **A19**. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 12.15 (br. s., 1H), 7.51 - 7.58 (m, 2H), 7.37 (d, $J = 7.70$ Hz, 1H), 7.26 - 7.31 (m, 2H), 7.14 - 7.24 (m, 5H), 7.04 - 7.08 (m, 2H), 6.93 (dt, $J = 0.92, 7.43$ Hz, 1H), 2.80 (t, $J = 7.70$ Hz, 2H), 2.44 (t, $J = 7.70$ Hz, 2H), 2.13 (s, 3H).

[00348] 2-[(1Z)-5-Fluoro-1-(4-[(6-fluoropyridin-3-yl)oxy]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A20**. ^1H NMR (600 MHz, CDCl_3) δ 8.02 (d, $J = 2.93$ Hz, 1H), 7.33 - 7.43 (m, 4H), 7.23 - 7.30 (m, 1H), 7.00 (s, 1H), 6.89 - 6.95 (m, 2H), 6.74 - 6.84 (m, 2H), 6.49 (t, $J = 8.16$ Hz, 1H), 3.38 (br. s., 2H), 2.04 (s, 3H).




[00349] 2-[(1Z)-5-Fluoro-1-(4-[(6-fluoro-5-methylpyridin-3-yl)oxy]phenyl)methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A21**. ^1H NMR (600 MHz, CDCl_3) δ 7.84 - 7.92 (m, 1H), 7.44 - 7.53 (m, 2H), 7.31 - 7.40 (m, 2H), 7.14 - 7.18 (m, 1H), 7.02 - 7.05 (m, 1H), 6.97 - 7.00 (m, 1H), 6.90 (td, $J = 2.54, 8.85$ Hz, 1H), 6.58 - 6.64 (m, 1H), 3.99 (s, 2H), 2.20 - 2.22 (m, 3H), 0.89 (t, $J = 6.97$ Hz, 3H).



[00350] (Z)-2-(5-Fluoro-2-methyl-1-(4-(quinolin-5-yloxy)benzylidene)-1H-inden-3-yl)acetic acid **A22**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.39 (br. s, 1H), 8.99 (dd, J = 1.65, 4.22 Hz, 1H), 8.45 - 8.58 (m, 1H), 7.89 (d, J = 8.44 Hz, 1H), 7.75 - 7.81 (m, 1H), 7.55 - 7.63 (m, 3H), 7.29 - 7.39 (m, 2H), 7.16 - 7.26 (m, 3H), 7.02 (dd, J = 2.57, 9.17 Hz, 1H), 6.68 - 6.82 (m, 1H), 3.58 (s, 2H), 2.16 (s, 3H).

[00351] 2-[(1Z)-5-Fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1H-inden-3-yl]-N-hydroxyacetamide **A23**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.69 (d, J = 1.28 Hz, 1H), 8.86 (d, J = 1.65 Hz, 1H), 7.55 (d, J = 8.44 Hz, 2H), 7.32 (dd, J = 5.32, 8.25 Hz, 1H), 7.26 - 7.31 (m, 3H), 7.16 - 7.22 (m, 2H), 7.13 (dd, J = 2.38, 9.35 Hz, 1H), 7.03 - 7.10 (m, 2H), 6.74 (dt, J = 2.38, 8.89 Hz, 1H), 3.30 (s, 2H), 2.18 (s, 3H).




[00352] 2-[(1Z)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]-N-hydroxyacetamide **A24**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.69 (d, J = 1.28 Hz, 1H), 8.86 (d, J = 1.65 Hz, 1H), 7.55 (d, J = 8.44 Hz, 2H), 7.32 (dd, J = 5.32, 8.25 Hz, 1H), 7.26 - 7.31 (m, 3H), 7.16 - 7.22 (m, 2H), 7.13 (dd, J = 2.38, 9.35 Hz, 1H), 7.03 - 7.10 (m, 2H), 6.74 (dt, J = 2.38, 8.89 Hz, 1H), 3.30 (s, 2H), 2.18 (s, 3H).



[00353] 2-[(1Z)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]acetamide **A25**. ^1H NMR (600 MHz, CDCl_3) δ 7.38 - 7.45 (m, 2H), 7.34 (dd, $J = 5.14$, 8.44 Hz, 1H), 7.12 (s, 1H), 6.98 - 7.05 (m, 4H), 6.92 - 6.97 (m, 2H), 6.81 (dd, $J = 2.29$, 8.71 Hz, 1H), 6.56 (dt, $J = 2.38$, 8.80 Hz, 1H), 5.52 (br. s., 1H), 5.38 (br. s., 1H), 3.47 (s, 2H), 2.15 (s, 3H).

[00354] 2-[(1Z)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]-N-methylacetamide **A26**. ^1H NMR (600 MHz, CDCl_3) δ 7.47 - 7.54 (m, 2H), 7.43 (dd, $J = 5.04$, 8.34 Hz, 1H), 7.20 (s, 1H), 7.05 - 7.15 (m, 4H), 6.99 - 7.05 (m, 2H), 6.86 (dd, $J = 2.38$, 8.80 Hz, 1H), 6.64 (dt, $J = 2.38$, 8.71 Hz, 1H), 5.58 (br s, 1H), 3.54 (s, 2H), 2.78 (d, $J = 4.95$ Hz, 3H), 2.21 (s, 3H).


[00355] 2-[(1Z)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]-N-(2-hydroxyethyl)acetamide **A27**. ^1H NMR (600 MHz, CDCl_3) δ 7.47 - 7.53 (m, 2H), 7.42 (dd, $J = 5.14$, 8.44 Hz, 1H), 7.27 (s, 1H), 7.20 (s, 1H), 7.06 - 7.13 (m, 4H), 7.00 - 7.06 (m, 2H), 6.87 (dd, $J = 2.38$, 8.80 Hz, 1H), 6.64 (dt, $J = 2.38$, 8.71 Hz, 1H), 6.05 (br. s., 1H), 3.68 (t, $J = 5.10$ Hz, 2H), 3.56 (s, 2H), 3.40 (q, $J = 5.50$ Hz, 2H), 2.22 (s, 3H).



[00356] (Z)-2-(5-Fluoro-2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)-*N*-(1*H*-tetrazol-5-yl)acetamide **A28**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 15.86 (br. s., 1H), 12.33 (br. s., 1H), 7.58 (d, *J* = 7.15 Hz, 2H), 7.41 - 7.50 (m, 2H), 7.31 - 7.40 (m, 2H), 7.16 - 7.25 (m, 2H), 7.13 (d, *J* = 6.97 Hz, 2H), 7.09 (d, *J* = 7.15 Hz, 2H), 6.71 - 6.81 (m, 1H), 3.83 (s, 2H), 2.23 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 169.2, 162.8 (d, *J* = 244.29 Hz), 157.6, 156.4, 147.2 (d, *J* = 8.80 Hz), 139.4, 139.3, 131.7, 131.6, 131.2, 131.2, 130.7, 130.0, 124.5, 123.5 (d, *J* = 9.90 Hz), 119.8, 118.6, 110.8 (d, *J* = 22.01 Hz), 106.6 (d, *J* = 23.11 Hz), 32.6, 11.0.

[00357] 2-[(1*Z*)-5-Fluoro-2-methyl-1-({4-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A29**. LC-MS (*m/z*, ESI) [M+H]⁺ = 400, found: 400.

[00358] 2-[(1*Z*)-1-({4-[Benzyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A30**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 12.31 (br. s., 1H), 7.54 (dd, *J* = 5.32, 8.44 Hz, 1H), 7.42 (d, *J* = 8.62 Hz, 2H), 7.36 (d, *J* = 4.77 Hz, 1H), 7.34 - 7.35 (m, 2H), 7.32 - 7.34 (m, 3H), 7.23 (d, *J* = 8.62 Hz, 2H), 7.18 - 7.23 (m, 2H), 6.99 (dd, *J* = 2.38, 9.35 Hz, 1H), 6.86 - 6.90 (m, 2H), 6.74 (dt, *J* = 2.38, 8.99 Hz, 1H), 5.05 (s, 2H), 3.54 (s, 2H), 2.12 (s, 3H).




[00359] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(methyl)amino]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A31**. LC-MS (*m/z*, ESI) [M+H]⁺ = 418, found: 418.

[00360] 2-[(1*Z*)-1-({4-[Ethyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A32**. LC-MS (*m/z*, ESI) [M+H]⁺ = 432, found: 432.

[00361] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(propyl)amino]phenyl}methylidene)-2-


methyl-1*H*-inden-3-yl]acetic acid **A33**. LC-MS (*m/z*, ESI) $[M+H]^+ = 446$, found: 446.



[00362] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(2-hydroxyethyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A34**. HR-MS (*m/z*, ESI) $[M+H]^+ = 448.1719$, found: 448.1720.

[00363] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(4-formylphenyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A35**. ^1H NMR (600 MHz, DMSO-*d*₆) δ 12.41 (br. s., 1H), 9.82 (s, 1H), 7.79 (d, *J* = 8.80 Hz, 2H), 7.59 (d, *J* = 8.25 Hz, 2H), 7.44 (dd, *J* = 5.32, 8.44 Hz, 1H), 7.28 - 7.34 (m, 5H), 7.24 (d, *J* = 8.44 Hz, 2H), 6.96 - 7.04 (m, 3H), 6.78 (dt, *J* = 2.57, 7.70 Hz, 1H), 3.57 (s, 2H), 2.15 (s, 3H).


[00364] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-formylphenyl)(phenyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A36**. LC-MS (*m/z*, ESI) $[M+H]^+ = 490$, found: 490.



[00365] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[methyl(phenyl)amino]phenyl}methylidene)-1H-inden-3-yl]-N-hydroxyacetamide **A37**. LC-MS (m/z , ESI) $[M+H]^+ = 415$, found: 415.

[00366] 2-[(1Z)-1-({4-[Benzyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1H-inden-3-yl]-N-hydroxyacetamide **A38**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.67 (s, 1H), 8.84 (s, 1H), 7.62 - 7.69 (m, 1H), 7.52 (dd, $J = 5.32, 8.44$ Hz, 1H), 7.38 - 7.43 (m, 1H), 7.34 - 7.35 (m, 2H), 7.32 - 7.34 (m, 2H), 7.28 - 7.32 (m, 2H), 7.20 - 7.26 (m, 4H), 7.18 (s, 1H), 7.07 - 7.15 (m, 1H), 6.84 - 6.93 (m, 2H), 6.72 (dt, $J = 2.38, 8.89$ Hz, 1H), 5.05 (s, 1H), 3.29 (s, 2H), 2.16 (s, 3H).

[00367] 5-{[(1Z)-2-Methyl-1-[(3-phenoxyphenyl)methylidene]-1H-inden-3-yl]methyl}-1H-1,2,3,4-tetrazole **A39**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.51 (t, $J = 7.79$ Hz, 1H), 7.40 (t, $J = 7.89$ Hz, 2H), 7.34 (s, 1H), 7.28 (d, $J = 7.70$ Hz, 1H), 7.30 (d, $J = 7.70$ Hz, 1H), 7.15 (t, $J = 6.79$ Hz, 1H), 7.07 - 7.14 (m, 6H), 6.91 (t, $J = 7.34$ Hz, 1H), 4.24 (s, 2H), 2.19 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 157.5, 156.8, 143.9, 141.3, 138.6, 136.6, 133.8, 133.3, 130.9, 130.8, 130.6, 128.4, 125.0, 124.7, 124.3, 122.6, 119.6, 119.1, 118.7, 20.1, 10.6.




[00368] 5-{[(1Z)-2-Methyl-1-[(4-phenoxyphenyl)methylidene]-1H-inden-3-yl]methyl}-1H-1,2,3,4-tetrazole **A40**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.58 (d, $J = 8.44$ Hz, 2H), 7.45 (q, $J = 1.00$ Hz, 2H), 7.41 (d, $J = 7.52$ Hz, 1H), 7.36 (s, 1H), 7.21 (t, $J = 1.00$ Hz, 1H), 7.14 (d, $J = 1.00$ Hz, 3H), 7.11 (d, $J = 8.44$ Hz, 1H), 7.09 (d, $J = 1.00$ Hz, 2H), 6.94 (q, $J = 1.00$ Hz, 1H), 4.25 (s, 2H), 2.23 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 157.5, 156.4, 143.8, 140.5, 136.7, 134.0, 132.8, 131.7, 131.4, 131.4, 130.7, 128.2, 125.0, 124.5, 122.4, 119.8, 118.6, 118.6, 20.2,

10.7.

[00369] 5-{2-[(1*Z*)-2-Methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A41**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.53 (d, J = 8.44 Hz, 2H), 7.39 (d, J = 7.70 Hz, 1H), 7.22 - 7.27 (m, 3H), 7.15 - 7.22 (m, 2H), 6.99 - 7.06 (m, 4H), 6.94 (dt, J = 0.73, 7.52 Hz, 1H), 3.10 (t, J = 7.34 Hz, 2H), 2.99 (t, J = 7.70 Hz, 2H), 2.31 (s, 3H), 1.96 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 158.0, 154.0, 144.2, 140.6, 137.0, 135.1, 134.3, 133.7, 131.6, 131.2, 131.0, 130.4, 128.3, 124.8, 122.4, 120.0, 118.3, 118.0, 23.9, 22.7, 20.8, 10.2.

[00370] 5-{2-[(1*Z*)-1-{[4-(4-Bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A42**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.61 (d, J = 8.99 Hz, 2H), 7.57 (d, J = 8.44 Hz, 2H), 7.40 (d, J = 7.70 Hz, 1H), 7.26 (d, J = 7.52 Hz, 1H), 7.23 (s, 1H), 7.20 (t, J = 7.34 Hz, 1H), 7.12 (d, J = 8.62 Hz, 2H), 7.09 (d, J = 8.80 Hz, 2H), 6.95 (t, J = 7.15 Hz, 1H), 3.13 (t, J = 7.52 Hz, 2H), 3.00 (t, J = 7.61 Hz, 2H), 1.98 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 156.8, 156.0, 144.2, 140.8, 137.1, 135.1, 134.2, 133.4, 132.1, 131.8, 130.2, 128.3, 124.9, 122.5, 121.7 (2 C), 118.9 (2 C), 118.3, 116.1, 23.9, 22.7, 10.2.






[00371] 5-{2-[(1*Z*)-2-Methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A43**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.54 (d, J = 8.44 Hz, 2H), 7.40 (d, J = 7.70 Hz, 1H), 7.31 (d, J = 8.44 Hz, 2H), 7.24 (d, J = 7.52 Hz, 1H), 7.21 (s, 1H), 7.19 (t, J = 7.00 Hz, 1H), 7.03 - 7.07 (m, 4H), 6.94 (dt, J = 1.00, 7.70 Hz, 1H), 3.11 (t, J = 7.52 Hz, 2H), 2.99 (t, J = 7.61 Hz, 2H), 2.92 (quin, J = 6.88 Hz, 1H), 1.97 (s, 3H), 1.22 (d, J =

6.79 Hz, 6H); ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ 157.8, 154.2, 144.6, 144.2, 140.6, 137.0, 135.1, 134.2, 131.7 (2 C), 131.2, 130.4, 128.4 (2 C) 128.3, 124.9, 122.4, 119.8 (2 C), 118.3, 118.1 (2 C), 33.3, 24.5 (3 C), 23.9, 22.7, 10.2.

[00372] 5-{2-[(1Z)-1-{[4-(4-Methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A44**. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 7.52 (d, J = 8.62 Hz, 2H), 7.41 (d, J = 7.52 Hz, 1H), 7.24 (d, J = 7.34 Hz, 1H), 7.16 - 7.21 (m, 2H), 7.11 (d, J = 8.99 Hz, 2H), 6.99 (d, J = 8.62 Hz, 2H), 7.01 (d, J = 9.17 Hz, 2H), 6.92 - 6.96 (m, 1H), 3.77 (s, 3H), 3.11 (t, J = 7.52 Hz, 2H), 2.99 (t, J = 7.43 Hz, 2H), 1.97 (s, 3H); ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ 158.3, 156.0, 148.7, 143.7, 140.0, 136.5, 134.6, 133.8, 131.2 (3 C), 130.3, 130.0, 127.8, 124.4, 122.0, 121.3 (2 C), 117.8, 116.8 (2 C), 115.2 (2 C), 55.4, 23.4, 22.2, 9.7.

[00373] 5-{2-[(1Z)-2-Methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A45**. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 7.79 (d, J = 8.44 Hz, 2H), 7.62 (d, J = 8.25 Hz, 2H), 7.37 (d, J = 7.52 Hz, 1H), 7.24 - 7.28 (m, 4H), 7.18 - 7.24 (m, 3H), 6.96 (t, J = 7.43 Hz, 1H), 3.13 (t, J = 7.52 Hz, 2H), 3.00 (t, J = 7.52 Hz, 2H), 1.99 (s, 3H); ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ 159.9, 155.2, 143.8, 140.6, 136.8, 134.6, 133.7, 132.6, 131.4 (2 C), 129.5, 127.9, 127.6 (q, J = 3.30 Hz), 124.5, 124.4 (d, J = 228.88 Hz), 123.6 (d, J = 73.73 Hz), 122.1, 119.6 (2 C), 118.6 (2 C), 117.9, 23.4, 22.2, 9.7.




[00374] 5-{2-[(1Z)-2-Methyl-1-({4-[4-(3-methylphenoxy)phenyl]methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A46**. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 7.53 - 7.56 (m, J = 8.44 Hz, 2H), 7.39 (d, J = 7.52 Hz, 1H), 7.32 (t, J = 7.79 Hz, 1H), 7.24 (d, J = 7.34 Hz, 1H), 7.22 (s, 1H), 7.19 (dt, J = 1.00, 7.20 Hz, 1H), 7.05 - 7.09 (m, 2H), 7.02 (d, J = 7.52 Hz, 1H), 6.93 - 6.97

(m, 2H), 6.91 (dd, $J = 2.20, 8.07$ Hz, 1H), 3.12 (t, $J = 7.61$ Hz, 2H), 3.00 (t, $J = 7.61$ Hz, 2H), 2.32 (s, 3H), 1.97 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 157.0, 156.0, 143.7, 140.2, 139.9, 136.6, 134.6, 133.8, 131.2 (2 C), 131.0, 129.9 (2 C), 129.9, 127.8, 124.7, 124.4, 122.0, 119.8, 118.0 (2 C), 117.8, 116.3, 23.4, 22.2, 20.9, 9.7.

[00375] 3-(4-{[(1Z)-2-Methyl-3-[2-(1H-1,2,3,4-tetrazol-5-yl)ethyl]-1H-inden-1-ylidene]methyl}phenoxy)benzonitrile **A47**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.61 - 7.66 (m, 3H), 7.59 (d, $J = 8.44$ Hz, 2H), 7.44 - 7.47 (m, 1H), 7.37 (d, $J = 7.70$ Hz, 1H), 7.25 (d, $J = 7.34$ Hz, 1H), 7.23 (s, 1H), 7.17 - 7.21 (m, 1H), 7.16 (d, $J = 8.62$ Hz, 2H), 6.94 (dt, $J = 0.70, 7.20$ Hz, 1H), 3.12 (t, $J = 7.50$ Hz, 2H), 3.00 (t, $J = 7.61$ Hz, 2H), 1.98 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 156.7, 155.7, 143.8, 140.6, 136.8, 134.6, 133.8, 132.3, 131.6, 131.4 (2 C), 129.6, 127.9, 127.6, 124.4, 123.9, 122.2 (2 C), 122.1, 118.9 (2 C), 118.2, 117.9, 112.9, 23.4, 22.2, 9.7.

[00376] 5-{2-[(1Z)-1-{[4-(3-Methoxyphenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]ethyl}-1H-1,2,3,4-tetrazole **A48**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.55 (d, $J = 8.44$ Hz, 2H), 7.38 (d, $J = 7.70$ Hz, 1H), 7.33 (t, $J = 8.25$ Hz, 1H), 7.24 (d, $J = 7.52$ Hz, 1H), 7.22 (s, 1H), 7.18 (t, $J = 7.34$ Hz, 1H), 7.09 (d, $J = 8.62$ Hz, 2H), 6.93 (qt, $J = 1.00, 7.70$ Hz, 1H), 6.77 (dd, $J = 2.20, 8.07$ Hz, 1H), 6.68 (t, $J = 2.29$ Hz, 1H), 6.64 - 6.67 (m, 1H), 3.76 (s, 3H), 3.11 (t, $J = 7.50$ Hz, 2H), 2.99 (t, $J = 7.61$ Hz, 2H), 1.97 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 160.8, 157.2, 156.7, 143.7, 140.3, 136.6, 134.6, 133.8, 131.3, 131.2 (2 C), 130.7 (2 C), 129.8, 127.8, 124.4, 122.0, 118.2 (2 C), 117.8, 111.1, 109.7, 105.2, 55.3, 23.4, 22.2, 9.7.




[00377] 5-{2-[(1Z)-1-{[4-(3-Bromophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]ethyl}-1H-1,2,3,4-tetrazole **A49**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.57 (d, $J = 8.25$ Hz, 2H),

7.36 (s, 2H), 7.35 (d, $J = 7.70$ Hz, 1H), 7.28 - 7.30 (m, 1H), 7.23 - 7.25 (m, 1H), 7.22 (s, 1H), 7.18 (dt, $J = 1.00, 7.70$ Hz, 1H), 7.10 - 7.15 (m, 3H), 6.93 (dt, $J = 1.00, 7.20$ Hz, 1H), 3.11 (t, $J = 7.61$ Hz, 2H), 2.99 (t, $J = 7.61$ Hz, 2H), 1.97 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 157.4, 156.0, 143.7, 140.5, 136.8, 134.6, 133.8, 132.0, 131.9, 131.3 (2 C), 129.6, 127.9, 126.6, 124.4, 122.3, 122.0, 121.6 (2 C), 118.8 (2 C), 117.9, 117.9, 23.4, 22.2, 9.7.

[00378] 5-{2-[(1*Z*)-2-Methyl-1-({4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A50**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.66 (t, $J = 7.90$ Hz, 1H), 7.59 (d, $J = 8.44$ Hz, 2H), 7.53 (d, $J = 7.70$ Hz, 1H), 7.38 - 7.44 (m, 2H), 7.35 (d, $J = 7.70$ Hz, 1H), 7.23 - 7.26 (m, 2H), 7.18 - 7.21 (m, 1H), 7.17 (d, $J = 8.62$ Hz, 2H), 6.92 (dt, $J = 1.00, 7.70$ Hz, 1H), 3.13 (t, $J = 7.61$ Hz, 2H), 3.00 (t, $J = 7.61$ Hz, 2H), 1.98 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 157.0, 155.7, 143.8, 140.6, 136.8, 134.6, 133.8, 132.3, 131.5, 131.4 (2 C), 130.9 (q, $J = 33.00$ Hz), 129.6, 127.9, 124.4, 122.7, 122.0, 123.4 (q, $J = 272.90$ Hz), 120.2 (q, $J = 4.40$ Hz), 119.0 (2 C), 117.9, 115.2 (q, $J = 3.30$ Hz), 23.4, 22.2, 9.7.


[00379] 5-{2-[(1*Z*)-2-Methyl-1-{[4-(naphthalen-2-yloxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A51**. ^1H NMR (600 MHz, DMSO- d_6) δ 8.02 (d, $J = 8.80$ Hz, 1H), 7.95 (d, $J = 8.07$ Hz, 1H), 7.88 (d, $J = 8.07$ Hz, 1H), 7.59 (d, $J = 8.62$ Hz, 2H), 7.55 (d, $J = 2.20$ Hz, 1H), 7.52 (dt, $J = 0.92, 7.90$ Hz, 1H), 7.48 (dt, $J = 1.00, 7.00$ Hz, 1H), 7.43 (d, $J = 7.52$ Hz, 1H), 7.38 (dd, $J = 2.38, 8.99$ Hz, 1H), 7.22 - 7.27 (m, 2H), 7.19 (t, $J = 7.34$ Hz, 1H), 7.15 (d, $J = 8.80$ Hz, 2H), 6.96 (t, $J = 7.34$ Hz, 1H), 3.12 (t, $J = 7.52$ Hz, 2H), 3.00 (t, $J = 7.52$ Hz, 2H), 1.98 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 156.9, 153.9, 143.8, 140.3, 136.6, 134.6, 134.0, 133.8, 131.4, 131.3 (2 C), 130.3, 130.1, 129.8, 127.8, 127.7, 127.2, 126.8, 125.1, 124.4, 122.0, 120.0, 118.4 (2 C), 117.8, 114.7 (2 C), 23.4, 22.2, 9.8.



[00380] (Z)-3-((2-Methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)methyl)-1,2,4-oxadiazol-5(4*H*)-one **A52**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 12.33 (br. s., 1H), 7.58 (d, *J* = 8.25 Hz, 2H), 7.40 - 7.49 (m, 3H), 7.35 (s, 1H), 7.15 - 7.24 (m, 3H), 7.06 - 7.15 (m, 4H), 6.96 (t, *J* = 7.24 Hz, 1H), 3.89 (s, 2H), 2.20 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 160.3, 158.6, 157.6, 156.4, 143.8, 140.3, 137.8, 133.9, 131.7, 131.6, 131.4, 130.7, 130.4, 128.3, 125.1, 124.5, 122.4, 119.8, 118.6, 118.5, 22.0, 10.8.

[00381] 5-{[(1*E*)-1-[(4-Phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A53**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.84 (dd, *J* = 3.30, 5.14 Hz, 1H), 7.71 (d, *J* = 8.62 Hz, 2H), 7.67 (s, 1H), 7.44 (q, *J* = 1.00 Hz, 2H), 7.23 - 7.30 (m, 3H), 7.21 (q, *J* = 1.00 Hz, 1H), 7.07 - 7.13 (m, 4H), 6.99 (s, 1H), 4.37 (s, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 157.5, 155.8, 141.5, 140.3, 138.0, 136.8, 132.0 (2 C), 131.4, 130.2 (3 C), 128.2, 127.2, 125.6, 124.1, 123.6, 119.4, 119.4 (2 C), 119.0, 118.5 (2 C), 22.2.


[00382] 5-{[(1*E*)-1-[(3-Phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A54**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.82 - 7.86 (m, 1H), 7.67 (s, 1H), 7.50 (t, *J* = 1.00 Hz, 1H), 7.40 - 7.45 (m, 3H), 7.23 - 7.29 (m, 4H), 7.18 (t, *J* = 1.00 Hz, 1H), 7.06 - 7.09 (m, 2H), 7.04 (d, *J* = 1.00 Hz, 1H), 6.87 (s, 1H), 4.36 (s, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 157.2, 156.3, 140.5, 138.5, 138.3, 137.7, 130.6, 130.2 (3 C), 129.7, 128.0, 127.6, 125.8, 124.9, 123.8, 123.4, 119.7, 119.6, 119.1, 119.0 (2 C), 118.7, 22.2.



[00383] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(morpholin-4-yl)phenyl]methylidene]-1H-inden-3-yl]acetic acid **A55**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.39 (br. s., 1H), 7.55 (dd, J = 5.32, 8.44 Hz, 1H), 7.47 (d, J = 8.80 Hz, 2H), 7.25 (s, 1H), 7.03 (d, J = 8.80 Hz, 2H), 7.00 (dd, J = 2.38, 9.35 Hz, 1H), 6.75 (d, J = 2.20 Hz, 1H), 3.74 - 3.79 (m, 4H), 3.56 (s, 2H), 3.21 - 3.25 (m, 4H), 2.14 (s, 3H).

[00384] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(piperidin-1-yl)phenyl]methylidene]-1H-inden-3-yl]acetic acid **A56**.


[00385] 2-[(1Z)-5-Fluoro-1-[[4-(1H-indol-1-yl)phenyl]methylidene]-2-methyl-1H-inden-3-yl]acetic acid **A57**.



[00386] 2-[(1Z)-1-[[4-(2-Amino-1H-imidazol-1-yl)phenyl]methylidene]-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **A58**.

[00387] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(pyrrolidin-1-yl)phenyl]methylidene]-1H-inden-3-yl]acetic acid **A59**. LC-MS (m/z , ESI) $[\text{M}+\text{H}]^+ = 364$, found: 364.


[00388] 2-[(1*Z*)-5-Fluoro-2-methyl-1-{[4-(1*H*-pyrrol-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A60**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.43 (br. s., 1H), 7.73 (d, J = 8.62 Hz, 2H), 7.63 (d, J = 8.44 Hz, 2H), 7.50 (t, J = 2.20 Hz, 2H), 7.31 - 7.39 (m, 2H), 7.02 (dd, J = 2.38, 9.17 Hz, 1H), 6.74 (d, J = 1.83 Hz, 1H), 6.31 (t, J = 2.20 Hz, 2H), 3.58 (s, 2H), 2.16 (s, 3H).



[00389] (2*E*)-3-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]prop-2-enoic acid **A61**.

[00390] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A62**.

[00391] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A63**.




[00392] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A64**.

[00393] 2-[(1*Z*)-5-Fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-

1*H*-inden-3-yl]acetic acid **A65**.


[00394] 2-[(1*Z*)-5-Fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A66**.



[00395] (2*E*)-4-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]but-2-enoic acid **A67**.

[00396] 2-[(1*Z*)-4,5-Difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A68**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.55 (d, *J* = 8.44 Hz, 2H), 7.34 (s, 1H), 7.25 - 7.31 (m, 2H), 7.21 - 7.25 (m, 1H), 7.20 (d, *J* = 4.40 Hz, 1H), 7.18 (d, *J* = 4.40 Hz, 1H), 7.15 (dd, *J* = 7.70, 11.37 Hz, 1H), 7.08 (d, *J* = 8.44 Hz, 2H), 3.48 (s, 2H), 2.12 (s, 3H); LC-MS (m/z, ESI) [M+H]⁺ = 423, found: 423.


[00397] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]acetic acid **A69**. ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.54 (d, *J* = 8.44 Hz, 2H), 7.23 - 7.31 (m, 2H), 7.12 - 7.20 (m, 4H), 7.07 (d, *J* = 8.62 Hz, 2H), 6.95 (d, *J* = 10.09 Hz, 1H), 3.37 (s, 2H), 2.09 (s, 3H), 2.04 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 172.6, 172.4, 161.4, 159.8, 159.3, 157.7, 157.2, 152.2 (d, *J* = 2.20 Hz, 1 C), 145.4 (d, *J* = 8.80 Hz, 1 C), 139.9, 135.4, 134.1, 131.2, 129.6, 128.7, 124.5 (d, *J* = 5.50 Hz, 1 C), 121.1, 121.1, 118.3 (d, *J* = 18.71 Hz, 1 C), 117.9, 116.8, 116.7, 105.8 (d, *J* = 24.21 Hz, 1 C), 33.5, 21.8, 10.3; LC-MS (m/z, ESI) [M+H]⁺ = 419, found: 419.



[00398] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(morpholin-4-yl)phenyl]methylidene]-1H-inden-3-yl]-N-hydroxyacetamide **A70**.

[00399] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(piperidin-1-yl)phenyl]methylidene]-1H-inden-3-yl]-N-hydroxyacetamide **A71**.


[00400] 2-[(1Z)-5-Fluoro-1-[[4-(1H-indol-1-yl)phenyl]methylidene]-2-methyl-1H-inden-3-yl]-N-hydroxyacetamide **A72**.



[00401] 2-[(1Z)-1-[[4-(2-Amino-1H-imidazol-1-yl)phenyl]methylidene]-5-fluoro-2-methyl-1H-inden-3-yl]-N-hydroxyacetamide **A73**.

[00402] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(pyrrolidin-1-yl)phenyl]methylidene]-1H-inden-3-yl]-N-hydroxyacetamide **A74**.


[00403] 2-[(1Z)-5-Fluoro-2-methyl-1-[[4-(1H-pyrrol-1-yl)phenyl]methylidene]-1H-inden-3-yl]-N-hydroxyacetamide **A75**.



[00404] (2*E*)-3-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyprop-2-enamide **A76**.

[00405] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A77**.


[00406] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorobenzenesulfinyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A78**.



[00407] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A79**.


[00408] 2-[(1*Z*)-5-Fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A80**.

[00409] 2-[(1*Z*)-5-Fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A81**.




[00410] (2*E*)-4-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxybut-2-enamide **A82**.

[00411] 2-[(1*Z*)-4,5-Difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A83**.



[00412] 2-[(1*Z*)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A84**.


[00413] 2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(2-hydroxyethyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A85**. HR-MS (*m/z*, ESI) [*M*+*H*]⁺ = 463.1828, found: 463.1825.



[00414] 2-[(1Z)-5-Fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1H-inden-3-yl]-N-hydroxy-N-methylacetamide **C1**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.06 (br s, 1H), 7.56 (d, J = 8.80 Hz, 2H), 7.45 (t, J = 7.89 Hz, 2H), 7.33 (dd, J = 5.23, 8.34 Hz, 1H), 7.28 (s, 1H), 7.20 (t, J = 7.34 Hz, 1H), 7.13 (d, J = 8.07 Hz, 2H), 7.09 (d, J = 8.44 Hz, 2H), 7.00 (dd, J = 2.38, 9.35 Hz, 1H), 6.73 (dt, J = 2.38, 8.89 Hz, 1H), 3.67 (s, 2H), 3.12 (s, 3H), 2.14 (s, 3H).

[00415] 2-[(1Z)-5-Fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]-N-hydroxy-N-methylacetamide **C2**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.13 (s, 1H), 7.60 (d, J = 8.25 Hz, 2H), 7.38 (dd, J = 5.32, 8.25 Hz, 1H), 7.36 - 7.31 (m, 3H), 7.27 - 7.21 (m, 2H), 7.15 - 7.09 (m, 2H), 7.05 (dd, J = 2.38, 9.17 Hz, 1H), 6.78 (dt, J = 2.57, 8.80 Hz, 1H), 3.73 (s, 2H), 3.17 (s, 3H), 2.19 (s, H); ^{13}C NMR (151 MHz, DMSO- d_6) 169.6, 163.1, 161.5, 159.4, 157.8, 157.4, 151.9, 147.3, 139.2, 137.9, 132.5, 131.2, 130.8, 129.8, 129.6, 122.9, 121.4, 117.7, 116.8, 116.7, 110.1, 106.1, 105.9, 36.1, 31.0, 10.4.


[00416] (Z)-2-(5-Fluoro-2-methyl-1-(3-phenoxybenzylidene)-1H-inden-3-yl)-N-hydroxy-N-methylacetamide **C3**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.06 (br s, 1H), 7.51 (t, J = 7.89 Hz, 1H), 7.45 - 7.37 (m, 2H), 7.31 - 7.25 (m, 2H), 7.20 (dd, J = 5.32, 8.25 Hz, 1H), 7.17 - 7.13 (m, 1H), 7.12 - 7.07 (m, 3H), 7.04 (br. s, 1H), 6.98 (dd, J = 2.20, 9.35 Hz, 1H), 6.70 (dt, J = 2.38, 7.70 Hz, 1H), 3.65 (s, 2H), 3.11 (s, 3H), 2.10 (s, 3H).



[00417] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]-N-hydroxyacetamide **D1**. ^1H NMR (600 MHz, DMSO- d_6) δ 10.75 (br s, 1H), 9.02 (br s, 1H), 7.54 (d, $J = 8.44$ Hz, 2H), 7.33 (dd, $J = 5.32, 7.89$ Hz, 1H), 7.32 - 7.26 (m, 3H), 7.13 (d, $J = 9.35$ Hz, 1H), 7.07 - 7.01 (m, 4H), 6.73 (td, $J = 1.80, 9.40$ Hz, 1H), 3.30 (s, 2H), 2.96 - 2.85 (m, 1H), 2.18 (s, 3H), 1.22 (d, $J = 6.79$ Hz, 6H).

[00418] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[4-(*tert*-butyl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D2**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.55 (d, $J = 8.44$ Hz, 2H), 7.36 (t, $J = 7.89$ Hz, 1H), 7.31 (dd, $J = 5.32, 8.44$ Hz, 1H), 7.29 (s, 1H), 7.22 (td, $J = 0.87, 7.79$ Hz, 1H), 7.12 (t, $J = 2.11$ Hz, 1H), 7.10 - 7.04 (m, 2H), 7.03 - 6.99 (m, 1H), 6.90 (ddd, $J = 0.73, 2.38, 8.25$ Hz, 1H), 6.70 (dt, $J = 2.38, 8.89$ Hz, 1H), 3.51 (s, 2H), 2.14 (s, 3H), 1.28 (s, 9H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.9, 163.1, 161.5, 157.1, 155.8, 153.3, 147.2 (d, $J = 9.90$ Hz, 1C), 144.0, 139.2, 137.5, 131.2 (2C), 130.8, 130.1, 129.7, 122.9 (d, $J = 9.90$ Hz, 1C), 120.9, 118.1 (2C), 116.3, 116.1, 110.0 (d, $J = 23.11$ Hz, 1C), 105.9 (d, $J = 24.21$ Hz, 1C), 34.5, 31.0 (3C), 10.3.

[00419] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[3-(*tert*-butyl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D3**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.55 (d, $J = 8.44$ Hz, 2H), 7.45 (d, $J = 8.62$ Hz, 2H), 7.35 (dd, $J = 5.23, 8.34$ Hz, 1H), 7.29 (s, 1H), 7.05 (dd, $J = 2.29, 8.71$ Hz, 4H), 7.01 (d, $J = 7.52$ Hz, 1H), 6.73 (dt, $J = 2.20, 9.90$ Hz, 1H), 3.54 (br s, 2H), 2.14 (s, 3H), 1.30 (s, 9H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.8, 163.1, 161.5, 157.4, 153.4, 147.0 (d, $J = 9.90$ Hz, 1C), 146.4, 139.0, 137.8, 132.0, 131.2 (2C), 130.5, 130.3, 129.6, 126.9 (2C), 123.0 (d, $J = 8.80$ Hz, 1C), 119.0 (2C), 117.8 (2C), 110.2 (d, $J = 23.11$ Hz, 1C), 105.8 (d, $J = 23.11$ Hz, 1C), 34.1, 31.2 (3C), 10.3.




[00420] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[3-fluoro-4-methylphenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D4**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.41 (br s, 1H), 7.57 (d, $J = 8.62$ Hz, 2H), 7.37 - 7.32 (m, 2H), 7.32 - 7.29 (m, 1H), 7.14 - 7.07 (m, 2H), 7.01 (dd, $J = 2.48, 9.26$ Hz, 1H), 6.98 (dd, $J = 2.38, 10.82$ Hz, 1H), 6.87 (dd, $J = 2.38, 8.25$ Hz, 1H), 6.74 (dt, $J = 1.83, 8.99$ Hz, 1H), 3.57 (s, 2H), 2.22 (d, $J = 1.47$ Hz, 3H), 2.15 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.6, 162.1 (d, $J = 243.19$ Hz, 1C), 160.9 (d, $J = 244.29$ Hz, 1C), 156.8, 155.0 (d, $J = 11.01$ Hz, 1C), 146.9 (d, $J = 8.80$ Hz, 1C), 139.1, 138.0, 132.4 (d, $J = 6.60$ Hz, 1C), 131.7 (d, $J = 2.20$ Hz, 1C), 131.3 (2C), 130.7 (d, $J = 114.44$ Hz, 1C), 129.5 (d, $J = 3.30$ Hz, 1C), 123.0 (d, $J = 8.80$ Hz, 1C), 119.8, 119.7, 118.2 (2C), 115.0 (d, $J = 3.30$ Hz, 1C), 110.3 (d, $J = 23.11$ Hz, 1C), 106.8 (d, $J = 25.31$ Hz, 1C), 105.8 (d, $J = 23.11$ Hz, 1C), 31.1, 13.6 (d, $J = 3.30$ Hz, 1C), 10.3.

[00421] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[3,4-difluorophenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D5**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.57 (d, $J = 8.44$ Hz, 2H), 7.50 (d, $J = 10.45$ Hz, 1H), 7.36 - 7.32 (m, 1H), 7.32 - 7.29 (m, 1H), 7.27 (s, 1H), 7.16 - 7.07 (m, 2H), 7.01 (dd, $J = 2.48, 9.26$ Hz, 1H), 7.00 - 6.92 (m, 1H), 6.72 (dt, $J = 2.38, 8.10$ Hz, 1H), 3.50 (s, 2H), 2.13 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.9, 163.1, 161.5, 156.6, 152.3 (dd, $J = 8.80, 3.30$ Hz, 1C), 149.8 (dd, $J = 246.49, 14.30$ Hz, 1C), 147.3 (d, $J = 8.80$ Hz, 1C), 146.2 (dd, $J = 238.78, 13.20$ Hz, 1C), 139.4, 137.3, 131.5, 131.3 (2C), 129.7, 129.6 (d, $J = 2.20$ Hz, 1C), 122.9 (d, $J = 8.80$ Hz, 1C), 118.3 (d, $J = 18.71$ Hz, 1C), 118.2 (2C), 115.8 (dd, $J = 6.60, 3.30$ Hz, 1C), 110.1 (d, $J = 22.01$ Hz, 1C), 109.4 (d, $J = 19.81$ Hz, 1C), 106.0 (d, $J = 24.21$ Hz, 1C), 32.2, 10.3.

[00422] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[3-nitrophenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D6**. ^1H NMR (600 MHz, DMSO- d_6) δ 8.03 (ddd, $J = 0.83, 2.15, 8.21$ Hz,


1H), 7.80 (t, $J = 2.29$ Hz, 1H), 7.72 (t, $J = 8.25$ Hz, 1H), 7.63 - 7.55 (m, 3H), 7.26 - 7.22 (m, 2H), 7.20 (s, 1H), 7.19 (dd, $J = 5.32, 7.89$ Hz, 1H), 7.05 (dd, $J = 2.48, 9.44$ Hz, 1H), 6.65 (dt, $J = 2.57, 8.99$ Hz, 1H), 3.20 (s, 2H), 2.11 (s, 3H).



[00423] 2-[(1Z)-5-Fluoro-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D7**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.42 (br s, 1H), 7.79 (d, $J = 8.62$ Hz, 2H), 7.62 (d, $J = 8.62$ Hz, 2H), 7.35 (s, 1H), 7.32 (dd, $J = 5.23, 8.34$ Hz, 1H), 7.26 (d, $J = 8.62$ Hz, 2H), 7.23 (d, $J = 8.44$ Hz, 2H), 7.02 (dd, $J = 2.38, 9.35$ Hz, 1H), 6.76 (dt, $J = 2.38, 8.89$ Hz, 1H), 3.58 (s, 2H), 2.16 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 172.1, 160.2, 155.8, 147.4 (d, $J = 8.80$ Hz, 1C), 139.9, 138.4, 132.8, 132.4 (2C), 131.9 (2C), 130.6, 129.9 (d, $J = 2.20$ Hz, 1C), 128.1 (q, $J = 3.30$ Hz, 1C), 125.6, 124.2 (d, $J = 31.91$ Hz, 1C), 123.8, 123.6 (d, $J = 8.80$ Hz, 1C), 120.2 (2C), 119.1 (2C), 110.7 (d, $J = 23.11$ Hz, 1C), 106.4 (d, $J = 23.11$ Hz, 1C), 31.6, 10.7.

[00424] 2-[(1Z)-5-Fluoro-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-2-methylpropyl]-1H-inden-3-yl]acetic acid **D8**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.40 (br s, 1H), 7.55 (d, $J = 8.62$ Hz, 2H), 7.33 (dd, $J = 5.32, 8.44$ Hz, 1H), 7.31 - 7.25 (m, 3H), 7.22 - 7.15 (m, 2H), 7.06 (d, $J = 8.62$ Hz, 2H), 7.01 (dd, $J = 2.38, 9.35$ Hz, 1H), 6.75 (dt, $J = 2.38, 8.89$ Hz, 1H), 3.58 (s, 2H), 2.48 (d, $J = 7.34$ Hz, 2H), 1.92 - 1.79 (m, 1H), 0.93 (d, $J = 6.60$ Hz, 6H).


[00425] 2-[(1Z)-5-Fluoro-2-benzyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D9**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.48 (br s, 1H), 7.46 (d, $J = 8.62$ Hz, 2H), 7.38 (dd, $J = 5.32, 8.44$ Hz, 1H), 7.33 - 7.22 (m, 7H), 7.19 - 7.13 (m, 3H), 7.07 (dd, $J = 2.48, 9.26$ Hz, 1H), 7.05 - 6.99 (m, 2H), 6.82 - 6.73 (m, 1H), 4.03 (s, 2H), 3.67 (s, 2H).



[00426] 2-[(1Z)-5-Methoxy-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D10**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.37 (br s, 1H), 7.55 (d, $J = 8.62$ Hz, 2H), 7.32 - 7.23 (m, 3H), 7.20 - 7.15 (m, 2H), 7.14 (s, 1H), 7.06 (d, $J = 8.62$ Hz, 2H), 6.76 (d, $J = 2.38$ Hz, 1H), 6.49 (dd, $J = 2.29, 8.34$ Hz, 1H), 3.73 (s, 3H), 3.53 (s, 2H), 2.12 (s, 3H).

[00427] 2-[(1Z)-5-Methoxy-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1H-inden-3-yl]acetic acid **D11**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.38 (br s, 1H), 7.56 (d, $J = 8.44$ Hz, 2H), 7.45 (t, $J = 7.98$ Hz, 2H), 7.30 (d, $J = 8.44$ Hz, 1H), 7.23 - 7.17 (m, 1H), 7.15 (s, 1H), 7.14 - 7.10 (m, 2H), 7.10 - 7.05 (m, 2H), 6.76 (d, $J = 2.20$ Hz, 1H), 6.50 (dd, $J = 2.38, 8.44$ Hz, 1H), 3.73 (s, 3H), 3.53 (s, 2H), 2.12 (s, 3H).

[00428] 2-[(1Z)-1-{{2-Trifluoromethyl-4-(4-fluorophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **D12**. ^1H NMR (600 MHz, DMSO- d_6) δ 7.60 (d, $J = 8.44$ Hz, 1H), 7.43 (d, $J = 2.38$ Hz, 1H), 7.36 - 7.28 (m, 3H), 7.28 - 7.25 (m, 2H), 7.23 (br s, 1H), 7.02 (dd, $J = 2.11, 9.26$ Hz, 1H), 6.67 (dt, $J = 2.38, 8.80$ Hz, 1H), 6.65 - 6.58 (m, 1H), 3.50 (s, 2H), 2.11 (s, 3H).




[00429] 2-[(1Z)-1-{{3-Methyl-4-(4-fluorophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1H-inden-3-yl]acetic acid **D13**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.45 (br. s, 1H), 7.49

(d, $J = 1.47$ Hz, 1H), 7.38 (dd, $J = 1.93, 8.34$ Hz, 1H), 7.35 (dd, $J = 5.23, 8.34$ Hz, 1H), 7.29 (s, 1H), 7.27 - 7.21 (m, 2H), 7.10 - 7.04 (m, 2H), 7.01 (dd, $J = 2.48, 9.26$ Hz, 1H), 6.89 (d, $J = 8.25$ Hz, 1H), 6.75 (dt, $J = 2.38, 8.89$ Hz, 1H), 3.57 (s, 2H), 2.25 (s, 3H), 2.14 (s, 3H).

[00430] 2-[(1Z)-1-{[2-Methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D14**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.46 (s, 1H), 7.38 (d, $J = 8.4$ Hz, 1H), 7.31 - 7.24 (m, 3H), 7.19 - 7.12 (m, 2H), 7.04 - 6.97 (m, 2H), 6.95 (dd, $J = 8.4, 5.3$ Hz, 1H), 6.87 (dd, $J = 8.4, 2.7$ Hz, 1H), 6.71 (td, $J = 9.1, 2.5$ Hz, 1H), 3.57 (s, 2H), 2.25 (s, 3H), 2.16 (s, 3H).

[00431] 2-[(1Z)-5,7-Difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D15**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.48 (s, 1H), 7.47 (s, 1H), 7.38 (dd, $J = 8.8, 2.8$ Hz, 2H), 7.30 - 7.26 (m, 2H), 7.16 - 7.12 (m, 2H), 7.02 - 6.97 (m, 3H), 6.83 (td, $J = 10.1, 2.2$ Hz, 1H), 3.61 (s, 2H), 2.19 (s, 3H).




[00432] 2-[(1Z)-4,6-Difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D16**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.38 (s, 1H), 7.57 (d, $J = 8.6$ Hz, 2H), 7.46 (s, 1H), 7.33 - 7.25 (m, 2H), 7.23 - 7.18 (m, 2H), 7.11 - 7.08 (m, 2H), 7.02 (dq, $J = 8.1, 2.1$ Hz, 1H), 6.97 - 6.91 (m, 1H), 3.63 (s, 2H), 2.11 (s, 3H).

[00433] 2-[(1Z)-5-*Tert*-butyl-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D17**.

[00434] (Z)-2-(5-Fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)acetic acid **D18**. ^1H NMR (600 MHz, DMSO- d_6) δ 12.42 (br. s., 1H), 7.51 (t, $J = 7.89$ Hz, 1H), 7.45 - 7.37 (m, 2H), 7.30 (s, 1H), 7.29 (d, $J = 8.07$ Hz, 1H), 7.21 (dd, $J = 5.23, 8.34$ Hz, 1H), 7.15 (t, $J = 7.43$ Hz, 1H), 7.11 (d, $J = 2.38$ Hz, 1H), 7.10 - 7.07 (m, 2H), 7.05 (s, 1H), 6.99 (dd, $J = 2.48,$


9.26 Hz, 1H), 6.72 (d, $J = 1.65$ Hz, 1H), 3.55 (s, 2H), 2.11 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 171.6, 163.2, 161.6, 157.1, 156.2, 146.9, 139.8, 137.9, 132.2, 130.4, 130.2, 130.0, 129.3, 124.2, 123.9, 123.2, 119.2, 118.5, 110.3, 105.9, 31.1, 10.2.



[00435] 2-[(1Z)-5-Fluoro-1-(2-(phenoxy)benzylidene)-2-methyl-1H-inden-3-yl]-acetic acid **D19**. LC-MS (m/z , ESI) $[\text{M}+\text{H}]^+ = 387$, found: 387.

[00436] 2-[(1Z)-5,7-Difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1H-inden-3-yl]-acetic acid **D20**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.53 (s, 1H), 7.46 (s, 1H), 7.40 (dt, $J = 15.5, 7.9$ Hz, 3H), 7.12 (t, $J = 7.6$ Hz, 2H), 7.04 (t, $J = 7.8$ Hz, 3H), 6.97 (d, $J = 8.5$ Hz, 1H), 6.87 (s, 1H), 6.82 (t, $J = 10.1$ Hz, 1H), 3.58 (s, 2H), 2.15 (s, 3H).

[00437] 2-[(1Z)-4,6-Difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1H-inden-3-yl]-acetic acid **D21**. ^1H NMR (500 MHz, DMSO- d_6) δ 7.55 (t, $J = 7.9$ Hz, 1H), 7.46 (s, 1H), 7.40 (t, $J = 7.8$ Hz, 2H), 7.30 (d, $J = 7.6$ Hz, 1H), 7.20 - 7.11 (m, 2H), 7.09 (d, $J = 8.0$ Hz, 2H), 7.05 (d, $J = 13.6$ Hz, 2H), 6.80 (d, $J = 9.2$ Hz, 1H), 3.60 (s, 2H), 2.08 (s, 3H).




[00438] 2-[(1Z)-5-Fluoro-2-methyl-1-({3-[4-methoxyphenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D22**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.47 (s, 1H), 7.53 - 7.43 (m, 1H),

7.28 (s, 1H), 7.26 - 7.19 (m, 2H), 7.10 - 7.06 (m, 2H), 7.04 (dd, $J = 8.2, 2.5$ Hz, 1H), 7.01 - 6.98 (m, 1H), 6.98 - 6.96 (m, 3H), 6.74 (ddd, $J = 9.4, 8.4, 2.5$ Hz, 1H), 3.73 (s, 3H), 3.55 (s, 2H), 2.11 (s, 3H).

[00439] 2-[(1Z)-5-Fluoro-1-(4-fluoro-3-(phenoxy)benzylidene)-2-methyl-1H-inden-3-yl]-acetic acid **D23**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.43 (s, 1H), 7.51 (ddq, $J = 15.2, 10.3, 4.5$ Hz, 1H), 7.44 - 7.32 (m, 3H), 7.29 - 7.04 (m, 6H), 6.98 (ddd, $J = 7.9, 5.5, 2.5$ Hz, 1H), 6.82 - 6.57 (m, 1H), 3.53 (s, 2H), 2.13 (s, 3H).




[00440] 2-[(1Z)-5-Fluoro-2-methyl-1-({3-[4-cyanophenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D24**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.50 (s, 1H), 7.87 (d, $J = 8.4$ Hz, 2H), 7.58 (t, $J = 8.2$ Hz, 1H), 7.42 (d, $J = 7.7$ Hz, 1H), 7.32 (s, 1H), 7.27 - 7.14 (m, 5H), 7.10 - 6.96 (m, 1H), 6.73 (d, $J = 8.8, 3.2$ Hz, 1H), 3.56 (s, 2H), 2.13 (s, 3H).



[00441] 2-[(1Z)-5-Fluoro-2-methyl-1-({3-[4-chlorophenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D25**. ^1H NMR (500 MHz, DMSO- d_6) δ 12.47 (s, 1H), 7.53 (t, $J = 7.9$ Hz, 1H), 7.50 - 7.41 (m, 2H), 7.38 - 7.29 (m, 2H), 7.21 (dd, $J = 8.4, 5.2$ Hz, 1H), 7.18 - 7.05 (m, 4H), 7.00 (dd, $J = 9.3, 2.5$ Hz, 1H), 6.73 (ddd, $J = 9.5, 8.3, 2.5$ Hz, 1H), 3.56 (s, 2H), 2.12 (s, 3H).

[00442] 2-[(1Z)-5-Fluoro-2-methyl-1-({3-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D26**. LC-MS (m/z , ESI) $[\text{M}+\text{H}]^+ = 455$, found: 455.




[00443] 2-[(1Z)-5-Fluoro-2-methyl-1-({3-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-1H-inden-3-yl]acetic acid **D27**. LC-MS (m/z , ESI) $[\text{M}+\text{H}]^+ = 455$, found: 455.



[00444] 2-[(1Z)-4-Methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D28**.

[00445] 2-[(1Z)-6-Methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D29**.




[00446] 2-[(1Z)-6-Trifluoromethyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)-methylidene)-1*H*-inden-3-yl]acetic acid **D30**.



[00447] 2-[(1Z)-5-Trifluoromethyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)-methylidene)-1*H*-inden-3-yl]acetic acid **D31**.

[00448] 2-[(1Z)-1-[4-(4-Fluorophenoxy)phenyl]methylidene)-1*H*-inden-3-yl]acetic acid **D32**.




[00449] 2-[(1Z)-5-Fluoro-1-[4-(4-fluorophenoxy)phenyl]methylidene)-1*H*-inden-3-yl]acetic acid **D33**.



[00450] 2-[(1Z)-5-Trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D34**.


[00451] 2-[(1Z)-6-Methoxy-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D35**.

[00452] 2-[(1Z)-6-Trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D36**.



[00453] 2-[(1Z)-5-Fluoro-2-methyl-1-({3-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D37**.

[00454] 2-[(1Z)-5-Fluoro-1-[(3-methoxy-5-phenoxyphenyl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **D38**.




[00455] 2-[(1*E*)-5-Fluoro-2-methyl-1-({4-[3,4-difluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E1**. ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 12.42 (br s, 1H), 7.79 (s, 1H), 7.73 (dd, $J = 5.14, 8.25$ Hz, 1H), 7.53 - 7.48 (m, 1H), 7.48 - 7.44 (m, 2H), 7.29 (ddd, $J = 2.93, 6.79, 11.74$ Hz, 1H), 7.11 - 7.07 (m, 2H), 7.06 (dd, $J = 2.38, 7.89$ Hz, 1H), 6.98 - 6.95 (m, 1H), 6.95 - 6.91 (m, 1H), 3.56 (s, 2H), 1.85 (s, 3H); ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 171.4, 162.4 (d, $J = 240.98$ Hz, 1C), 156.5, 152.4 (d, $J = 8.80$ Hz, 1C), 149.8 (dd, $J = 246.49, 14.31$ Hz, 1C), 146.1 (dd, $J = 240.99, 12.10$ Hz, 1C), 143.7 (d, $J = 9.90$ Hz, 1C), 138.6, 136.3 (d, $J = 2.20$ Hz, 1C), 134.5, 133.2, 131.6 (2C), 131.4, 129.3, 120.1 (d, $J = 8.80$ Hz, 1C), 118.3 (d, $J = 18.71$ Hz, 1C), 117.8 (2C), 115.6 (dd, $J = 5.50, 3.30$ Hz, 1C), 110.6 (d, $J = 23.11$ Hz, 1C), 109.2 (d, $J = 19.81$ Hz, 1C), 105.5 (d, $J = 24.21$ Hz, 1C), 31.2, 14.0.

[00456] 2-[(1*E*)-5-Fluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E2**. ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 7.77 (s, 1H), 7.72 (dd, $J = 5.14, 8.25$ Hz, 1H), 7.44 (d, $J = 8.44$ Hz, 2H), 7.30 - 7.23 (m, 2H), 7.16 - 7.12 (m, 2H), 7.03 (dd, $J = 2.38, 9.17$ Hz, 1H), 7.03 - 7.00 (m, 2H), 6.97 - 6.91 (m, 1H), 3.55 (s, 2H), 1.84 (s, 3H).

[00457] 2-[(1*E*)-5-Fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **E3**. ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 12.42 (br. s., 1H), 7.78 (s, 1H), 7.72 (dd, $J = 4.95, 8.25$ Hz, 1H), 7.46 - 7.44 (m, 2H), 7.44 - 7.41 (m, 2H), 7.19 (t, $J = 7.43$ Hz, 1H), 7.10 - 7.07 (m, 2H), 7.06 - 7.05 (m, $J = 2.40$ Hz, 1H), 7.05 - 7.04 (m, 1H), 7.04 - 7.02 (m, 1H), 6.95 (dt, $J = 2.40, 8.80$ Hz, 1H), 3.56 (s, 2H), 1.85 (s, 3H); ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 171.5, 162.4 (d, $J = 242.09$ Hz, 1C), 156.9, 156.1, 143.7 (d, $J = 8.80$ Hz, 1C), 138.4, 136.2 (d, $J = 2.20$ Hz, 1C), 134.5, 133.2 (d, $J = 2.20$ Hz, 1C), 131.6 (2C), 130.9, 130.2 (2C), 129.4, 123.9, 120.1 (d, $J = 9.90$ Hz, 1C), 119.1 (2C), 117.8 (2C), 110.6 (d, $J = 24.21$ Hz, 1C), 105.5 (d, $J = 24.21$ Hz,


1C), 31.2, 14.0.



[00458] 2-[(1*E*)-5,7-Difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E4**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 12.49 (s, 1H), 7.87 (d, $J = 2.6$ Hz, 1H), 7.48 - 7.41 (m, 2H), 7.33 - 7.23 (m, 2H), 7.20 - 7.11 (m, 2H), 7.06 - 6.96 (m, 4H), 3.58 (s, 2H), 1.80 (s, 3H).

[00459] 5-{2-[(1*E*)-1-[(4-Phenoxyphenyl)methylidene]-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **E5**. ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 7.81 (d, $J = 7.15$ Hz, 1H), 7.71 (d, $J = 8.80$ Hz, 2H), 7.56 (s, 1H), 7.43 - 7.49 (m, 2H), 7.38 (d, $J = 7.15$ Hz, 1H), 7.29 (dt, $J = 1.01, 7.29$ Hz, 1H), 7.25 (dt, $J = 1.10, 7.30$ Hz, 1H), 7.20 - 7.24 (m, 1H), 7.10 - 7.15 (m, 2H), 7.08 (d, $J = 8.99$ Hz, 2H), 6.91 (s, 1H), 3.35 (t, $J = 7.30$ Hz, 2H), 3.11 (t, $J = 7.52$ Hz, 2H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 157.8, 156.3, 146.7, 141.4, 138.5, 137.6, 132.5, 132.0, 130.7, 127.7, 127.3, 125.9, 124.6, 121.9, 119.9, 119.8, 119.2, 118.8, 25.8, 22.1.

[00460] 2-[(1*E*)-5,7-Difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **E6**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 12.51 (s, 1H), 7.86 (d, $J = 2.6$ Hz, 1H), 7.46 (t, $J = 7.9$ Hz, 1H), 7.45 - 7.37 (m, 2H), 7.22 - 7.13 (m, 2H), 7.09 - 6.97 (m, 6H), 3.56 (s, 2H), 1.73 (s, 3H).



Example B1

Inhibition of Alpha-Smooth Muscle Actin

[00461] The ability of a compound to inhibit the TGF- β induced expression of alpha-smooth muscle actin (α -SMA) was evaluated in CCl₄-treated fat storing (CFSC) cells. α -SMA is considered as a reliable marker of hepatic stellate cell activation and a key biomarker for liver fibrosis. See, e.g., Meng *et al.*, *Nat. Rev. Nephrol.* **2016**, 12, 325-38; Fabregat *et al.*, *FEBS J.* **2016**, 283, 2219-32.

[00462] CFSC cells maintained in a DMEM medium supplemented with 10% fetal bovine serum were seeded to 12-well culture dishes and grown to a confluence of 60-70% the next day. Culture was changed to a serum-free DMEM medium and treated with a compound at 10 μ M in the presence of TGF- β (10 ng/mL). The cells were incubated for another 24 hours. All culture was maintained at 37 °C in 5% carbon dioxide.

[00463] A NP-40 lysate solution (50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40) with EDTA free cocktail added was used to lyse the cells on ice for 30 min. The lysate was collected and centrifuged at 4 °C for 10 min at 12,000 rpm. The pellet was discarded and the supernatant was transferred to a new tube. Cell lysates were loaded with 5 $\times$ loading buffer and boiled for 10 min, resolved by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to PVDF membrane. The membrane was blocked with 5% skim milk in Tris-buffered saline and TWEEN® 20 (TBST; 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% TWEEN® 20) for 1 h at room temperature and then incubated with α -SMA and β -actin antibodies overnight at 4 °C. After washing twice with TBST, the membrane was probed with a horseradish peroxide-linked anti-immunoglobulin (1:5000 dilution) for 1 h at room temperature. After two subsequent rinses in TBST, immunoreactive products were reacted with ECL and visualized by a UVP CHEMSTUDIO™ imaging system. The western blotting bands are quantitated using an ImageJ software. The percentage of inhibition was obtained by calculating the percentage decrease in the band intensity compared to the one treated with TGF- β only.

[00464] The results are summarized in Table 1, wherein A represents a value no less of 90% inhibition, B represents a value less than 90% but no less than 80% inhibition, C represents a value less than 80% but no less than 70% inhibition, D represents a value less than 70% but no less than 50% inhibition, and E represents a value less than 50% with a compound at 10 μ M.

TABLE 1. Inhibition of α -SMA

Cmpd.	Activity	Cmpd.	Activity	Cmpd.	Activity	Cmpd.	Activity
A1	A	A25	C	A60	E	D8	A
A2	A	A26	C	A68	A	D9	E
A3	A	A27	B	A69	A	D10	A
A4	A	A29	C	A85	A	D11	A
A5	A	A30	C	B9	A	D12	E
A6	A	A31	A	B10	C	D13	E
A7	A	A32	A	B30	A	D14	A
A9	A	A33	C	B34	A	D15	A
A10	A	A34	A	B35	A	D16	E
A11	B	A35	A	B36	A	D18	A
A12	A	A36	A	B37	B	D19	E
A13	E	A38	C	B39	E	D20	A
A14	A	A39	A	B42	B	D21	A
A15	B	A40	A	C1	B	D22	A
A16	A	A42	C	C2	A	D23	A
A17	A	A43	A	C3	B	D25	A
A18	C	A45	A	D1	A	D26	A
A19	A	A46	A	D2	A	D27	A
A20	E	A47	A	D3	A	E1	A
A21	B	A48	A	D4	E	E2	A
A22	D	A51	A	D5	A	E3	A
A23	A	A54	A	D6	E	E4	A
A24	B	A55	E	D7	A	E6	A

Example B2
Antifibrotic Activity

[00465] CCl₄-induced liver fibrosis was described previously. Henderson *et al.*, *Proc. Nat'l. Acad. Sci. U.S.A.* **2006**, *103*, 5060-5; Henderson *et al.*, *Nat. Med.* **2013**, *19*, 1617-24. Briefly, eight-week-old C57BL/6 mice were randomly divided into two groups: a control group and a CCl₄ administered group. Liver fibrosis was induced by intraperitoneal administration of 25% CCl₄ at 0.5 mL/kg body weight (diluted in corn oil) twice weekly for 6 weeks. Dosing was started during the last 2 weeks of CCl₄ administration. Malotilate (Mal) as a reference and compounds **A11**, **A23**, and **B9** were each freshly prepared by dissolving in PEG 400 and orally administered in a dosing volume of 10 mL/kg. The mice were stratified (n = 6–8 per group) based on their body weights and dosed once daily for 2 weeks with a vehicle, malotilate (60 mg/kg), compound **A11** (50 mg/kg), compound **A23** (50 mg/kg), or compound **B9** (50 mg/kg). Their body weights were monitored daily during the intervention period. At the terminal of treatment, the mice were sacrificed and their liver samples were processed as below.

[00466] The mice liver samples were all taken at the same position of each large lobe, and then post-fixed in a 10% buffered formaldehyde for 48 h. The fixed livers were embedded in paraffin for microtome slicing into 5- μ m-thick sections. The tissue sections were mounted onto MS-coated glass slides, deparaffinized, and stained with picric acid-Sirius red. Stained sections were photographed using a microscope with a digital camera. Images were taken at a full resolution with a single image dimension set at 1,360 $\times$ 1,024 pixels.

[00467] Total RNA was extracted from the liver using an MOLPURE® TRIEASY™ Plus Total RNA Kit (Yeasen, Shanghai, China). Total RNA (5 μ g) was reverse-transcribed using 1st strand cDNA Synthesis SuperMix for qPCR (gDNA digester plus) Kit (Yeasen, Shanghai, China). The following primer sets were used: α -SMA, 5'-GTTTCAGTGGTGCCTCTGTCA-3' (sense) (SEQ ID NO: 1) and 5'-ACTGGGACGACATGGAAAAG-3' (antisense) (SEQ ID NO: 2); Col1a1, 5'-TAGGCCATTG-TGTATGCAGC-3' (sense) (SEQ ID NO: 3) and 5'-ACATGTT-CAGCTTTGTGGACC-3' (antisense) (SEQ ID NO: 4); HPRT, 5'-GTTAAGCAGTACAGC-CCCAAA-3' (sense) (SEQ ID NO: 5) and 5'-AGGGCATATCCAACAACAACTT-3' (antisense) (SEQ ID NO: 6). qRT-PCR was conducted using a STEPONE real-time PCR


instrument and qPCR SYBR Green Master Mix (Low Rox Plus) Kit (Yeasen, Shanghai, China). The expression was normalized to that of HPRT RNA. The results are shown in FIGS. 1 to 6.

* * * * *

[00468] The examples set forth above are provided to give those of ordinary skill in the art with a complete disclosure and description of how to make and use the claimed embodiments, and are not intended to limit the scope of what is disclosed herein. Modifications that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference as if each such publication, patent or patent application were specifically and individually indicated to be incorporated herein by reference.

What is claimed is:

1. A compound of Formula (I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, or heteroaryl; wherein R^{2a} , R^{2b} , and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3 , R^4 , R^5 , and R^6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

R^A is C_{6-14} arylene or heteroarylene;

R^B and X are (i), (ii), or (iii):

(vii) X is $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$; and

R^B is C_{6-14} aryl or heteroaryl;

(viii) X is $-N(R^X)-$;

R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or

(ix) X is $-N(R^X)-$; and

R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl;

L is C_{1-6} alkylene, C_{2-6} alkenylene, C_{3-10} cycloalkylene, or heterocyclylene; and each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$,

$-\text{OS}(\text{O})\text{R}^c$, $-\text{OS}(\text{O})_2\text{R}^c$, $-\text{OS}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OS}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{NR}^f\text{R}^g$, $-\text{NR}^c\text{C}(\text{O})\text{R}^h$, $-\text{NR}^c\text{C}(\text{O})\text{OR}^f$, $-\text{NR}^c\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^c\text{C}(\text{O})\text{SR}^f$, $-\text{NR}^c\text{C}(\text{NR}^h)\text{NR}^f\text{R}^g$, $-\text{NR}^c\text{C}(\text{S})\text{R}^h$, $-\text{NR}^c\text{C}(\text{S})\text{OR}^f$, $-\text{NR}^c\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{NR}^c\text{S}(\text{O})\text{R}^h$, $-\text{NR}^c\text{S}(\text{O})_2\text{R}^h$, $-\text{NR}^c\text{S}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^c\text{S}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{SR}^c$, $-\text{S}(\text{O})\text{R}^c$, $-\text{S}(\text{O})_2\text{R}^c$, $-\text{S}(\text{O})\text{NR}^f\text{R}^g$, and $-\text{S}(\text{O})_2\text{NR}^f\text{R}^g$; wherein each R^c , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

2. The compound of claim 1, wherein R^A is C_{6-14} arylene, optionally substituted with one or more substituents Q.


3. The compound of claim 1, wherein R^A is heteroarylene, optionally substituted with one or more substituents Q.

4. The compound of claim 1 or 3, wherein R^A is monocyclic heteroarylene, optionally substituted with one or more substituents Q.

5. The compound of claim 1, 3, or 4, wherein R^A is 6-membered heteroarylene, optionally substituted with one or more substituents Q.

6. The compound of any one of claims 1 and 3 to 5, wherein R^A is pyridylene, optionally substituted with one or more substituents Q.

7. The compound of any one of claims 1 to 6, having the structure of Formula (III):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

U^1 , V^1 , W^1 , and X^1 are each independently (i) C or N; or (ii) $-\text{CR}^{7a}=$, $-\text{N}=\text{}$,

$-\text{NR}^{7b}-$, $-\text{O}-$, or $-\text{S}-$;

Y^1 is (i) C or N; or (ii) a bond, $-\text{CR}^{7a}=$, $-\text{N}=$, $-\text{NR}^{7b}-$, $-\text{O}-$, or $-\text{S}-$;


Z^1 is C or N;

each R^{7a} is independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$, $-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$; and

each R^{7b} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more substituents Q.

8. The compound of any one of claims 1 to 7, having the structure of Formula (IX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

each R^7 is independently (a) deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (c) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$, $-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$,

$-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$,
 $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$; and

n is an integer of 0, 1, 2, 3, or 4.

9. The compound of any one of claims 1 to 8, wherein L is C_{1-6} alkylene, optionally substituted with one or more substituents Q .

10. The compound of any one of claims 1 to 9, wherein L is methylene, ethylene, or propylene, each of which is optionally substituted with one or more substituents Q .

11. The compound of any one of claims 1 to 8, wherein L is C_{2-6} alkenylene, optionally substituted with one or more substituents Q .

12. The compound of any one of claims 1 to 8 and 11, wherein L is ethenylene, optionally substituted with one or more substituents Q .

13. The compound of any one of claims 1 to 12, wherein X is $-\text{O}-$ or $-\text{NR}^X-$, wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one or more substituents Q .

14. The compound of any one of claims 1 to 13, wherein X is $-\text{O}-$.

15. The compound of any one of claims 1 to 14, wherein R^2 is $-\text{C}(\text{O})\text{OR}^{2a}$.

16. The compound of claim 15, wherein R^2 is $-\text{C}(\text{O})\text{OH}$.

17. The compound of any one of claims 1 to 14, wherein R^2 is $-\text{C}(\text{O})\text{NR}^{2b}\text{R}^{2c}$.

18. The compound of claim 17, wherein R^2 is $-\text{C}(\text{O})\text{NHR}^{2c}$, and R^{2c} is C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q .


19. The compound of claim 17, wherein R^2 is $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHCH}_3$, $-\text{C}(\text{O})\text{NHCH}_2\text{CH}_2\text{OH}$, or $-\text{C}(\text{O})\text{NH}(\text{tetrazolyl})$.

20. The compound of any one of claims 1 to 14, wherein R^2 is $-\text{C}(\text{O})\text{N}(\text{R}^{2b})\text{OR}^{2c}$.

21. The compound of claim 20, wherein R^2 is $-\text{C}(\text{O})\text{NHOR}^{2c}$.


22. The compound of claim 20, wherein R^2 is $-C(O)NHOH$.

23. The compound of any one of claims 1 to 22, having the structure of Formula (XIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^{2A} is $-OR^{2a}$, $-NR^{2b}R^{2c}$, or $-N(R^{2b})OR^{2c}$; and p is an integer of 1, 2, or 3.

24. The compound of claim 23, having the structure of Formula (XV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

25. The compound of claim 23, having the structure of Formula (XVI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

26. The compound of claim 23, having the structure of Formula (XVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

27. The compound of any one of claims 23 to 26, wherein R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.

28. The compound of claim 27, wherein R^7 is chloro or methoxy.

29. The compound of claim 23, having the structure of Formula (XVII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

30. The compound of claim 29, wherein R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.

31. The compound of claim 29 or 30, wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.

32. The compound of any one of claims 1 to 31, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q.

33. The compound of any one of claims 1 to 32, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl.


34. The compound of any one of claims 1 to 33, wherein R^B is phenyl, naphthyl, pyridyl, or quinolinyl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, and methoxy.

35. The compound of any one of claims 1 to 34, wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl,

fluoropyridyl, fluoro-methylpyridyl, or quinoliny.


36. The compound of any one of claims 1 to 35, wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.

37. The compound of any one of claims 1 to 22, having the structure of Formula (XIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

38. The compound of claim 37, having the structure of Formula (XX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

39. The compound of claim 37, having the structure of Formula (XXI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

40. The compound of claim 37, having the structure of Formula (XXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

41. The compound of any one of claims 37 to 40, wherein R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.

42. The compound of claim 41, wherein R^7 is chloro or methoxy.

43. The compound of claim 37, having the structure of Formula (XXII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

44. The compound of claim 43, wherein R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.

45. The compound of claim 43 or 44, wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.

46. The compound of any one of claims 37 to 45, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q.

47. The compound of any one of claims 37 to 46, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl.

48. The compound of any one of claims 37 to 47, wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl.

49. The compound of any one of claims 37 to 48, wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-

methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.

50. The compound of any one of claims 37 to 49, wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q.

51. The compound of any one of claims 37 to 50, wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl.

52. The compound of any one of claims 37 to 51, wherein R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl.

53. The compound of any one of claims 37 to 52, wherein R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl.

54. The compound of any one of claims 37 to 45, wherein R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl, each optionally substituted with one or more substituents Q.

55. The compound of claim 54, wherein R^B and R^X together with the N atom to which they are attached form heteroaryl, optionally substituted with one or more substituents Q.

56. The compound of claim 54 or 55, wherein R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, each optionally substituted with one or more substituents Q.

57. The compound of any one of claims 54 to 56, wherein R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, or indol-1-yl.

58. The compound of claim 54, wherein R^B and R^X together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q.

59. The compound of claim 54 or 58, wherein R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heterocyclyl, each optionally substituted with one or more substituents Q.

60. The compound of claim 54, 58, or 59, wherein R^B and R^X together with the N atom to which they are attached form pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl.

61. The compound of any one of claims 23 to 60, wherein R^{2A} is $-OR^{2a}$.

62. The compound of claim 61, wherein R^{2A} is $-OH$.

63. The compound of any one of claims 23 to 60, wherein R^{2A} is $-NR^{2b}R^{2c}$.

64. The compound of claim 63, wherein R^{2A} is $-NHR^{2c}$, and R^{2c} is C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q.

65. The compound of claim 63 or 64, wherein R^{2A} is $-NH_2$, $-NHCH_3$, $-NHCH_2CH_2OH$, or $-NH(tetrazolyl)$.

66. The compound of any one of claims 23 to 60, wherein R^{2A} is $-N(R^{2b})OR^{2c}$.

67. The compound of claim 66, wherein R^{2A} is $-NHOR^{2c}$.


68. The compound of claim 66 or 67, wherein R^{2A} is $-NHOH$.

69. The compound of any one of claims 1 to 14, wherein R^2 is heteroaryl, optionally substituted with one or more substituents Q.

70. The compound of any one of claims 1 to 14 or 69, wherein R^2 is monocyclic heteroaryl, optionally substituted with one or more substituents Q.


71. The compound of any one of claims 1 to 14, 69, or 70, wherein R^2 is 5-membered heteroaryl, optionally substituted with one or more substituents Q.

72. The compound of any one of claims 1 to 14 and 69 to 71, having the structure of Formula (XXIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein U^2 is $-N=$ or $-O-$; and V^2 is $-N=$ or $-C(OH)=$.

73. The compound of claim 72, wherein the compound is a compound of Formula (XXV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

74. The compound of claim 72, wherein the compound is a compound of Formula (XXVI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

75. The compound of claim 72, wherein the compound is a compound of Formula (XXVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

76. The compound of any one of claims 72 to 75, wherein R⁷ is deuterium, halo, or —O—C₁₋₆ alkyl optionally substituted with one or more substituents Q.


77. The compound of claim 76, wherein R⁷ is chloro or methoxy.

78. The compound of claim 72, wherein the compound is a compound of Formula (XXVII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

79. The compound of claim 78, wherein R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.
80. The compound of claim 78 or 79, wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.
81. The compound of any one of claims 72 to 80, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q.
82. The compound of any one of claims 72 to 81, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl.
83. The compound of any one of claims 72 to 82, wherein R^B is phenyl, naphthyl, pyridyl, or quinoliny, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, and methoxy.
84. The compound of any one of claims 72 to 83, wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinoliny.
85. The compound of any one of claims 72 to 84, wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.
86. The compound of any one of claims 1 to 14 and 69 to 71, having the structure of Formula (XXIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

87. The compound of claim 86, having the structure of Formula (XXX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


88. The compound of claim 86, having the structure of Formula (XXXI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or

a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

89. The compound of claim 86, having the structure of Formula (XXXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

90. The compound of any one of claims 86 to 89, wherein R^7 is deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.

91. The compound of claim 90, wherein R^7 is chloro or methoxy.

92. The compound of claim 86, having the structure of Formula (XXXII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

93. The compound of claim 92, wherein R^{7a} is hydrogen, deuterium, halo, or $-O-C_{1-6}$ alkyl optionally substituted with one or more substituents Q.

94. The compound of claim 92 or 93, wherein R^{7a} is hydrogen, deuterium, chloro, or

methoxy.

95. The compound of any one of claims 86 to 94, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q.

96. The compound of any one of claims 86 to 95, wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl.

97. The compound of any one of claims 86 to 96, wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl.

98. The compound of any one of claims 86 to 97, wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.

99. The compound of any one of claims 86 to 98, wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q.

100. The compound of any one of claims 86 to 99, wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl.

101. The compound of any one of claims 86 to 100, wherein R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl.

102. The compound of any one of claims 86 to 101, wherein R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl.

103. The compound of any one of claims 86 to 94, wherein R^B and R^X together with the N atom to which they are attached form heteroaryl or heterocyclyl, each optionally substituted with one or more substituents Q.

104. The compound of claim 103, wherein R^B and R^X together with the N atom to which they are attached form heteroaryl, optionally substituted with one or more substituents Q.

105. The compound of claim 103 or 104, wherein R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, each optionally substituted with one or more substituents Q.

106. The compound of any one of claims 103 to 105, wherein R^B and R^X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, or indol-1-yl.

107. The compound of claim 103, wherein R^B and R^X together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q.

108. The compound of claim 107, wherein R^B and R^X together with the N atom to which they are attached form monocyclic or bicyclic heterocyclyl, each optionally substituted with one or more substituents Q.

109. The compound of claim 107 or 108, wherein R^B and R^X together with the N atom to which they are attached form pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl.

110. The compound of any one of claims 86 to 109, wherein U^2 is $-N=$.

111. The compound of any one of claims 86 to 109, wherein U^2 is $-O-$.

112. The compound of any one of claims 86 to 111, wherein V^2 is $-N=$.

113. The compound of any one of claims 86 to 111, wherein V^2 is $-C(OH)=$.

114. The compound of any one of claims 86 to 109, wherein U^2 and V^2 are each $-N=$.
115. The compound of any one of claims 86 to 109, wherein U^2 is $-O-$ and V^2 is $-C(OH)=$.
116. The compound of any one of claims 1 to 115, wherein R^3 is hydrogen, deuterium, halo, or C_{1-6} alkyl optionally substituted with one, two, or three substituents Q.
117. The compound of any one of claims 1 to 116, wherein R^3 is hydrogen, deuterium, or methyl.
118. The compound of any one of claims 1 to 117, wherein R^4 is hydrogen, deuterium, halo, or C_{1-6} alkyl optionally substituted with one, two, or three substituents Q.
119. The compound of any one of claims 1 to 118, wherein R^4 is hydrogen or deuterium.
120. The compound of any one of claims 1 to 118, wherein R^4 is halo.
121. The compound of any one of claims 1 to 118 and 120, wherein R^4 is fluoro.
122. The compound of any one of claims 1 to 118, wherein R^4 is C_{1-6} alkyl, optionally substituted with one, two, or three substituents Q.
123. The compound of any one of claims 1 to 118 and 122, wherein R^4 is methyl.
124. The compound of any one of claims 1 to 123, wherein R^5 is hydrogen or deuterium.
125. The compound of any one of claims 1 to 123, wherein R^6 is hydrogen or deuterium.
126. The compound of claim 1, wherein the compound is:
2-[(1Z)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1H-inden-3-yl]acetic acid **A1**;
2-[(1Z)-5-fluoro-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1H-

inden-3-yl]acetic acid **A2**;

2-[(1*Z*)-1-({2-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{{4-(4-methylphenoxy)phenyl}methylidene}-1*H*-inden-3-yl]acetic acid **A4**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A5**;

2-[(1*Z*)-1-{{4-(4-bromophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A6**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{{4-(3-methylphenoxy)phenyl}methylidene}-1*H*-inden-3-yl]acetic acid **A7**;

2-[(1*Z*)-1-{{4-(3-cyanophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A8**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(3-(trifluoromethyl)phenoxy)benzylidene)-1*H*-inden-3-yl)acetic acid **A9**;

2-[(1*Z*)-1-{{4-(4-ethylphenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A10**;

2-[(1*Z*)-5-fluoro-1-{{4-(4-fluorophenoxy)phenyl}methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A11**;

2-[(1*Z*)-1-{{2-chloro-4-(4-methoxyphenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A12**;

2-[(1*Z*)-5-fluoro-1-({2-methoxy-4-[4-(propan-2-yl)phenoxy]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A13**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{{4-(naphthalen-2-yloxy)phenyl}methylidene}-1*H*-inden-3-yl]acetic acid **A14**;

2-[(1*Z*)-1-({2-chloro-4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A15**;

2-[(1*Z*)-1-{{4-(2,4-difluorophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A16**;

2-[(1*Z*)-1-{{4-(2-bromo-4-fluorophenoxy)phenyl}methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A17**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[[4-(2,4,5-trifluorophenoxy)phenyl]methylidene]-1*H*-inden-3-yl]acetic acid **A18**;

3-[(1*Z*)-1-[[4-(4-fluorophenoxy)phenyl]methylidene]-2-methyl-1*H*-inden-3-yl]propanoic acid **A19**;

2-[(1*Z*)-5-fluoro-1-({4-[(6-fluoropyridin-3-yl)oxy]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A20**;

2-[(1*Z*)-5-fluoro-1-({4-[(6-fluoro-5-methylpyridin-3-yl)oxy]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A21**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(quinolin-5-yloxy)benzylidene)-1*H*-inden-3-yl)acetic acid **A22**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A23**;

2-[(1*Z*)-5-fluoro-1-{{4-(4-fluorophenoxy)phenyl}methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A24**;

2-[(1*Z*)-5-fluoro-1-{{4-(4-fluorophenoxy)phenyl}methylidene}-2-methyl-1*H*-inden-3-yl]acetamide **A25**;

2-[(1*Z*)-5-fluoro-1-{{4-(4-fluorophenoxy)phenyl}methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-methylacetamid **A26**;

2-[(1*Z*)-5-fluoro-1-{{4-(4-fluorophenoxy)phenyl}methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-(2-hydroxyethyl)acetamide **A27**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)-*N*-(1*H*-tetrazol-5-yl)acetamide **A28**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A29**;

2-[(1*Z*)-1-({4-[benzyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A30**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(methyl)amino]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A31**;

2-[(1*Z*)-1-({4-[ethyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A32**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(propyl)amino]phenyl}methylidene)-2-

methyl-1*H*-inden-3-yl]acetic acid **A33**;

(*Z*)-2-(5-fluoro-1-(4-((4-fluorophenyl)(2-hydroxyethyl)amino)benzylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A34**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(4-formylphenyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A35**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-formylphenyl)(phenyl)amino]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A36**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A37**;

2-[(1*Z*)-1-({4-[benzyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A38**;

5-{[(1*Z*)-2-methyl-1-[(3-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A39**;

5-{[(1*Z*)-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A40**;

5-{2-[(1*Z*)-2-methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A41**;

5-{2-[(1*Z*)-1-{[4-(4-bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A42**;

5-{2-[(1*Z*)-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A43**;

5-{2-[(1*Z*)-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A44**;

5-{2-[(1*Z*)-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A45**;

5-{2-[(1*Z*)-2-methyl-1-{[4-(3-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A46**;

3-(4-{[(1*Z*)-2-methyl-3-[2-(1*H*-1,2,3,4-tetrazol-5-yl)ethyl]-1*H*-inden-1-ylidene]methyl}phenoxy)benzonitrile **A47**;

5-{2-[(1*Z*)-1-{[4-(3-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A48**;

5-{2-[(1Z)-1-{[4-(3-bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A49**;

5-{2-[(1Z)-2-methyl-1-({4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A50**;

5-{2-[(1Z)-2-methyl-1-({4-(naphthalen-2-yloxy)phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A51**;

(Z)-3-((2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)methyl)-1,2,4-oxadiazol-5(4*H*)-one **A52**;

5-{[(1*E*)-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A53**;

5-{[(1*E*)-1-[(3-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A54**;

2-[(1Z)-5-fluoro-2-methyl-1-({4-(morpholin-4-yl)phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A55**;

2-[(1Z)-5-fluoro-2-methyl-1-({4-(piperidin-1-yl)phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A56**;

2-[(1Z)-5-fluoro-1-({4-(1*H*-indol-1-yl)phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A57**;

2-[(1Z)-1-({4-(2-amino-1*H*-imidazol-1-yl)phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A58**;

2-[(1Z)-5-fluoro-2-methyl-1-({4-(pyrrolidin-1-yl)phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A59**;

2-[(1Z)-5-fluoro-2-methyl-1-({4-(1*H*-pyrrol-1-yl)phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A60**;

(2*E*)-3-[(1Z)-5-fluoro-1-({4-(4-fluorophenoxy)phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]prop-2-enoic acid **A61**;

2-[(1Z)-5-fluoro-1-({4-(4-fluorobenzenesulfonyl)phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A62**;

2-[(1Z)-5-fluoro-1-({4-(4-fluorobenzenesulfinyl)phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A63**;

2-[(1Z)-5-fluoro-1-({4-[(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-

1*H*-inden-3-yl]acetic acid **A64**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A65**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A66**;

(2*E*)-4-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]but-2-enoic acid **A67**;

2-[(1*Z*)-4,5-difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A68**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]acetic acid **A69**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(morpholin-4-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A70**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(piperidin-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A71**;

2-[(1*Z*)-5-fluoro-1-{[4-(1*H*-indol-1-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A72**;

2-[(1*Z*)-1-{[4-(2-amino-1*H*-imidazol-1-yl)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A73**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(pyrrolidin-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A74**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(1*H*-pyrrol-1-yl)phenyl]methylidene}-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A75**;

(2*E*)-3-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyprop-2-enamide **A76**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A77**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfinyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A78**;

2-[(1*Z*)-5-fluoro-1-({[4-(4-fluorophenyl)sulfonyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A79**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A80**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A81**;

(2*E*)-4-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxybut-2-enamide **A82**;

2-[(1*Z*)-4,5-difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A83**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A84**; or

2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(2-hydroxyethyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A85**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]-*N*-hydroxy-*N*-methylacetamide **C1**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxy-*N*-methylacetamide **C2**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)-*N*-hydroxy-*N*-methylacetamide **C3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]-*N*-hydroxyacetamide **D1**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(*tert*-butyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D2**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-(*tert*-butyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-fluoro-4-methylphenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D4**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3,4-difluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D5**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-nitrophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D6**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}-

methylidene)-1*H*-inden-3-yl]acetic acid **D7**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-(2-methylpropyl)-1*H*-inden-3-yl]acetic acid **D8**;

2-[(1*Z*)-5-fluoro-2-benzyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D9**;

2-[(1*Z*)-5-methoxy-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D10**;

2-[(1*Z*)-5-methoxy-2-methyl-1-(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **D11**;

2-[(1*Z*)-1-{[2-trifluoromethyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D12**;

2-[(1*Z*)-1-{[3-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D13**;

2-[(1*Z*)-1-{[2-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D14**;

2-[(1*Z*)-5,7-difluoro-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D15**;

2-[(1*Z*)-4,6-difluoro-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D16**;

2-[(1*Z*)-5-*tert*-butyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D17**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)acetic acid **D18**;

2-[(1*Z*)-5-fluoro-1-(2-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D19**;

2-[(1*Z*)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D20**;

2-[(1*Z*)-4,6-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D21**;

2-[(1*Z*)-5-fluoro-2-methyl-1-(3-[4-methoxyphenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D22**;

2-[(1Z)-5-fluoro-1-(4-fluoro-3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D23**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[4-cyanophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D24**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[4-chlorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D25**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[4-trifluoromethylphenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D26**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[3-trifluoromethylphenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D27**;

2-[(1Z)-4-methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D28**;

2-[(1Z)-6-methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D29**;

2-[(1Z)-6-trifluoromethyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D30**;

2-[(1Z)-5-trifluoromethyl-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D31**;

2-[(1Z)-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **D32**;

2-[(1Z)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **D33**;

2-[(1Z)-5-trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D34**;

2-[(1Z)-6-methoxy-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D35**;

2-[(1Z)-6-trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D36**;

2-[(1Z)-5-fluoro-2-methyl-1-(3-[methyl(phenyl)amino]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **D37**;

2-[(1Z)-5-fluoro-1-[(3-methoxy-5-phenoxyphenyl)methylidene]-2-methyl-1*H*-

inden-3-yl]acetic acid **D38**;

2-[(1*E*)-5-fluoro-2-methyl-1-(4-[3,4-difluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **E1**;

2-[(1*E*)-5-fluoro-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **E2**;

2-[(1*E*)-5-fluoro-2-methyl-1-(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **E3**;

2-[(1*E*)-5,7-difluoro-2-methyl-1-(4-[4-fluorophenoxy]phenyl)methylidene)-1*H*-inden-3-yl]acetic acid **E4**;

5-{2-[(1*E*)-1-(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **E5**; and

2-[(1*E*)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **E6**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

127. A pharmaceutical composition comprising the compound of any one of claims 1 to 126, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and a pharmaceutically acceptable excipient.

128. A method of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of the compound of any one of claims 1 to 126.

129. The method of claim 128, wherein the fibrotic disease is a metabolic disease.

130. The method of claim 128 or 129, wherein the fibrotic disease is a liver disease.

131. The method of any one of claims 128 to 130, wherein the fibrotic disease is nonalcoholic fatty liver disease (NAFLD).

132. The method of any one of claims 128 to 131, wherein the fibrotic disease is

nonalcoholic steatohepatitis (NASH).

133. A method of treating, preventing, or ameliorating one or more symptoms of a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1 to 126.


134. The method of claim 133, wherein the proliferative disease is cancer.

135. The method of any one of claims 128 to 134, wherein the subject is a human.

136. A method of inhibiting the growth of a cell, comprising contacting the cell with an effective amount of the compound of any one of claims 1 to 126.

137. The method of claim 136, wherein the cell is a cancerous cell.

138. A method of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a therapeutically effective amount of a compound of Formula (I-A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $-CN$, $-C(O)OR^{2a}$, $-C(O)NR^{2b}R^{2c}$, $-C(O)N(R^{2b})OR^{2c}$, $-OR^{2a}$, $-NR^{2b}R^{2c}$, or heteroaryl; wherein R^{2a} , R^{2b} , and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3 , R^4 , R^5 , and R^6 are each independently (a) hydrogen, deuterium, cyano, halo,

or nitro; (b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

each R⁷ is independently (a) deuterium, cyano, halo, or nitro; (b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (c) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; or two adjacent R⁷ together with the phenyl group to which they are attached form naphthyl or bicyclic heteroaryl;

R^C is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (c) $-OR^{1a}$, $-NR^{1b}R^{1c}$, or $-NR^{1a}C(O)R^{1d}$;

L is C₁₋₆ alkylene or C₂₋₆ alkenylene;

n is an integer of 0, 1, 2, 3, or 4; and

each R^{1a}, R^{1b}, R^{1c}, and R^{1d} is independently hydrogen, deuterium, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents

Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$, $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

139. The method of claim 138, wherein the fibrotic disease is a metabolic disease.

140. The method of claim 138 or 139, wherein the fibrotic disease is a liver disease.

141. The method of any one of claims 138 to 140, wherein the fibrotic disease is nonalcoholic fatty liver disease (NAFLD).

142. The method of any one of claims 138 to 141, wherein the fibrotic disease is

nonalcoholic steatohepatitis (NASH).

143. The method of any one of claims 138 to 142, wherein the subject is a human.
144. The method of any one of claims 138 to 143, wherein the compound is:
 - (*Z*)-2-(2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B1**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(benzylidene)-1*H*-inden-3-yl)acetic acid **B2**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(3-cyanobenzylidene)-1*H*-inden-3-yl)acetic acid **B3**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-cyanobenzylidene)-1*H*-inden-3-yl)acetic acid **B4**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-methylbenzylidene)-1*H*-inden-3-yl)acetic acid **B5**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(3-trifluoromethylbenzylidene)-1*H*-inden-3-yl)acetic acid **B6**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-trifluoromethylbenzylidene)-1*H*-inden-3-yl)acetic acid **B7**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-ethylbenzylidene)-1*H*-inden-3-yl)acetic acid **B8**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B9**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-*t*-butylbenzylidene)-1*H*-inden-3-yl)acetic acid **B10**;
 - (*Z*)-2-(5-fluoro-2-ethyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B11**;
 - (*Z*)-2-(5-fluoro-2-(2-methylpropyl)-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B12**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(3-methoxybenzylidene)-1*H*-inden-3-yl)acetic acid **B13**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-methoxybenzylidene)-1*H*-inden-3-yl)acetic acid **B14**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-ethoxybenzylidene)-1*H*-inden-3-yl)acetic acid **B15**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-(pyrrolidin-1-yl)benzylidene)-1*H*-inden-3-yl)acetic acid **B16**;
 - (*Z*)-2-(5-fluoro-2-methyl-1-(4-(pyrid-2-yl) benzylidene)-1*H*-inden-3-yl)acetic acid **B17**;
 - (*Z*)-2-(5-chloro-2-methyl-1-(4-*t*-butylbenzylidene)-1*H*-inden-3-yl)acetic acid **B18**;
 - (*Z*)-2-(5-methyl-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid

B19;(Z)-2-(5-ethyl-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid**B20;**(Z)-2-(5-isopropyl-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)aceticacid **B21;**(Z)-2-(5-methoxy-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid**B22;**(Z)-2-(5-ethoxy-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid**B23;**(Z)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)acetamide**B24;**(Z)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)-*N*-methylacetamide **B25;**(Z)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)-*N,N*-dimethylacetamide **B26;**(Z)-2-(1-(4-acetamidobenzylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl)acetic acid**B27;**(Z)-3-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)propanoicacid **B28;**(Z)-5-(2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethyl)-1*H*-tetrazole **B29;**(Z)-5-(2-(1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethyl)-1*H*-tetrazole**B30;**(Z)-2-(4-fluoro-2-methyl-1-(benzylidene)-1*H*-inden-3-yl)acetic acid **B31;**(Z)-2-(5-fluoro-1-(4-dimethylaminobenzylidene)-2-methyl-1*H*-inden-3-yl)propanoic acid **B32;**2-[(1*Z*)-5-fluoro-1-[(2-hydroxynaphthalen-1-yl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **B33;**2-[(1*Z*)-5-fluoro-2-methyl-1-[(naphthalen-2-yl)methylidene]-1*H*-inden-3-yl]aceticacid **B34;**2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-methylnaphthalen-1-yl)methylidene]-1*H*-inden-

3-yl]acetic acid **B35**;

2-[(1*Z*)-5-fluoro-1-[(2-methoxynaphthalen-1-yl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **B36**;

2-[(1*Z*)-1-[(4-cyclopropylphenyl)methylidene]-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B37**;

2-[(1*Z*)-1-[(4-cyclopentylphenyl)methylidene]-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B38**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(prop-1-en-2-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **B39**;

2-[(1*Z*)-5-fluoro-1-{[4-(2-fluoropropan-2-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **B40**;

2-[(1*Z*)-1-{[4-(dimethylamino)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B41**;

2-[(1*Z*)-5-fluoro-1-{[4-(1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **B42**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1*H*-inden-3-yl]propanoic acid **B43**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(trifluoromethyl)phenyl]methylidene}-1*H*-inden-3-yl]propanoic acid **B44**;

2-[(1*Z*)-7-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **B45**;

2-[(1*Z*)-7-fluoro-2-methyl-1-{[4-(trifluoromethyl)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **B46**;

2-[(1*Z*)-1-{[4-(1,3-difluoropropan-2-yl)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **B47**;

2-[(1*Z*)-5-fluoro-1-{[3-fluoro-4-(propan-2-yl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **B48**;

(*E*)-2-(5-fluoro-2-methyl-1-(4-isopropylbenzylidene)-1*H*-inden-3-yl)acetic acid **B49**;

(*E*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)acetamide **B50**;

(*E*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)-*N*-methylacetamide **B51**;

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethan-1-ol **B52**;

(*Z*)-2-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)ethan-1-amino **B53**; or

(*Z*)-3-(5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1*H*-inden-3-yl)propanenitrile **B54**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6



INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2021/099626

A. CLASSIFICATION OF SUBJECT MATTER

C07C 13/465(2006.01)i; A61K 31/015(2006.01)i; A61P 1/16(2006.01)i; A61P 35/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07C; A61K; A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CNABS; CNTXT; DWPI; SIPOABS; CNKI; Web of Science; STNext; Sulindac, 38194-50-2, fibrosis, nonalcoholic fatty liver disease, NAFLD, nonalcoholic steatohepatitis, NASH, proliferative disease, cancer, NUCMITO PHARMACEUTICALS, structure search based on formula (I)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	HUANG, Fengyu et al. "Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPAR γ with potential anti-diabetic efficacy." <i>European Journal of Medicinal Chemistry</i> , Vol. 222, 24 May 2021 (2021-05-24), pages 113542(1-14)	1-53, 61-102, 110-127, 133-137
X	WO 2011140525 A2 (SANFORD-BURNHAM MED. RES. INST.) 10 November 2011 (2011-11-10) claims 40, 53, description page 57 compound K-80003 Analog No. 29	1-12, 15-22, 37-45, 54-71, 86-94, 103-127, 133-137
Y	WO 2011140525 A2 (SANFORD-BURNHAM MED. RES. INST.) 10 November 2011 (2011-11-10) claims 40, 53, description page 57 compound K-80003 Analog No. 29	128-132, 138-144
X	DE 10163426 A1 (MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.) 03 July 2003 (2003-07-03) description paragraphs 13-19, 22, drawings 6/4, compounds mc-623, mc-2323, mc-624, mc-2323, mc-4224, drawings 6/7, compounds EG149, EG186, EG168, EG187, EG167, EG188, EG166	1-53, 61-102, 110-127, 133-137



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 August 2021

Date of mailing of the international search report

15 September 2021

Name and mailing address of the ISA/CN

National Intellectual Property Administration, PRC
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing
100088
China

Authorized officer

WANG, Fangfei

Facsimile No. (86-10)62019451

Telephone No. (86-10)53962085

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2021/099626

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 10163426 A1 (MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.) 03 July 2003 (2003-07-03) description paragraphs 13-19, 22, drawings 6/4, compounds mc-623, mc-2323, mc-624, mc-2323, mc-4224, drawings 6/7, compounds EG149, EG186, EG168, EG187, EG167, EG188, EG166	128-132, 138-144
Y	WO 9916453 A1 (ELI LILLY AND COMPANY) 08 April 1999 (1999-04-08) claim 24, description pages 96-97, compound 14e	128-132, 138-144
Y	LIU, Shuai. "The RXR α -mediated anti-inflammatory effect of sulindac analog K-80003 and the underlying molecular mechanism." <i>Chinese Doctoral Dissertations & Master's Theses Full-text Database (Master) Medicine and Health Sciences.</i> , No. 6, 15 June 2019 (2019-06-15), the abstract, page 8 Table 1	128-132, 138-144
A	WO 9603120 A1 (ELI LILLY AND COMPANY) 08 February 1996 (1996-02-08) Claims 1-19	1-144
A	WO 2009090414 A1 (OXAGEN LTD.) 23 July 2009 (2009-07-23) claims 1-24	1-144
A	HWU, Jih Ru et al. "Syntheses of Platinum-Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs." <i>Chem. Eur. J.</i> , Vol. 22, No. 6, 11 January 2016 (2016-01-11), pages 1926-1930	1-144
A	REDDY, Virsinha et al. "Catalyst-Controlled Regioselective Approach to 1-Aminoisoquinolines and/or 1-Aminoisoindolines through Aminative Domino Cyclization of 2-Alkynylbenzonitriles." <i>Eur. J. Org. Chem.</i> , Vol. 2016, No. 3, 04 December 2015 (2015-12-04), pages 453-458	1-144
A	ZHOU, Xue et al. "Sulindac has strong antifibrotic effects by suppressing STAT3-related miR-21." <i>J. Cell. Mol. Med.</i> , Vol. 19, No. 5, 31 December 2015 (2015-12-31), pages 1103-1113	1-144
A	BAI, Han et al. "The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis." <i>BMC Gastroenterology</i> , Vol. 12, No. 115, 31 December 2012 (2012-12-31), pages 1-11	1-144

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2021/099626

Box No. I **Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13*ter*.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13*ter*.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13*ter*.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2021/099626**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **128-144**
because they relate to subject matter not required to be searched by this Authority, namely:
 - [1] Claims 128-132, 138-144 relate to methods of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject, claims 133-137 relate to methods of treating, preventing, or ameliorating one or more symptoms of a proliferative disease in a subject, which fall within the criteria set out in PCT Rule 39.1(iv). The search has been carried out and based on the uses of formula (I) for the manufacturing of medicaments of treating such diseases.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2021/099626

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
WO	2011140525	A2	10 November 2011	CN	107050007	A	18 August 2017
				US	10087156	B2	02 October 2018
				CN	103002887	B	21 December 2016
				CN	103002887	A	27 March 2013
				US	9611235	B2	04 April 2017
				EP	2571497	A2	27 March 2013
				CA	2798692	C	30 April 2019
				KR	20130113932	A	16 October 2013
				AU	2011249857	A1	06 December 2012
				US	2015266842	A1	24 September 2015
				ES	2702532	T3	01 March 2019
				AU	2011249857	B2	12 March 2015
				EP	2571497	B1	19 September 2018
				JP	2017008050	A	12 January 2017
				WO	2011140525	A3	22 March 2012
				CA	2798692	A1	10 November 2011
				JP	6375340	B2	15 August 2018
				KR	101889290	B1	20 August 2018
				US	2017313668	A1	02 November 2017
				CN	107050007	B	30 June 2020
				JP	2013533212	A	22 August 2013
				EP	2571497	A4	04 December 2013
DE	10163426	A1	03 July 2003	None			
WO	9916453	A1	08 April 1999	AU	9664198	A	23 April 1999
				CA	2304482	A1	08 April 1999
				JP	2001517707	A	09 October 2001
				EP	1007056	A1	14 June 2000
WO	9603120	A1	08 February 1996	AU	3198095	A	22 February 1996
				EP	0769940	B1	17 September 2003
				DE	69531787	D1	23 October 2003
				CA	2195432	A1	08 February 1996
				JP	H10505336	A	26 May 1998
				EP	0769940	A1	02 May 1997
				US	6214876	B1	10 April 2001
				EP	0769940	A4	11 June 1997
WO	2009090414	A1	23 July 2009	ZA	201005799	B	25 January 2012
				US	2009186923	A1	23 July 2009
				AU	2009204700	A1	23 July 2009
				MX	2010007833	A	11 August 2010
				PT	2250161	E	21 January 2014
				IL	206959	D0	30 December 2010
				RU	2503672	C2	10 January 2014
				EP	2250161	B1	16 October 2013
				BR	PI0906786	A2	14 July 2015
				KR	101644170	B1	01 August 2016
				HR	P20140045	T1	14 February 2014
				NZ	587251	A	22 December 2011
				CN	101932571	B	23 April 2014
				JP	5855162	B2	09 February 2016

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2021/099626

Patent document cited in search report	Publication date (day/month/year)	Patent family member(s)	Publication date (day/month/year)
		RU 2010129027 A	27 February 2012
		SI 2250161 T1	30 April 2014
		HK 1145175 A1	08 April 2011
		MY 155133 A	15 September 2015
		CY 1114748 T1	14 December 2016
		CN 101932571 A	29 December 2010
		RS 53142 B	30 June 2014
		MA 32075 B1	01 February 2011
		EP 2250161 A1	17 November 2010
		CA 2712017 C	09 August 2016
		KR 20100110361 A	12 October 2010
		IL 206959 A	30 September 2014
		SI EP2250161 T1	30 April 2014
		AU 2009204700 B2	04 July 2013
		JP 2014159465 A	04 September 2014
		PL 2250161 T3	30 May 2014
		JP 2011509988 A	31 March 2011
		CA 2712017 A1	23 July 2009
		ES 2442717 T3	13 February 2014
		DK 2250161 T3	27 January 2014